[
  {
    "id": 10,
    "user_query": "Name synonym of Acrokeratosis paraneoplastica.",
    "llama-2-7b-chat-hf_response": "Based on the information provided, a synonym for Acrokeratosis paraneoplastica is Bazex syndrome.",
    "llama-2-7b-chat-hf_fact_raw": "1. Acrokeratosis paraneoplastica is also known as Bazex syndrome.",
    "llama-2-7b-chat-hf_fact": [
      "Acrokeratosis paraneoplastica is also known as Bazex syndrome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 47,
    "user_query": "Is Weaver syndrome similar to Sotos?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, Weaver syndrome and Sotos syndrome do share some similarities, but they are not the same condition. While both syndromes can present with phenotypic overlap, such as broad forehead and face, ocular hypertelorism, prominent wide philtrum, micrognathia, deep horizontal chin groove, and deep-set nails, there are distinct differences in their clinical features.\nWeaver syndrome is characterized by advanced carpal bone development, which is not typically seen in Sotos syndrome. Additionally, the facial features of Weaver syndrome are often more pronounced and distinct than those seen in Sotos syndrome.\nTherefore, while Weaver syndrome and Sotos syndrome may share some similarities, they are distinct conditions that require careful evaluation and diagnosis to differentiate between them.",
    "llama-2-7b-chat-hf_fact_raw": "1. Weaver syndrome and Sotos syndrome share some phenotypic similarities, such as broad forehead and face, ocular hypertelorism, prominent wide philtrum, micrognathia, deep horizontal chin groove, and deep-set nails.\n2. Weaver syndrome is characterized by advanced carpal bone development, which is not typically seen in Sotos syndrome.\n3. The facial features of Weaver syndrome are often more pronounced and distinct than those seen in Sotos syndrome.\n4. Weaver syndrome and Sotos syndrome are distinct conditions that require careful evaluation and diagnosis to differentiate between them.",
    "llama-2-7b-chat-hf_fact": [
      "Weaver syndrome and Sotos syndrome share some phenotypic similarities, such as broad forehead and face, ocular hypertelorism, prominent wide philtrum, micrognathia, deep horizontal chin groove, and deep-set nails.",
      "Weaver syndrome is characterized by advanced carpal bone development, which is not typically seen in Sotos syndrome.",
      "The facial features of Weaver syndrome are often more pronounced and distinct than those seen in Sotos syndrome.",
      "Weaver syndrome and Sotos syndrome are distinct conditions that require careful evaluation and diagnosis to differentiate between them."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 81,
    "user_query": "List the releases of JASPAR database",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the releases of JASPAR database are:\n1. JASPAR 2022: the 9th release of the open-access database of transcription factor binding profiles. This is the most recent release of the database, as mentioned in the article \"JASPAR 2022: the 9th release of the open-access database of transcription factor binding profiles\" published in Nucleic Acids Research in 2022.\nHere is the full list of releases of JASPAR database, based on the information provided:\n1. JASPAR 2022\nNote: The JASPAR database is updated regularly, so there may be additional releases beyond what is listed here.",
    "llama-2-7b-chat-hf_fact_raw": "1. JASPAR 2022 is the 9th release of the JASPAR database.\n2. The release of JASPAR 2022 was mentioned in an article published in Nucleic Acids Research in 2022.\n3. The JASPAR database is an open-access database of transcription factor binding profiles.\n4. The JASPAR database is updated regularly.",
    "llama-2-7b-chat-hf_fact": [
      "JASPAR 2022 is the 9th release of the JASPAR database.",
      "The release of JASPAR 2022 was mentioned in an article published in Nucleic Acids Research in 2022.",
      "The JASPAR database is an open-access database of transcription factor binding profiles.",
      "The JASPAR database is updated regularly."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 99,
    "user_query": "What is the function of the viral KP4 protein?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the function of the viral KP4 protein is likely related to the life cycle of the fungus Ustilago maydis, specifically during the dikaryon formation and development phase. As the document states, dikaryon formation and development are restricted to host (maize) tissue, indicating that the KP4 protein plays a role in the interaction between the fungus and its host plant.\nThe KP4 protein is a viral protein that has been shown to be involved in the infection and multiplication of Ustilago maydis within its host plant. Studies have shown that the KP4 protein is required for the formation of dikaryons, which are the infective stages of the fungus that are capable of producing spores and infecting new hosts.\nTherefore, the function of the KP4 protein is likely to be involved in the process of dikaryon formation and development, which is a critical stage in the life cycle of Ustilago maydis.",
    "llama-2-7b-chat-hf_fact_raw": "1. The KP4 protein is related to the life cycle of the fungus Ustilago maydis.\n2. The KP4 protein plays a role during the dikaryon formation and development phase of Ustilago maydis.\n3. Dikaryon formation and development in Ustilago maydis are restricted to host (maize) tissue.\n4. The KP4 protein is involved in the infection and multiplication of Ustilago maydis within its host plant.\n5. The KP4 protein is required for the formation of dikaryons in Ustilago maydis.",
    "llama-2-7b-chat-hf_fact": [
      "The KP4 protein is related to the life cycle of the fungus Ustilago maydis.",
      "The KP4 protein plays a role during the dikaryon formation and development phase of Ustilago maydis.",
      "Dikaryon formation and development in Ustilago maydis are restricted to host (maize) tissue.",
      "The KP4 protein is involved in the infection and multiplication of Ustilago maydis within its host plant.",
      "The KP4 protein is required for the formation of dikaryons in Ustilago maydis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The KP4 protein is not involved in the infection and multiplication of Ustilago maydis within its host plant; it is a viral protein that inhibits fungal growth and protects plants against fungal pathogens.\n5. FALSE [correction]: The KP4 protein is not required for the formation of dikaryons in Ustilago maydis; it is a toxin produced by Ustilago maydis that has antifungal activity.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 124,
    "user_query": "Is DITPA a thyroid hormone analog utilized in experimental and clinical studies",
    "llama-2-7b-chat-hf_response": "Yes, DITPA (3,5-diiodothyropropionic acid) is a thyroid hormone analog that has been utilized in both experimental and clinical studies. The document you provided mentions that DITPA was identified as an analogue with inotropic selectivity and low metabolic activity in hypothyroid rats, suggesting that it may have potential as a therapeutic agent for treating hypothyroidism.\nIn addition, DITPA has been studied in various experimental models of thyroid hormone deficiency, including hypothyroid rats and mice. These studies have shown that DITPA can restore normal thyroid hormone levels and improve cardiovascular function in these animals, suggesting that it may have potential as a treatment for hypothyroidism in humans.\nHowever, it is important to note that DITPA is still a relatively new compound, and more research is needed to fully understand its mechanisms of action and potential side effects in humans. Therefore, while DITPA shows promise as a thyroid hormone analog, further clinical trials are needed to determine its safety and efficacy in humans.",
    "llama-2-7b-chat-hf_fact_raw": "1. DITPA (3,5-diiodothyropropionic acid) is a thyroid hormone analog.\n2. DITPA has been used in both experimental and clinical studies.\n3. DITPA was identified as having inotropic selectivity and low metabolic activity in hypothyroid rats.\n4. Studies have shown that DITPA can restore normal thyroid hormone levels and improve cardiovascular function in hypothyroid rats and mice.\n5. DITPA is considered a new compound and requires more research to fully understand its mechanisms of action and potential side effects in humans.",
    "llama-2-7b-chat-hf_fact": [
      "DITPA (3,5-diiodothyropropionic acid) is a thyroid hormone analog.",
      "DITPA has been used in both experimental and clinical studies.",
      "DITPA was identified as having inotropic selectivity and low metabolic activity in hypothyroid rats.",
      "Studies have shown that DITPA can restore normal thyroid hormone levels and improve cardiovascular function in hypothyroid rats and mice.",
      "DITPA is considered a new compound and requires more research to fully understand its mechanisms of action and potential side effects in humans."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nThe first four statements are consistent with what is known about DITPA as a thyroid hormone analog that has been used in research settings, including its effects on cardiovascular function in animal models. The fifth statement is vague without specific information on the current status of research and development of DITPA, including how \"new\" it is considered to be and the extent of existing research on its mechanisms and side effects in humans.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 144,
    "user_query": "What is the COUGER tool?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the COUGER tool appears to be a framework or methodology for conducting course-level assessments. COUGER is an acronym that stands for:\nC - Content: This refers to the knowledge and skills that students should have acquired by the end of the course.\nO - Objectives: This refers to the specific learning outcomes or goals that the course is designed to achieve.\nU - Understanding: This refers to the students' ability to apply and integrate the knowledge and skills they have acquired throughout the course.\nG - Gaps: This refers to any areas where the course may be falling short in terms of achieving its learning objectives.\nE - Evidence: This refers to the methods and tools used to collect data and evaluate student learning.\nR - Refine: This refers to the process of using the information gathered through assessment to improve and refine the course.\nBy using the COUGER tool, educators can systematically evaluate the fit between the course activities and what students should know at the end of the course, and make adjustments as needed to improve student learning outcomes.",
    "llama-2-7b-chat-hf_fact_raw": "1. COUGER is an acronym used in the context of course-level assessments.\n2. The \"C\" in COUGER stands for Content, referring to the knowledge and skills students should acquire by the end of a course.\n3. The \"O\" in COUGER represents Objectives, which are the specific learning outcomes or goals of a course.\n4. The \"U\" in COUGER signifies Understanding, which is the students' ability to apply and integrate acquired knowledge and skills.\n5. The \"R\" in COUGER stands for Refine, which is the process of improving and refining a course based on assessment information.",
    "llama-2-7b-chat-hf_fact": [
      "COUGER is an acronym used in the context of course-level assessments.",
      "The \"C\" in COUGER stands for Content, referring to the knowledge and skills students should acquire by the end of a course.",
      "The \"O\" in COUGER represents Objectives, which are the specific learning outcomes or goals of a course.",
      "The \"U\" in COUGER signifies Understanding, which is the students' ability to apply and integrate acquired knowledge and skills.",
      "The \"R\" in COUGER stands for Refine, which is the process of improving and refining a course based on assessment information."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe acronym COUGER is not a widely recognized or standard acronym in the context of course-level assessments, and without additional context, it is not possible to verify the meanings of the letters or the validity of the statements provided. Therefore, the truthfulness of these statements cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 145,
    "user_query": "Are there drugs for Tick-borne Encephalitis?",
    "llama-2-7b-chat-hf_response": "Yes, there are drugs available to treat tick-borne encephalitis (TBE). The most commonly used drugs for TBE treatment are:\n1. Ribavirin: This drug is an antiviral medication that has been shown to be effective in treating TBE. It works by reducing the replication of the virus in the body.\n2. Atovaquone and azithromycin: This combination of drugs has been shown to be effective in treating TBE. Atovaquone is an antiviral medication that works by inhibiting the replication of the virus, while azithromycin is an antibiotic that helps to reduce inflammation in the body.\n3. Doxycycline: This antibiotic is often used to treat TBE, as it can help to reduce the inflammation caused by the virus.\nIt's important to note that the choice of drug and the effectiveness of treatment may vary depending on the severity and location of the infection, as well as the individual patient's medical history and other factors. Therefore, it's important to consult with a healthcare professional for proper diagnosis and treatment.\nIn addition to these drugs, there are also some experimental treatments being studied for TBE, including:\n1. Immunoglobulins: These are antibodies that are given intravenously to help boost the body's immune system and fight off the virus.\n2. Interferons: These are proteins that are given to help stimulate the body's immune system and reduce the replication of the virus.\n3. Flavivirus inhibitors: These are drugs that are being developed to specifically target the Flavivirus family of viruses, including TBE.\nIt's important to note that these experimental treatments are still in the early stages of development and have not yet been widely tested for safety and effectiveness. Therefore, they may not be available or recommended for all patients with TBE.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ribavirin is an antiviral medication used to treat tick-borne encephalitis (TBE).\n2. A combination of atovaquone and azithromycin has been shown to be effective in treating TBE.\n3. Doxycycline, an antibiotic, is often used to treat TBE to reduce inflammation caused by the virus.\n4. Immunoglobulins are antibodies given intravenously as an experimental treatment for TBE to boost the immune system.\n5. Interferons are proteins used in experimental treatments for TBE to stimulate the immune system and reduce virus replication.",
    "llama-2-7b-chat-hf_fact": [
      "Ribavirin is an antiviral medication used to treat tick-borne encephalitis (TBE).",
      "A combination of atovaquone and azithromycin has been shown to be effective in treating TBE.",
      "Doxycycline, an antibiotic, is often used to treat TBE to reduce inflammation caused by the virus.",
      "Immunoglobulins are antibodies given intravenously as an experimental treatment for TBE to boost the immune system.",
      "Interferons are proteins used in experimental treatments for TBE to stimulate the immune system and reduce virus replication."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Ribavirin is an antiviral medication, but it is not typically used to treat tick-borne encephalitis (TBE). It is more commonly used for hepatitis C and some viral hemorrhagic fevers.\n2. FALSE [correction]: Atovaquone and azithromycin are used to treat babesiosis, not tick-borne encephalitis (TBE).\n3. FALSE [correction]: Doxycycline is an antibiotic used to treat bacterial infections, such as Lyme disease, which is also transmitted by ticks, but it is not used to treat TBE, which is caused by a virus.\n4. TRUE: Immunoglobulins, specifically intravenous immunoglobulins (IVIG), may be used as a treatment for TBE in some cases, although this is considered an experimental approach.\n5. TRUE: Interferons, particularly interferon-alpha, have been studied as an experimental treatment for TBE to enhance the immune response and inhibit viral replication.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 151,
    "user_query": "Which genome browser database for DNA shape annotations is available?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the genome browser database for DNA shape annotations that is available is GBshape. According to Document 0, GBshape can be used to visualize DNA shape annotations qualitatively in a genome browser track format, and to download quantitative values of DNA shape features as a function of genomic position at nucleotide resolution. This suggests that GBshape is a comprehensive and user-friendly database for exploring and analyzing DNA shape annotations in a genome browser context.",
    "llama-2-7b-chat-hf_fact_raw": "1. GBshape is a genome browser database for DNA shape annotations.\n2. GBshape allows visualization of DNA shape annotations in a genome browser track format.\n3. GBshape provides the ability to download quantitative values of DNA shape features.\n4. DNA shape features in GBshape are available at nucleotide resolution.",
    "llama-2-7b-chat-hf_fact": [
      "GBshape is a genome browser database for DNA shape annotations.",
      "GBshape allows visualization of DNA shape annotations in a genome browser track format.",
      "GBshape provides the ability to download quantitative values of DNA shape features.",
      "DNA shape features in GBshape are available at nucleotide resolution."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n\nWithout specific information about the database \"GBshape,\" it is not possible to verify these statements as true or false. If \"GBshape\" is a hypothetical or proprietary database not publicly documented, the details provided cannot be confirmed.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 174,
    "user_query": "Which syndromes are associated with mutations in the EZH2 gene?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, mutations in the EZH2 gene have been associated with several myeloid neoplasms, including:\n1. Myelodysplastic syndrome (MDS): MDS is a group of disorders characterized by ineffective hematopoiesis and a high risk of developing acute myeloid leukemia (AML). Mutations in the EZH2 gene have been identified in a significant proportion of MDS cases.\n2. Myeloproliferative neoplasms (MPNs): MPNs are a group of disorders characterized by overproduction of one or more lineages of blood cells. Mutations in the EZH2 gene have been identified in some MPNs, including polycythemia vera, essential thrombocythemia, and primary myelofibrosis.\nIt is important to note that the frequency and distribution of EZH2 mutations may vary across different MDS/MPN overlap syndromes. Therefore, it is essential to perform targeted sequencing to identify specific genetic alterations in each patient's case.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutations in the EZH2 gene have been associated with myelodysplastic syndrome (MDS).\n2. Myelodysplastic syndrome is characterized by ineffective hematopoiesis and a high risk of developing acute myeloid leukemia (AML).\n3. Mutations in the EZH2 gene have been identified in a significant proportion of MDS cases.\n4. Myeloproliferative neoplasms (MPNs) are characterized by the overproduction of one or more blood cell lineages.\n5. Mutations in the EZH2 gene have been identified in some cases of myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia, and primary myelofibrosis.",
    "llama-2-7b-chat-hf_fact": [
      "Mutations in the EZH2 gene have been associated with myelodysplastic syndrome (MDS).",
      "Myelodysplastic syndrome is characterized by ineffective hematopoiesis and a high risk of developing acute myeloid leukemia (AML).",
      "Mutations in the EZH2 gene have been identified in a significant proportion of MDS cases.",
      "Myeloproliferative neoplasms (MPNs) are characterized by the overproduction of one or more blood cell lineages.",
      "Mutations in the EZH2 gene have been identified in some cases of myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia, and primary myelofibrosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 193,
    "user_query": "List human proteins that are subject to a dimer-to-tetramer transition.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the following human proteins are known to undergo a dimer-to-tetramer transition:\n1. Synaptotagmin: This protein is involved in the release of neurotransmitters from synapses and has been shown to undergo a dimer-to-tetramer transition.\n2. Inflammatory response proteins (IRPs): IRPs are involved in the regulation of inflammation and have been shown to undergo a dimer-to-tetramer transition.\n3. Calcium-binding proteins: Calcium-binding proteins are involved in a variety of cellular processes, including muscle contraction, neurotransmission, and cell signaling. Some of these proteins, such as troponin and actin, have been shown to undergo a dimer-to-tetramer transition.\n4. G-protein-coupled receptors (GPCRs): GPCRs are involved in a variety of cellular processes, including signal transduction and regulation of gene expression. Some GPCRs, such as the β-adrenergic receptor, have been shown to undergo a dimer-to-tetramer transition.\n5. Signal transducer and activator of transcription 3 (STAT3): STAT3 is involved in the regulation of gene expression and cellular signaling. It has been shown to undergo a dimer-to-tetramer transition in response to certain stimuli.\nIt is important to note that this list is not exhaustive and there may be other human proteins that undergo a dimer-to-tetramer transition. Further research and experimental validation are needed to confirm the existence of these transitions and to fully understand their functional implications.",
    "llama-2-7b-chat-hf_fact_raw": "1. Synaptotagmin undergoes a dimer-to-tetramer transition and is involved in neurotransmitter release at synapses.\n2. Inflammatory response proteins (IRPs) undergo a dimer-to-tetramer transition and are involved in regulating inflammation.\n3. Some calcium-binding proteins, such as troponin and actin, undergo a dimer-to-tetramer transition and are involved in cellular processes like muscle contraction and neurotransmission.\n4. Certain G-protein-coupled receptors (GPCRs), including the β-adrenergic receptor, undergo a dimer-to-tetramer transition and are involved in signal transduction and gene expression regulation.\n5. Signal transducer and activator of transcription 3 (STAT3) undergoes a dimer-to-tetramer transition in response to certain stimuli and is involved in gene expression regulation and cellular signaling.",
    "llama-2-7b-chat-hf_fact": [
      "Synaptotagmin undergoes a dimer-to-tetramer transition and is involved in neurotransmitter release at synapses.",
      "Inflammatory response proteins (IRPs) undergo a dimer-to-tetramer transition and are involved in regulating inflammation.",
      "Some calcium-binding proteins, such as troponin and actin, undergo a dimer-to-tetramer transition and are involved in cellular processes like muscle contraction and neurotransmission.",
      "Certain G-protein-coupled receptors (GPCRs), including the β-adrenergic receptor, undergo a dimer-to-tetramer transition and are involved in signal transduction and gene expression regulation.",
      "Signal transducer and activator of transcription 3 (STAT3) undergoes a dimer-to-tetramer transition in response to certain stimuli and is involved in gene expression regulation and cellular signaling."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Synaptotagmin does not undergo a dimer-to-tetramer transition; it acts as a calcium sensor and is involved in triggering neurotransmitter release at synapses, but it functions as a monomer or possibly forms dimers.\n2. UNKNOWN: The term \"Inflammatory response proteins (IRPs)\" is not specific to a particular set of proteins, and without more context, it is not possible to determine the accuracy of the statement regarding their oligomerization state or function.\n3. FALSE [correction]: Troponin and actin are indeed involved in muscle contraction, but they do not undergo a dimer-to-tetramer transition as described. Troponin is a complex of three proteins that binds to actin, which exists as a filamentous polymer, not as a dimer or tetramer.\n4. UNKNOWN: While G-protein-coupled receptors (GPCRs), including the β-adrenergic receptor, can form dimers, the statement about a dimer-to-tetramer transition is not well-established in the literature, and the oligomerization state of GPCRs can be complex and context-dependent.\n5. TRUE: Signal transducer and activator of transcription 3 (STAT3) can undergo dimerization in response to certain stimuli, such as cytokine signaling, and is involved in gene expression regulation and cellular signaling. However, the statement about a dimer-to-tetramer transition is not commonly described; STAT3 primarily functions as a dimer when activated.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 210,
    "user_query": "Which protein has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the protein that has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein is likely to be Bcl-2.\nBcl-2 is a protein that has been shown to interact with PLN and inhibit apoptosis (programmed cell death). Bcl-2 is a member of the Bcl-2 family of proteins, which play a crucial role in regulating mitochondrial outer membrane permeabilization (MOMP) and apoptosis. MOMP is a critical step in the execution of apoptosis, and Bcl-2 has been shown to inhibit MOMP by binding to and neutralizing pro-apoptotic Bcl-2 family members.\nStudies have shown that PLN can bind to Bcl-2 and inhibit its pro-apoptotic activity [1,2]. This suggests that PLN may play a role in regulating Bcl-2-mediated apoptosis, and that PLN and Bcl-2 may interact to modulate the balance between pro- and anti-apoptotic signals in cells.\nIn addition, Bcl-2 has been shown to be an anti-apoptotic protein that can inhibit apoptosis by interacting with and neutralizing pro-apoptotic Bcl-2 family members [3,4]. This is consistent with the idea that Bcl-2 is an anti-apoptotic protein that can interact with PLN to inhibit apoptosis.\nIn conclusion, based on the information provided, it is likely that Bcl-2 is the protein that has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein.\nReferences:\n[1] Kim J, et al. (2013). Phospholamban inhibits Bcl-2-mediated apoptosis by binding to Bcl-2 and preventing its interaction with pro-apoptotic Bcl-2 family members. Biochim Biophys Acta, 1833(11), 2070-2078.\n[2] Liu Y, et al. (2015). Phospholamban regulates Bcl-2-medi",
    "llama-2-7b-chat-hf_fact_raw": "1. Bcl-2 is a protein that interacts with phospholamban (PLN).\n2. Bcl-2 inhibits apoptosis, which is programmed cell death.\n3. Bcl-2 is a member of the Bcl-2 family of proteins, which are involved in regulating mitochondrial outer membrane permeabilization (MOMP) and apoptosis.\n4. Phospholamban (PLN) can bind to Bcl-2 and inhibit its pro-apoptotic activity.\n5. Bcl-2 can inhibit apoptosis by interacting with and neutralizing pro-apoptotic Bcl-2 family members.",
    "llama-2-7b-chat-hf_fact": [
      "Bcl-2 is a protein that interacts with phospholamban (PLN).",
      "Bcl-2 inhibits apoptosis, which is programmed cell death.",
      "Bcl-2 is a member of the Bcl-2 family of proteins, which are involved in regulating mitochondrial outer membrane permeabilization (MOMP) and apoptosis.",
      "Phospholamban (PLN) can bind to Bcl-2 and inhibit its pro-apoptotic activity.",
      "Bcl-2 can inhibit apoptosis by interacting with and neutralizing pro-apoptotic Bcl-2 family members."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Phospholamban (PLN) is involved in regulating calcium uptake into the sarcoplasmic reticulum in cardiac muscle cells and is not known to bind to Bcl-2 or inhibit its activity.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 218,
    "user_query": "Has vitamin D has been shown to reduce incidence of falls in older people in clinical trials?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, there is no conclusive evidence to suggest that taking vitamin D supplements reduces the incidence of falls in most community-dwelling older people. The document states that \"taking vitamin D supplements does not appear to reduce falls in most community-dwelling older people.\" However, it does suggest that vitamin D supplements may be effective in reducing falls in certain populations, such as those who are at higher risk of falling or when carried out by occupational therapists. Therefore, while there is no definitive answer to the user's question based on the provided information, there is some suggestion that vitamin D supplements may be beneficial in certain contexts.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is no conclusive evidence that taking vitamin D supplements reduces the incidence of falls in most community-dwelling older people.\n2. Vitamin D supplements may be effective in reducing falls in certain populations at higher risk of falling.\n3. The effectiveness of vitamin D supplements in reducing falls may be context-dependent, such as when used by occupational therapists.",
    "llama-2-7b-chat-hf_fact": [
      "There is no conclusive evidence that taking vitamin D supplements reduces the incidence of falls in most community-dwelling older people.",
      "Vitamin D supplements may be effective in reducing falls in certain populations at higher risk of falling.",
      "The effectiveness of vitamin D supplements in reducing falls may be context-dependent, such as when used by occupational therapists."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 222,
    "user_query": "Is there any association between Jarid2 and miR-155 in Th17 cells?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there is some evidence to suggest an association between Jarid2 and miR-155 in Th17 cells.\nIn Document 0, Stanczyk et al. reported that the expression levels of miR-155 and miR-146 are increased in synovial fibroblasts from patients with rheumatoid arthritis (RA) compared to those from osteoarthritis patients. This suggests that miR-155 and miR-146 may play a role in the pathogenesis of RA.\nJarid2 is a histone methyltransferase that has been shown to be involved in the regulation of miRNA expression. In particular, Jarid2 has been shown to methylate the histone H3 lysine 4 (H3K4) residue, which is a mark of active gene transcription.\nStudies have shown that miR-155 is a target of Jarid2-mediated methylation in certain cell types. For example, one study found that Jarid2 methylates the 3' untranslated region (UTR) of miR-155 in breast cancer cells, leading to its downregulation (1). Another study found that Jarid2 methylation of miR-155 is required for the maintenance of stem cell self-renewal in hematopoietic cells (2).\nGiven the increased expression of miR-155 in synovial fibroblasts from RA patients reported in Document 0, it is possible that Jarid2 may play a role in regulating miR-155 expression in these cells. However, further research is needed to confirm this association and to determine the specific mechanisms by which Jarid2 regulates miR-155 expression in Th17 cells.\nIn summary, while there is no direct evidence provided in the given information to suggest an association between Jarid2 and miR-155 in Th17 cells, the available data suggest that Jarid2 may play a role in regulating miR-155 expression in certain cell types, including synovial fibroblasts from RA patients. Further research is needed to confirm this association and to elucidate the underlying",
    "llama-2-7b-chat-hf_fact_raw": "1. Stanczyk et al. reported increased expression levels of miR-155 and miR-146 in synovial fibroblasts from patients with rheumatoid arthritis compared to those from osteoarthritis patients.\n2. Jarid2 is a histone methyltransferase involved in the regulation of miRNA expression.\n3. Jarid2 has been shown to methylate the histone H3 lysine 4 (H3K4) residue.\n4. Studies have indicated that miR-155 is a target of Jarid2-mediated methylation in certain cell types.\n5. Jarid2 methylation of miR-155 has been linked to the maintenance of stem cell self-renewal in hematopoietic cells.",
    "llama-2-7b-chat-hf_fact": [
      "Stanczyk et al. reported increased expression levels of miR-155 and miR-146 in synovial fibroblasts from patients with rheumatoid arthritis compared to those from osteoarthritis patients.",
      "Jarid2 is a histone methyltransferase involved in the regulation of miRNA expression.",
      "Jarid2 has been shown to methylate the histone H3 lysine 4 (H3K4) residue.",
      "Studies have indicated that miR-155 is a target of Jarid2-mediated methylation in certain cell types.",
      "Jarid2 methylation of miR-155 has been linked to the maintenance of stem cell self-renewal in hematopoietic cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Jarid2 is not a histone methyltransferase; it is a member of the Polycomb group (PcG) proteins and is involved in the regulation of gene expression, but it does not have methyltransferase activity itself.\n3. FALSE [correction]: Jarid2 does not methylate histones; it is associated with the Polycomb repressive complex 2 (PRC2) which can methylate histone H3 on lysine 27 (H3K27), not lysine 4 (H3K4).\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 224,
    "user_query": "How many genes does the human hoxD cluster contain?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the human HoxD cluster contains 9 genes.",
    "llama-2-7b-chat-hf_fact_raw": "1. The human HoxD cluster contains 9 genes.",
    "llama-2-7b-chat-hf_fact": [
      "The human HoxD cluster contains 9 genes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The human HoxD cluster contains 9-11 genes, depending on the source and classification, but it is commonly accepted to have 9 major genes (HOXD1 to HOXD13, with some numbers skipped due to historical naming conventions).",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 268,
    "user_query": "List phosphorylation consensus motifs for Casein Kinase 1 (CK1)?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the consensus phosphorylation motifs for Casein Kinase 1 (CK1) are:\nType I CK1α sites:\n* D/E n XXS/T\nType II sites:\n* S/T(P)X n S/T\nWhere \"n\" represents any nucleotide, and \"S\" and \"T\" represent serine and threonine residues, respectively. The underlined serine or threonine residues are the potential phosphorylation sites.",
    "llama-2-7b-chat-hf_fact_raw": "1. Type I CK1α consensus phosphorylation motif is D/E n XXS/T.\n2. Type II consensus phosphorylation motif is S/T(P)X n S/T.\n3. In the motifs, \"n\" represents any nucleotide.\n4. \"S\" and \"T\" in the motifs represent serine and threonine residues, respectively.\n5. The underlined serine or threonine residues in the motifs are the potential phosphorylation sites.",
    "llama-2-7b-chat-hf_fact": [
      "Type I CK1α consensus phosphorylation motif is D/E n XXS/T.",
      "Type II consensus phosphorylation motif is S/T(P)X n S/T.",
      "In the motifs, \"n\" represents any nucleotide.",
      "\"S\" and \"T\" in the motifs represent serine and threonine residues, respectively.",
      "The underlined serine or threonine residues in the motifs are the potential phosphorylation sites."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: In the motifs, \"n\" represents any amino acid, not any nucleotide.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 305,
    "user_query": "Which are the different proteins/isoforms encoded but the ASPH (aspartate beta-hydroxylase) gene in humans?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the different proteins/isoforms encoded by the ASPH (aspartate beta-hydroxylase) gene in humans are:\n1. Aspartyl (asparaginyl)-beta-hydroxylase (HAAH): This is the primary isoform encoded by the ASPH gene, and it is expressed in an enzymatically active form in certain tumor lines.\n2. Deduced 744-amino acid polypeptide: This is the full-length protein encoded by the ASPH gene, which shares high homology (81%) with the bovine gene.\nIt is important to note that the exact number and types of proteins/isoforms encoded by the ASPH gene may vary depending on the specific cell type, tissue, or disease state.",
    "llama-2-7b-chat-hf_fact_raw": "1. The ASPH gene encodes the aspartyl (asparaginyl)-beta-hydroxylase (HAAH) isoform.\n2. The aspartyl (asparaginyl)-beta-hydroxylase (HAAH) isoform is expressed in an enzymatically active form in certain tumor lines.\n3. The ASPH gene encodes a deduced 744-amino acid polypeptide.\n4. The deduced 744-amino acid polypeptide shares 81% homology with the bovine gene.\n5. The number and types of proteins/isoforms encoded by the ASPH gene can vary depending on the cell type, tissue, or disease state.",
    "llama-2-7b-chat-hf_fact": [
      "The ASPH gene encodes the aspartyl (asparaginyl)-beta-hydroxylase (HAAH) isoform.",
      "The aspartyl (asparaginyl)-beta-hydroxylase (HAAH) isoform is expressed in an enzymatically active form in certain tumor lines.",
      "The ASPH gene encodes a deduced 744-amino acid polypeptide.",
      "The deduced 744-amino acid polypeptide shares 81% homology with the bovine gene.",
      "The number and types of proteins/isoforms encoded by the ASPH gene can vary depending on the cell type, tissue, or disease state."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The ASPH gene encodes a deduced 758-amino acid polypeptide, not 744.\n4. UNKNOWN (The percentage of homology with the bovine gene would require specific scientific data which is not provided here.)\n5. TRUE (It is common for genes to encode different isoforms of a protein that can vary depending on the cell type, tissue, or disease state, although specific information about the ASPH gene would be needed to confirm this statement.)",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 330,
    "user_query": "When was empagliflozin FDA approved?",
    "llama-2-7b-chat-hf_response": "Thank you for asking! Based on the information provided, empagliflozin, marketed as Jardiance, was initially approved by the FDA in 2014 for glucose control among patients with type 2 diabetes.",
    "llama-2-7b-chat-hf_fact_raw": "1. Empagliflozin is marketed under the name Jardiance.\n2. Empagliflozin was approved by the FDA in 2014.\n3. The FDA approved empagliflozin for glucose control in patients with type 2 diabetes.",
    "llama-2-7b-chat-hf_fact": [
      "Empagliflozin is marketed under the name Jardiance.",
      "Empagliflozin was approved by the FDA in 2014.",
      "The FDA approved empagliflozin for glucose control in patients with type 2 diabetes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 350,
    "user_query": "What are the results of loss of the protein Lon1 in the plant Arabidopsis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the loss of the protein Lon1 in the plant Arabidopsis leads to changes in the degradation rates of various mitochondrial proteins. The study found that 140 proteins exhibited higher degradation rates in the Lon1-deficient mutant (lon1-1) compared to the wild type, while another 65 proteins were less degraded in the lon1-1 mutant.\nIt is likely that the loss of Lon1 in Arabidopsis leads to an imbalance in the degradation of mitochondrial proteins, resulting in changes in the levels of these proteins and potentially affecting various cellular processes. The specific consequences of Lon1 loss may depend on the particular proteins that are affected, as well as the overall cellular environment.\nSome possible consequences of Lon1 loss in Arabidopsis include:\n1. Impaired mitochondrial function: The loss of Lon1 may lead to changes in the levels of proteins involved in mitochondrial function, such as enzymes involved in energy production, transport, and regulation. This could result in impaired mitochondrial function, which could have downstream effects on cellular metabolism and energy production.\n2. Disrupted cellular signaling pathways: Lon1 is involved in the regulation of protein degradation, which can also affect signaling pathways that rely on specific protein levels or activities. Disruption of these pathways could lead to changes in cellular behavior and physiology.\n3. Increased oxidative stress: The loss of Lon1 may lead to changes in the levels of proteins involved in antioxidant defense, which could result in increased oxidative stress and damage to cellular components.\n4. Altered plant growth and development: The changes in mitochondrial protein levels and function could have downstream effects on plant growth and development, such as altered leaf morphology, reduced plant height, or changes in flowering time.\nOverall, the loss of Lon1 in Arabidopsis is likely to have significant effects on cellular processes, including mitochondrial function, protein degradation, and cellular signaling pathways. Further research is needed to fully understand the consequences of Lon1 loss in this",
    "llama-2-7b-chat-hf_fact_raw": "1. The loss of the protein Lon1 in Arabidopsis leads to changes in the degradation rates of various mitochondrial proteins.\n2. In the Lon1-deficient mutant (lon1-1) of Arabidopsis, 140 proteins exhibited higher degradation rates compared to the wild type.\n3. Another 65 proteins were less degraded in the lon1-1 mutant compared to the wild type.\n4. The loss of Lon1 in Arabidopsis may lead to impaired mitochondrial function.\n5. The loss of Lon1 in Arabidopsis could result in increased oxidative stress.",
    "llama-2-7b-chat-hf_fact": [
      "The loss of the protein Lon1 in Arabidopsis leads to changes in the degradation rates of various mitochondrial proteins.",
      "In the Lon1-deficient mutant (lon1-1) of Arabidopsis, 140 proteins exhibited higher degradation rates compared to the wild type.",
      "Another 65 proteins were less degraded in the lon1-1 mutant compared to the wild type.",
      "The loss of Lon1 in Arabidopsis may lead to impaired mitochondrial function.",
      "The loss of Lon1 in Arabidopsis could result in increased oxidative stress."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: In the Lon1-deficient mutant (lon1-1) of Arabidopsis, 140 proteins exhibited lower degradation rates compared to the wild type.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 409,
    "user_query": "Does a linker histone exist in the yeast genome?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, a linker histone does exist in the yeast genome. The passage states that one mechanism used by the cell to keep chromatin fluid is histone exchange, which involves the removal of parts of the nucleosome or the entire nucleosome, followed by replacement with either a linker histone or a new nucleosome. This suggests that a linker histone is present in the yeast genome and plays a role in maintaining the fluidity of chromatin.",
    "llama-2-7b-chat-hf_fact_raw": "1. A linker histone exists in the yeast genome.\n2. Histone exchange is a mechanism used by the cell to keep chromatin fluid.\n3. Histone exchange involves the removal of parts of the nucleosome or the entire nucleosome.\n4. Replacement in histone exchange can be with either a linker histone or a new nucleosome.\n5. The presence of a linker histone in the yeast genome plays a role in maintaining the fluidity of chromatin.",
    "llama-2-7b-chat-hf_fact": [
      "A linker histone exists in the yeast genome.",
      "Histone exchange is a mechanism used by the cell to keep chromatin fluid.",
      "Histone exchange involves the removal of parts of the nucleosome or the entire nucleosome.",
      "Replacement in histone exchange can be with either a linker histone or a new nucleosome.",
      "The presence of a linker histone in the yeast genome plays a role in maintaining the fluidity of chromatin."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Yeast genomes typically do not contain linker histones. Instead, they have non-histone proteins that fulfill similar roles.\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Since yeast genomes do not typically contain linker histones, they do not play a role in maintaining the fluidity of chromatin in yeast. Non-histone proteins are involved in this process in yeast.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 418,
    "user_query": "Is there evidence that tomato juice lowers cholesterol levels?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there is some evidence to suggest that tomato juice may help lower cholesterol levels. A study conducted by Jacob et al. found that consuming tomato juice (500 mL) for 2 weeks reduced total cholesterol and CRP (C-reactive protein) levels, which is a marker of inflammation. The effect was stronger when vitamin C was also consumed.\nWhile the study did not specifically investigate the effect of tomato juice on cancer prevention, the finding that it may help lower cholesterol levels suggests that it may have potential health benefits beyond cancer prevention. However, it is important to note that this study had a small sample size and further research is needed to confirm these findings and establish a clear cause-and-effect relationship between tomato juice consumption and cholesterol lowering.\nIn summary, while there is some evidence to suggest that tomato juice may help lower cholesterol levels, more research is needed to fully understand its potential health benefits and how it may interact with other nutrients and factors. As with any dietary intervention, it is important to consult with a healthcare professional before making significant changes to your diet.",
    "llama-2-7b-chat-hf_fact_raw": "1. A study by Jacob et al. found that consuming 500 mL of tomato juice for 2 weeks reduced total cholesterol levels.\n2. The same study by Jacob et al. indicated that consuming tomato juice also reduced CRP (C-reactive protein) levels.\n3. The cholesterol-lowering effect of tomato juice was stronger when vitamin C was also consumed, according to the study mentioned.\n4. The study mentioned had a small sample size.\n5. Further research is needed to confirm the findings of the study regarding tomato juice and cholesterol lowering.",
    "llama-2-7b-chat-hf_fact": [
      "A study by Jacob et al. found that consuming 500 mL of tomato juice for 2 weeks reduced total cholesterol levels.",
      "The same study by Jacob et al. indicated that consuming tomato juice also reduced CRP (C-reactive protein) levels.",
      "The cholesterol-lowering effect of tomato juice was stronger when vitamin C was also consumed, according to the study mentioned.",
      "The study mentioned had a small sample size.",
      "Further research is needed to confirm the findings of the study regarding tomato juice and cholesterol lowering."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE\n\nWithout access to the specific study by Jacob et al., it is not possible to verify the details of the findings regarding tomato juice and cholesterol or CRP levels, or whether the effect was stronger with vitamin C consumption. The statement about the sample size is also not verifiable without more information. However, it is a common conclusion in scientific research to state that further research is needed to confirm findings, so that statement is generally true.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 472,
    "user_query": "How do Hsp70 and Hsp110 affect mRNA stability?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, Hsp70 and Hsp110 are heat shock proteins that play a crucial role in maintaining mRNA stability in response to cellular stress. The abstract states that abnormal environmental and physiological conditions can damage protein structures, leading to a toxic state in the cell due to loss of protein function and homeostasis.\nHsp70 and Hsp110 are involved in the folding and stabilization of mRNA, which is essential for its translation into proteins. When the cell experiences stress, these proteins help to protect mRNA from degradation, allowing it to maintain its stability and function. This is important for maintaining cellular homeostasis and preventing the accumulation of toxic proteins that can lead to cell death.\nIn summary, Hsp70 and Hsp110 play a critical role in maintaining mRNA stability by protecting it from degradation in response to cellular stress.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hsp70 and Hsp110 are heat shock proteins.\n2. Hsp70 and Hsp110 play a role in maintaining mRNA stability.\n3. These proteins are involved in the folding and stabilization of mRNA.\n4. Hsp70 and Hsp110 help protect mRNA from degradation during cellular stress.\n5. The function of Hsp70 and Hsp110 is important for maintaining cellular homeostasis.",
    "llama-2-7b-chat-hf_fact": [
      "Hsp70 and Hsp110 are heat shock proteins.",
      "Hsp70 and Hsp110 play a role in maintaining mRNA stability.",
      "These proteins are involved in the folding and stabilization of mRNA.",
      "Hsp70 and Hsp110 help protect mRNA from degradation during cellular stress.",
      "The function of Hsp70 and Hsp110 is important for maintaining cellular homeostasis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Hsp70 and Hsp110 are primarily known for their roles in protein folding and stabilization, not mRNA stability.\n3. FALSE [correction]: Hsp70 and Hsp110 are involved in the folding and stabilization of proteins, not mRNA.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 481,
    "user_query": "Which deiodinases are present in skeletal  muscle?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the two deiodinases present in skeletal muscle are:\n1. Type 1 deiodinase (D1)\n2. Type 2 deiodinase (D2)\nThese enzymes are responsible for activating T4 by removing an iodine atom from its outer or phenolic ring, converting it from an inactive prohormone to the active hormone T3.",
    "llama-2-7b-chat-hf_fact_raw": "1. Type 1 deiodinase (D1) is present in skeletal muscle.\n2. Type 2 deiodinase (D2) is present in skeletal muscle.\n3. These deiodinases activate T4 by removing an iodine atom from its outer or phenolic ring.\n4. The activation process converts T4 from an inactive prohormone to the active hormone T3.",
    "llama-2-7b-chat-hf_fact": [
      "Type 1 deiodinase (D1) is present in skeletal muscle.",
      "Type 2 deiodinase (D2) is present in skeletal muscle.",
      "These deiodinases activate T4 by removing an iodine atom from its outer or phenolic ring.",
      "The activation process converts T4 from an inactive prohormone to the active hormone T3."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Type 1 deiodinase (D1) is not highly expressed in skeletal muscle; it is primarily found in the liver and kidney.\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 534,
    "user_query": "List inflammatory caspase proteins?",
    "llama-2-7b-chat-hf_response": "Certainly! Based on the information provided, the inflammatory caspase proteins are:\n1. Caspase-1\n2. Caspase-4\n3. Caspase-5\nThese caspases are activated by the inflammasome, a cytoplasmic multiprotein complex, in response to pathogen- and/or damage-associated signals. Once activated, these caspases play a crucial role in the inflammatory response by cleaving and activating various downstream targets, including pro-inflammatory cytokines and cell death effectors.",
    "llama-2-7b-chat-hf_fact_raw": "1. Caspase-1 is an inflammatory caspase protein.\n2. Caspase-4 is an inflammatory caspase protein.\n3. Caspase-5 is an inflammatory caspase protein.\n4. Inflammatory caspases are activated by the inflammasome.\n5. Activated inflammatory caspases cleave and activate pro-inflammatory cytokines and cell death effectors.",
    "llama-2-7b-chat-hf_fact": [
      "Caspase-1 is an inflammatory caspase protein.",
      "Caspase-4 is an inflammatory caspase protein.",
      "Caspase-5 is an inflammatory caspase protein.",
      "Inflammatory caspases are activated by the inflammasome.",
      "Activated inflammatory caspases cleave and activate pro-inflammatory cytokines and cell death effectors."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 579,
    "user_query": "Is there any link between the aurora B kinase and the polycomb protein ring1B?",
    "llama-2-7b-chat-hf_response": "Yes, there is a link between Aurora B kinase and Polycomb protein Ring1B. Both proteins have been shown to play important roles in regulating chromosome segregation during mitosis.\nAurora B kinase is a key component of the chromosome passenger complex, which is responsible for the proper separation of chromosomes during cell division. Aurora B concentrates at the centromere and kinetochore regions early in mitosis, where it helps to establish and maintain the proper attachment of chromosomes to the spindle microtubules.\nPolycomb protein Ring1B, on the other hand, is a component of the Polycomb repressive complex 2 (PRC2), which is involved in the regulation of gene expression and chromatin modification. Ring1B has been shown to play a role in the deposition of histone 3 lysine 27 trimethylation (H3K27me3), a mark that is associated with gene silencing.\nRecent studies have suggested that Aurora B and Ring1B may interact and cooperate in the regulation of chromosome segregation. For example, one study found that Ring1B is required for the proper localization of Aurora B to the centromere and kinetochore regions during mitosis. Another study found that Aurora B and Ring1B cooperate in the regulation of H3K27me3 deposition and gene silencing during mitosis.\nOverall, while Aurora B and Ring1B have distinct functions in the cell, they have been shown to interact and cooperate in the regulation of chromosome segregation during mitosis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Aurora B kinase and Polycomb protein Ring1B play important roles in regulating chromosome segregation during mitosis.\n2. Aurora B kinase is a component of the chromosome passenger complex, which is responsible for the proper separation of chromosomes during cell division.\n3. Aurora B kinase concentrates at the centromere and kinetochore regions early in mitosis to help establish and maintain the proper attachment of chromosomes to the spindle microtubules.\n4. Polycomb protein Ring1B is a component of the Polycomb repressive complex 2 (PRC2), which is involved in the regulation of gene expression and chromatin modification.\n5. Ring1B is involved in the deposition of histone 3 lysine 27 trimethylation (H3K27me3), a mark associated with gene silencing.",
    "llama-2-7b-chat-hf_fact": [
      "Aurora B kinase and Polycomb protein Ring1B play important roles in regulating chromosome segregation during mitosis.",
      "Aurora B kinase is a component of the chromosome passenger complex, which is responsible for the proper separation of chromosomes during cell division.",
      "Aurora B kinase concentrates at the centromere and kinetochore regions early in mitosis to help establish and maintain the proper attachment of chromosomes to the spindle microtubules.",
      "Polycomb protein Ring1B is a component of the Polycomb repressive complex 2 (PRC2), which is involved in the regulation of gene expression and chromatin modification.",
      "Ring1B is involved in the deposition of histone 3 lysine 27 trimethylation (H3K27me3), a mark associated with gene silencing."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Polycomb protein Ring1B is a component of the Polycomb repressive complex 1 (PRC1), not PRC2, which is involved in the regulation of gene expression and chromatin modification.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 597,
    "user_query": "What are the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates are:\nDonor splice sites:\n1. GU-rich motifs: These are the most common non-canonical motifs found at donor splice sites in vertebrates. They are characterized by the presence of a GU-rich sequence followed by a conserved 5' G or A base.\n2. AG-rich motifs: These motifs are also common at donor splice sites and are characterized by the presence of an AG-rich sequence followed by a conserved 5' G or A base.\n3. G/C-rich motifs: These motifs are found in some vertebrate donor splice sites and are characterized by the presence of a G/C-rich sequence followed by a conserved 5' G or A base.\nAcceptor splice sites:\n1. GT-rich motifs: These are the most common non-canonical motifs found at acceptor splice sites in vertebrates. They are characterized by the presence of a GT-rich sequence followed by a conserved 3' G or C base.\n2. AG-rich motifs: These motifs are also common at acceptor splice sites and are characterized by the presence of an AG-rich sequence followed by a conserved 3' G or C base.\n3. G/C-rich motifs: These motifs are found in some vertebrate acceptor splice sites and are characterized by the presence of a G/C-rich sequence followed by a conserved 3' G or C base.\nIt is important to note that the frequency and distribution of these non-canonical motifs can vary depending on the species and tissue type, and that the presence of these motifs does not necessarily indicate the presence of a non-canonical splice site.",
    "llama-2-7b-chat-hf_fact_raw": "1. GU-rich motifs are the most common non-canonical motifs found at donor splice sites in vertebrates.\n2. AG-rich motifs are common at donor splice sites in vertebrates and are characterized by an AG-rich sequence followed by a conserved 5' G or A base.\n3. GT-rich motifs are the most common non-canonical motifs found at acceptor splice sites in vertebrates.\n4. AG-rich motifs at acceptor splice sites in vertebrates are characterized by an AG-rich sequence followed by a conserved 3' G or C base.\n5. The frequency and distribution of non-canonical motifs at splice sites can vary depending on the species and tissue type.",
    "llama-2-7b-chat-hf_fact": [
      "GU-rich motifs are the most common non-canonical motifs found at donor splice sites in vertebrates.",
      "AG-rich motifs are common at donor splice sites in vertebrates and are characterized by an AG-rich sequence followed by a conserved 5' G or A base.",
      "GT-rich motifs are the most common non-canonical motifs found at acceptor splice sites in vertebrates.",
      "AG-rich motifs at acceptor splice sites in vertebrates are characterized by an AG-rich sequence followed by a conserved 3' G or C base.",
      "The frequency and distribution of non-canonical motifs at splice sites can vary depending on the species and tissue type."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: GT-rich motifs, not GU-rich motifs, are the most common canonical motifs found at donor splice sites in vertebrates, characterized by the conserved sequence GT at the 5' end of introns.\n2. FALSE [correction]: AG-rich motifs are not common at donor splice sites; instead, the consensus sequence at the donor splice site is typically GT-rich. The AG-rich sequence is actually found at the 3' end of introns, at the acceptor splice site, and is characterized by a conserved AG at the end of the intron.\n3. FALSE [correction]: GT-rich motifs are the most common canonical motifs found at donor splice sites, not acceptor splice sites. The most common motif at acceptor splice sites is an AG-rich sequence.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 629,
    "user_query": "Which event results in the acetylation of S6K1?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the event that results in the acetylation of S6K1 is cellular stress. According to the passage, S6K1 is acetylated in response to cellular stress, which activates its ability to govern cell size by facilitating mRNA transcription, splicing, and protein synthesis. Additionally, S6K1 plays a pivotal role in directing cell apoptosis, metabolism, and feedback regulation, among other cellular processes.",
    "llama-2-7b-chat-hf_fact_raw": "1. S6K1 is acetylated in response to cellular stress.\n2. Acetylation of S6K1 activates its ability to govern cell size.\n3. S6K1 facilitates mRNA transcription, splicing, and protein synthesis.\n4. S6K1 plays a role in directing cell apoptosis.\n5. S6K1 is involved in cell metabolism and feedback regulation.",
    "llama-2-7b-chat-hf_fact": [
      "S6K1 is acetylated in response to cellular stress.",
      "Acetylation of S6K1 activates its ability to govern cell size.",
      "S6K1 facilitates mRNA transcription, splicing, and protein synthesis.",
      "S6K1 plays a role in directing cell apoptosis.",
      "S6K1 is involved in cell metabolism and feedback regulation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: S6K1 can be acetylated in response to cellular stress, which is a post-translational modification that can affect its function.\n2. UNKNOWN: The effect of acetylation on S6K1's activity towards cell size regulation is not specified and can vary depending on the context and the specific site of acetylation.\n3. TRUE: S6K1 is known to be involved in protein synthesis, and it can indirectly influence mRNA transcription and splicing through its role in signaling pathways that regulate these processes.\n4. TRUE: S6K1 can play a role in directing cell apoptosis, as it is involved in various signaling pathways that can promote or inhibit apoptosis depending on the context.\n5. TRUE: S6K1 is involved in cell metabolism, particularly in the regulation of protein synthesis, and it is subject to feedback regulation by various mechanisms, including insulin signaling.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 632,
    "user_query": "What is the cause of episodic ataxia type 6?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the cause of episodic ataxia type 6 is monoallelic mutations in the SLC1A3 gene, which encodes for the excitatory amino acid transporter 1 (EAAT1). The EAAT1 transporter is involved in regulating neurotransmitter concentrations in glutamatergic synapses in the cerebellum, diencephalon, and brainstem. The mutations in the SLC1A3 gene lead to the dysfunction of the EAAT1 transporter, resulting in the episodic ataxia type 6.",
    "llama-2-7b-chat-hf_fact_raw": "1. Episodic ataxia type 6 is caused by monoallelic mutations in the SLC1A3 gene.\n2. The SLC1A3 gene encodes for the excitatory amino acid transporter 1 (EAAT1).\n3. The EAAT1 transporter is involved in regulating neurotransmitter concentrations in glutamatergic synapses.\n4. The cerebellum, diencephalon, and brainstem are areas where the EAAT1 transporter operates.\n5. Mutations in the SLC1A3 gene lead to dysfunction of the EAAT1 transporter, which results in episodic ataxia type 6.",
    "llama-2-7b-chat-hf_fact": [
      "Episodic ataxia type 6 is caused by monoallelic mutations in the SLC1A3 gene.",
      "The SLC1A3 gene encodes for the excitatory amino acid transporter 1 (EAAT1).",
      "The EAAT1 transporter is involved in regulating neurotransmitter concentrations in glutamatergic synapses.",
      "The cerebellum, diencephalon, and brainstem are areas where the EAAT1 transporter operates.",
      "Mutations in the SLC1A3 gene lead to dysfunction of the EAAT1 transporter, which results in episodic ataxia type 6."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Episodic ataxia type 6 is caused by mutations in the SLC1A3 gene, but it is typically associated with biallelic mutations, not monoallelic mutations.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 646,
    "user_query": "Are chromomethylases present in animal genomes?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, chromomethylases are present in animal genomes. The document mentions that chromomethylases bind to nucleosomes marked by histone 3 lysine 4 trimethylation (H3K4me3), which is a modification that is known to be involved in the regulation of gene expression in animals. Additionally, the document mentions that long introns containing heterochromatic sequence are common in animal genomes, and that these introns are often decorated with CHG methylation and H3K9me2, which are both modifications that are known to be involved in the regulation of gene expression. Therefore, it can be inferred that chromomethylases are present in animal genomes and play a role in the regulation of gene expression.",
    "llama-2-7b-chat-hf_fact_raw": "1. Chromomethylases are present in animal genomes.\n2. Chromomethylases bind to nucleosomes marked by histone 3 lysine 4 trimethylation (H3K4me3).\n3. H3K4me3 is a modification involved in the regulation of gene expression in animals.\n4. Long introns containing heterochromatic sequence are common in animal genomes.\n5. CHG methylation and H3K9me2 are modifications involved in the regulation of gene expression in animal genomes.",
    "llama-2-7b-chat-hf_fact": [
      "Chromomethylases are present in animal genomes.",
      "Chromomethylases bind to nucleosomes marked by histone 3 lysine 4 trimethylation (H3K4me3).",
      "H3K4me3 is a modification involved in the regulation of gene expression in animals.",
      "Long introns containing heterochromatic sequence are common in animal genomes.",
      "CHG methylation and H3K9me2 are modifications involved in the regulation of gene expression in animal genomes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Chromomethylases are not present in animal genomes; they are typically found in plant genomes.\n2. FALSE [correction]: Since chromomethylases are not present in animal genomes, they do not bind to nucleosomes marked by H3K4me3 in animals. This statement would be more relevant to plant chromomethylases, which can bind to nucleosomes, but not necessarily marked by H3K4me3.\n3. TRUE: H3K4me3 is indeed a modification involved in the regulation of gene expression in animals, often associated with active transcription.\n4. UNKNOWN: The prevalence of long introns containing heterochromatic sequence in animal genomes can vary widely among different species and is not a universally established fact.\n5. FALSE [correction]: CHG methylation is a DNA modification found predominantly in plant genomes, not in animal genomes. H3K9me2 is a histone modification involved in the regulation of gene expression and the formation of heterochromatin in both plant and animal genomes.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 650,
    "user_query": "List packages for transcription factor binding sites' (TFBS) analysis available in R/Bioconductor",
    "llama-2-7b-chat-hf_response": "Thank you for providing the necessary information! Based on the information provided, here are some packages available in R/Bioconductor for transcription factor binding site (TFBS) analysis:\n1. TFBSTools: As you mentioned, TFBSTools is an R/Bioconductor package for the analysis and manipulation of TFBSs and their associated transcription factor profile matrices. It provides a toolkit for handling TFBS profile matrices, scanning sequences and alignments including whole genomes, and querying the JASPAR database.\n2. TRANSFAC: TRANSFAC is a widely used package in R/Bioconductor for TFBS analysis. It provides a comprehensive collection of transcription factor databases, including JASPAR, TRANSFAC, and MatInspector, which can be used for the prediction of TFBSs.\n3. TFSEM: TFSEM is another popular package in R/Bioconductor for TFBS analysis. It provides a set of tools for the analysis of TFBSs, including the prediction of TFBSs, the analysis of ChIP-seq data, and the identification of novel TFBSs.\n4. ChIPseek: ChIPseek is a package in R/Bioconductor that provides tools for the analysis of ChIP-seq data, including the identification of TFBSs. It uses a Bayesian approach to predict TFBSs and can be used for both peak calling and motif discovery.\n5. HISAT2: HISAT2 is a spliced aligner package in R/Bioconductor that can be used for the analysis of TFBSs. It provides a toolkit for aligning RNA-seq reads to a reference genome and can be used for the identification of TFBSs.\nThese packages provide a range of tools and methods for the analysis of TFBSs, and can be used for a variety of applications, including the prediction of TFBSs, the analysis of ChIP-seq data, and the identification of novel TFBSs.",
    "llama-2-7b-chat-hf_fact_raw": "1. TFBSTools is an R/Bioconductor package designed for the analysis and manipulation of transcription factor binding sites (TFBSs).\n2. TRANSFAC is a package in R/Bioconductor that includes a comprehensive collection of transcription factor databases for TFBS prediction.\n3. TFSEM is a package in R/Bioconductor that offers tools for TFBS analysis, including prediction and analysis of ChIP-seq data.\n4. ChIPseek is an R/Bioconductor package that provides tools for analyzing ChIP-seq data and predicting TFBSs using a Bayesian approach.\n5. HISAT2 is a spliced aligner package in R/Bioconductor that can be utilized for aligning RNA-seq reads to a reference genome and identifying TFBSs.",
    "llama-2-7b-chat-hf_fact": [
      "TFBSTools is an R/Bioconductor package designed for the analysis and manipulation of transcription factor binding sites (TFBSs).",
      "TRANSFAC is a package in R/Bioconductor that includes a comprehensive collection of transcription factor databases for TFBS prediction.",
      "TFSEM is a package in R/Bioconductor that offers tools for TFBS analysis, including prediction and analysis of ChIP-seq data.",
      "ChIPseek is an R/Bioconductor package that provides tools for analyzing ChIP-seq data and predicting TFBSs using a Bayesian approach.",
      "HISAT2 is a spliced aligner package in R/Bioconductor that can be utilized for aligning RNA-seq reads to a reference genome and identifying TFBSs."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: TRANSFAC is not a package but a database that contains information about transcription factors and their binding sites. However, there are R/Bioconductor packages that can interface with TRANSFAC data.\n3. UNKNOWN\n4. FALSE [correction]: ChIPseeker is an R/Bioconductor package that provides tools for analyzing ChIP-seq data. It does not predict TFBSs using a Bayesian approach.\n5. FALSE [correction]: HISAT2 is a fast and sensitive alignment program for mapping next-generation sequencing reads (both DNA and RNA) to a population of genomes or a reference genome. It is not specifically designed for identifying TFBSs and is not a package in R/Bioconductor, although it can be used in conjunction with Bioconductor tools.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "false",
      "false"
    ]
  },
  {
    "id": 721,
    "user_query": "List clinical trials for prevention of sarcopenia",
    "llama-2-7b-chat-hf_response": "Based on the information provided, here are some clinical trials for the prevention of sarcopenia:\n1. Exercise Intervention Trial for Sarcopenia (EXIST): This trial, published in the Journal of the American Medical Directors Association in 2019, evaluated the effectiveness of a 12-month exercise program in preventing sarcopenia in older adults. The program consisted of resistance training, aerobic exercise, and balance training, and was found to significantly reduce the risk of sarcopenia.\n2. Nutraceutical Interventions for Sarcopenia Prevention (NISP): This trial, published in the Journal of the American Geriatrics Society in 2018, investigated the effectiveness of a nutraceutical supplement in preventing sarcopenia. The supplement contained a combination of vitamins, minerals, and plant extracts, and was found to significantly reduce the risk of sarcopenia in older adults.\n3. Pharmaceutical Interventions for Sarcopenia Prevention (PISP): This trial, published in the Journal of Clinical Interventions in Aging in 2019, evaluated the effectiveness of a pharmaceutical intervention in preventing sarcopenia. The intervention consisted of a drug that targeted the underlying pathophysiology of sarcopenia, and was found to significantly reduce the risk of sarcopenia in older adults.\n4. Resistance Training and Nutrition Intervention for Sarcopenia Prevention (REPS): This trial, published in the Journal of Aging and Physical Activity in 2019, investigated the effectiveness of a combination of resistance training and nutrition interventions in preventing sarcopenia. The intervention consisted of a 12-month program of resistance training and nutritional counseling, and was found to significantly reduce the risk of sarcopenia.\n5. Tai Chi Exercise for Sarcopenia Prevention (TES): This trial, published in the Journal of the American Geriatrics Society in 2019, evaluated the effectiveness of tai chi exercise in preventing sarcopenia. The intervention consisted of a 12-month program of tai chi",
    "llama-2-7b-chat-hf_fact_raw": "1. The Exercise Intervention Trial for Sarcopenia (EXIST) was published in the Journal of the American Medical Directors Association in 2019.\n2. The Nutraceutical Interventions for Sarcopenia Prevention (NISP) trial was published in the Journal of the American Geriatrics Society in 2018.\n3. The Pharmaceutical Interventions for Sarcopenia Prevention (PISP) trial was published in the Journal of Clinical Interventions in Aging in 2019.\n4. The Resistance Training and Nutrition Intervention for Sarcopenia Prevention (REPS) trial was published in the Journal of Aging and Physical Activity in 2019.\n5. The Tai Chi Exercise for Sarcopenia Prevention (TES) trial was published in the Journal of the American Geriatrics Society in 2019.",
    "llama-2-7b-chat-hf_fact": [
      "The Exercise Intervention Trial for Sarcopenia (EXIST) was published in the Journal of the American Medical Directors Association in 2019.",
      "The Nutraceutical Interventions for Sarcopenia Prevention (NISP) trial was published in the Journal of the American Geriatrics Society in 2018.",
      "The Pharmaceutical Interventions for Sarcopenia Prevention (PISP) trial was published in the Journal of Clinical Interventions in Aging in 2019.",
      "The Resistance Training and Nutrition Intervention for Sarcopenia Prevention (REPS) trial was published in the Journal of Aging and Physical Activity in 2019.",
      "The Tai Chi Exercise for Sarcopenia Prevention (TES) trial was published in the Journal of the American Geriatrics Society in 2019."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout access to the specific publication records or databases that list the publication details of these trials, it is not possible to verify the accuracy of the statements regarding the publication details of the EXIST, NISP, PISP, REPS, and TES trials.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 722,
    "user_query": "Which is the database of molecular recognition features in membrane proteins?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the database of molecular recognition features in membrane proteins is called mpMoRFsDB.",
    "llama-2-7b-chat-hf_fact_raw": "1. mpMoRFsDB is a database of molecular recognition features in membrane proteins.",
    "llama-2-7b-chat-hf_fact": [
      "mpMoRFsDB is a database of molecular recognition features in membrane proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 745,
    "user_query": "Is rivaroxaban metabolized in kidneys?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, rivaroxaban is not metabolized in the kidneys. The mechanism of action of rivaroxaban is described as a selective, reversible, direct Factor Xa inhibitor that does not require cofactors for its anticoagulant effect [3-4]. This suggests that the drug is metabolized in a different pathway than the kidneys, which are responsible for metabolizing many other drugs. Therefore, it is unlikely that rivaroxaban is metabolized in the kidneys.",
    "llama-2-7b-chat-hf_fact_raw": "1. Rivaroxaban is not metabolized in the kidneys.\n2. Rivaroxaban is a selective, reversible, direct Factor Xa inhibitor.\n3. Rivaroxaban does not require cofactors for its anticoagulant effect.",
    "llama-2-7b-chat-hf_fact": [
      "Rivaroxaban is not metabolized in the kidneys.",
      "Rivaroxaban is a selective, reversible, direct Factor Xa inhibitor.",
      "Rivaroxaban does not require cofactors for its anticoagulant effect."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Rivaroxaban is partially metabolized in the kidneys, with about one-third of the active substance being eliminated by the kidneys.\n2. TRUE\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 763,
    "user_query": "Which genes are regulated by TRalpha2  in the heart?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, TRalpha2 is a gene that is regulated in the heart by thyroid hormones. The document highlights recent and past data on the metabolic effects of thyroid hormones, with particular emphasis on the effects exerted via mitochondria. Thyroid hormones, including triiodothyronine (T3) and thyroxine (T4), play a crucial role in regulating the metabolism of the heart, and TRalpha2 is a key transcription factor involved in this process.\nStudies have shown that TRalpha2 is expressed in the heart and is involved in the regulation of genes involved in cardiac metabolism, including genes involved in fatty acid oxidation, glucose metabolism, and mitochondrial biogenesis. Thyroid hormones have been shown to regulate TRalpha2 expression in the heart, with increased TRalpha2 expression observed in response to thyroid hormone stimulation.\nTherefore, based on the information provided in Document 0, it can be concluded that TRalpha2 is a gene that is regulated by thyroid hormones in the heart.",
    "llama-2-7b-chat-hf_fact_raw": "1. TRalpha2 is a gene that is regulated in the heart by thyroid hormones.\n2. Thyroid hormones play a crucial role in regulating the metabolism of the heart.\n3. TRalpha2 is a key transcription factor involved in the metabolic regulation process in the heart.\n4. TRalpha2 is expressed in the heart and regulates genes involved in cardiac metabolism.\n5. Increased TRalpha2 expression in the heart is observed in response to thyroid hormone stimulation.",
    "llama-2-7b-chat-hf_fact": [
      "TRalpha2 is a gene that is regulated in the heart by thyroid hormones.",
      "Thyroid hormones play a crucial role in regulating the metabolism of the heart.",
      "TRalpha2 is a key transcription factor involved in the metabolic regulation process in the heart.",
      "TRalpha2 is expressed in the heart and regulates genes involved in cardiac metabolism.",
      "Increased TRalpha2 expression in the heart is observed in response to thyroid hormone stimulation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: TRalpha2 is not a transcription factor; it is an isoform of the thyroid hormone receptor that can modulate the activity of transcription factors.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 786,
    "user_query": "List available biomedical question answering systems.",
    "llama-2-7b-chat-hf_response": "Thank you for your question! Based on the information provided, here are some available biomedical question answering systems:\n1. SemBioNLQA: As you mentioned, this is a new semantic biomedical question answering system that uses natural language processing (NLP) methods to retrieve exact and ideal answers to natural language questions.\n2. BioASQ: This is a biomedical question answering system that uses a combination of NLP and machine learning techniques to answer questions related to biomedicine.\n3. PubTator: This is a system that uses NLP to extract information from biomedical literature, including answers to questions.\n4. BioQA: This is a question answering system that uses a combination of NLP and machine learning techniques to answer questions related to biomedicine.\n5. MedQA: This is a question answering system that uses NLP to extract information from biomedical literature and answer questions related to medicine.\n6. BioRxivQA: This is a question answering system that uses NLP to extract information from preprints and answers questions related to biomedicine.\n7. MedlinePlus: This is a question answering system provided by the National Library of Medicine that uses a combination of NLP and machine learning techniques to answer questions related to medicine.\n8. Google Scholar: This is a search engine that indexes biomedical literature and can be used to find answers to biomedical questions.\n9. PubMed: This is a database of biomedical literature that can be used to find answers to biomedical questions.\n10. Wikipedia: This is a collaboratively edited encyclopedia that contains information on a wide range of biomedical topics and can be used to find answers to biomedical questions.\nI hope this helps! Let me know if you have any further questions.",
    "llama-2-7b-chat-hf_fact_raw": "1. SemBioNLQA is a semantic biomedical question answering system that uses natural language processing methods.\n2. BioASQ is a biomedical question answering system that employs a combination of NLP and machine learning techniques.\n3. PubTator is a system that utilizes NLP to extract information from biomedical literature.\n4. MedQA is a question answering system that extracts information from biomedical literature using NLP.\n5. MedlinePlus is a question answering system provided by the National Library of Medicine that uses NLP and machine learning techniques.",
    "llama-2-7b-chat-hf_fact": [
      "SemBioNLQA is a semantic biomedical question answering system that uses natural language processing methods.",
      "BioASQ is a biomedical question answering system that employs a combination of NLP and machine learning techniques.",
      "PubTator is a system that utilizes NLP to extract information from biomedical literature.",
      "MedQA is a question answering system that extracts information from biomedical literature using NLP.",
      "MedlinePlus is a question answering system provided by the National Library of Medicine that uses NLP and machine learning techniques."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: MedlinePlus is a health information website provided by the National Library of Medicine, but it is not specifically described as a question answering system that uses NLP and machine learning techniques. It offers information about diseases, conditions, and wellness issues in language that is easy to understand for the general public.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 794,
    "user_query": "Which trancription factor activates the betalain pathway?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the trancription factor that activates the betalain pathway is the MBW transcription factor complex consisting of MYB, bHLH, and WD-repeat proteins.",
    "llama-2-7b-chat-hf_fact_raw": "1. The MBW transcription factor complex activates the betalain pathway.\n2. The MBW transcription factor complex consists of MYB, bHLH, and WD-repeat proteins.",
    "llama-2-7b-chat-hf_fact": [
      "The MBW transcription factor complex activates the betalain pathway.",
      "The MBW transcription factor complex consists of MYB, bHLH, and WD-repeat proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 883,
    "user_query": "Global quantitative phosphoproteomic analyses are emerging. List the preferred technologies for the enrichment for phosphorylated peptides?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the preferred technologies for enrichment of phosphorylated peptides for global quantitative phosphoproteomic analyses are:\n1. TiO2-based enrichment: This method uses titanium dioxide (TiO2) to selectively capture phosphorylated peptides based on their higher affinity for the surface of the bead.\n2. C18-based enrichment: This method uses a C18 column to separate phosphorylated peptides from non-phosphorylated peptides based on their differences in hydrophobicity.\n3. IMAC (Immobilized Metal Affinity Chromatography): This method uses metal ions (e.g. Ni2+ or Cu2+) to selectively bind to phosphorylated peptides, which are then separated from non-phosphorylated peptides using a column.\n4. PEG-based enrichment: This method uses a PEG (polyethylene glycol) ligand to selectively bind to phosphorylated peptides, which are then separated from non-phosphorylated peptides using a column.\n5. Hydrophobic interaction chromatography (HIC): This method separates phosphorylated peptides based on their hydrophobicity, which is higher for phosphorylated peptides than for non-phosphorylated peptides.\n6. LC-MS/MS: This method uses liquid chromatography (LC) to separate phosphorylated peptides from non-phosphorylated peptides based on their differences in mobility, and then uses mass spectrometry (MS/MS) to identify and quantify the phosphorylated peptides.\nIt's worth noting that the choice of enrichment technology will depend on the specific research question and experimental design, as well as the properties of the sample being analyzed.",
    "llama-2-7b-chat-hf_fact_raw": "1. TiO2-based enrichment uses titanium dioxide to selectively capture phosphorylated peptides.\n2. C18-based enrichment separates phosphorylated peptides from non-phosphorylated peptides using a C18 column.\n3. Immobilized Metal Affinity Chromatography (IMAC) uses metal ions to bind to phosphorylated peptides for separation.\n4. PEG-based enrichment uses a polyethylene glycol ligand to selectively bind to phosphorylated peptides.\n5. Hydrophobic interaction chromatography (HIC) separates phosphorylated peptides based on their hydrophobicity.",
    "llama-2-7b-chat-hf_fact": [
      "TiO2-based enrichment uses titanium dioxide to selectively capture phosphorylated peptides.",
      "C18-based enrichment separates phosphorylated peptides from non-phosphorylated peptides using a C18 column.",
      "Immobilized Metal Affinity Chromatography (IMAC) uses metal ions to bind to phosphorylated peptides for separation.",
      "PEG-based enrichment uses a polyethylene glycol ligand to selectively bind to phosphorylated peptides.",
      "Hydrophobic interaction chromatography (HIC) separates phosphorylated peptides based on their hydrophobicity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: C18-based enrichment is a method that separates peptides based on hydrophobicity, not specifically for separating phosphorylated from non-phosphorylated peptides.\n3. TRUE\n4. FALSE [correction]: PEG-based enrichment is not a standard method for selectively binding to phosphorylated peptides. PEGylation is more commonly associated with the modification of proteins or drugs to improve their pharmacokinetics.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 901,
    "user_query": "Which disorder is rated by Palmini classification?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the disorder that is rated by the Palmini classification is FCD (Fronto-Cerebellar Dysplasia).",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 905,
    "user_query": "Are viruses involved in the etiology of human subacute thyroiditis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, there is a possibility that viruses may be involved in the etiology of human subacute thyroiditis (SAT). The document states that viral infection may represent one of the major environmental factors related to common thyroid disorders, including SAT, nonthyroidal illness syndrome (NTIS), and autoimmune thyroid diseases (AITDs) such as Graves' disease (GD) and Hashimoto's thyroiditis (HT).\nWhile the document does not specifically mention viruses as a cause of SAT, it does suggest that viral infection may play a role in the development of thyroid disorders. Therefore, it is possible that viruses may be involved in the etiology of SAT, although further research is needed to confirm this association.\nIn summary, based on the information provided in Document 0, there is a possibility that viruses may be involved in the etiology of human subacute thyroiditis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Viral infection may represent one of the major environmental factors related to common thyroid disorders.\n2. Subacute thyroiditis (SAT), nonthyroidal illness syndrome (NTIS), and autoimmune thyroid diseases (AITDs) are types of thyroid disorders.\n3. Graves' disease (GD) and Hashimoto's thyroiditis (HT) are examples of autoimmune thyroid diseases (AITDs).\n4. The document suggests that viral infection may play a role in the development of thyroid disorders.\n5. Further research is needed to confirm the association between viruses and the etiology of subacute thyroiditis (SAT).",
    "llama-2-7b-chat-hf_fact": [
      "Viral infection may represent one of the major environmental factors related to common thyroid disorders.",
      "Subacute thyroiditis (SAT), nonthyroidal illness syndrome (NTIS), and autoimmune thyroid diseases (AITDs) are types of thyroid disorders.",
      "Graves' disease (GD) and Hashimoto's thyroiditis (HT) are examples of autoimmune thyroid diseases (AITDs).",
      "The document suggests that viral infection may play a role in the development of thyroid disorders.",
      "Further research is needed to confirm the association between viruses and the etiology of subacute thyroiditis (SAT)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nAll statements are consistent with current medical understanding. Viral infections are indeed considered as potential environmental factors that could be related to thyroid disorders. Subacute thyroiditis, nonthyroidal illness syndrome, and autoimmune thyroid diseases are recognized types of thyroid disorders. Graves' disease and Hashimoto's thyroiditis are well-known examples of autoimmune thyroid diseases. The document's suggestion that viral infection may play a role in the development of thyroid disorders is a reasonable statement based on existing hypotheses and research. Lastly, it is a common scientific stance that further research is often needed to confirm associations in medical studies, including the relationship between viruses and the etiology of conditions like subacute thyroiditis.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 963,
    "user_query": "Is STAT3 involved in EIF2AK2-dependent suppression of autophagy?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, it appears that STAT3 is involved in the suppression of autophagy through its interaction with EIF2AK2. According to Document 0, STAT3 constitutively inhibits autophagy by sequestering EIF2AK2, which is a key regulator of autophagy. Additionally, STAT3 has been shown to interact with other autophagy-related signaling molecules such as FOXO1 and FOXO3, which may also contribute to its inhibitory effects on autophagy. Therefore, it is likely that STAT3 plays a role in the regulation of autophagy through its interactions with EIF2AK2 and other autophagy-related signaling molecules.",
    "llama-2-7b-chat-hf_fact_raw": "1. STAT3 is involved in the suppression of autophagy through its interaction with EIF2AK2.\n2. STAT3 constitutively inhibits autophagy by sequestering EIF2AK2.\n3. EIF2AK2 is a key regulator of autophagy.\n4. STAT3 has been shown to interact with other autophagy-related signaling molecules such as FOXO1 and FOXO3.\n5. STAT3's interactions with EIF2AK2 and other autophagy-related signaling molecules contribute to its inhibitory effects on autophagy.",
    "llama-2-7b-chat-hf_fact": [
      "STAT3 is involved in the suppression of autophagy through its interaction with EIF2AK2.",
      "STAT3 constitutively inhibits autophagy by sequestering EIF2AK2.",
      "EIF2AK2 is a key regulator of autophagy.",
      "STAT3 has been shown to interact with other autophagy-related signaling molecules such as FOXO1 and FOXO3.",
      "STAT3's interactions with EIF2AK2 and other autophagy-related signaling molecules contribute to its inhibitory effects on autophagy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: STAT3 (Signal Transducer and Activator of Transcription 3) has been reported to be involved in the suppression of autophagy, and its interaction with EIF2AK2 (also known as PKR) can contribute to this process.\n2. UNKNOWN: While STAT3 has been implicated in the regulation of autophagy, whether it constitutively inhibits autophagy by sequestering EIF2AK2 is specific and would require a direct reference to a scientific study for confirmation.\n3. TRUE: EIF2AK2 (PKR) is known to be a key regulator of autophagy, among other cellular processes.\n4. TRUE: STAT3 is known to interact with various signaling molecules, and there is evidence in scientific literature that it can interact with members of the FOXO family, such as FOXO1 and FOXO3, which are involved in autophagy regulation.\n5. TRUE: The interactions of STAT3 with EIF2AK2 and other autophagy-related signaling molecules like FOXO1 and FOXO3 are part of the mechanisms through which STAT3 can exert its inhibitory effects on autophagy.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 973,
    "user_query": "Describe what is the usage of the Theatre software tool for genomic analysis.",
    "llama-2-7b-chat-hf_response": "Theatre is a software tool designed for genomic analysis, specifically for identifying and analyzing coding regions, repetitive sequences, and other features in a genomic sequence. Here are some of the key usage scenarios for Theatre:\n1. Identifying coding regions: Theatre can help identify the locations of coding regions in a genomic sequence, which are essential for understanding the function and evolution of genes.\n2. Predicting gene structure: Theatre can predict the structure of genes, including the location of introns and exons, which is important for understanding the regulation of gene expression.\n3. Identifying repetitive sequences: Theatre can identify repetitive sequences in a genomic sequence, which can provide insights into the evolutionary history of the genome and the potential functions of these sequences.\n4. Analyzing gene expression: Theatre can be used to analyze gene expression data, such as RNA-seq data, to identify differentially expressed genes and understand the regulatory mechanisms underlying gene expression.\n5. Identifying regulatory elements: Theatre can identify regulatory elements, such as promoters, enhancers, and silencers, which are important for understanding the regulation of gene expression.\n6. Analyzing genomic variations: Theatre can be used to analyze genomic variations, such as single nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations, to understand their impact on gene function and disease susceptibility.\n7. Identifying gene fusion: Theatre can identify gene fusions, which are important for understanding the mechanisms of cancer and other diseases.\n8. Analyzing RNA structure: Theatre can be used to analyze the structure of RNA molecules, including the secondary and tertiary structure, which is important for understanding the function of RNA molecules.\n9. Identifying non-coding RNAs: Theatre can identify non-coding RNAs, such as microRNAs and long non-coding RNAs, which play important roles in regulating gene expression and other cellular processes.\n10. Analyzing genomic data: Theatre can be used to analyze large-scale genomic data sets, such as those generated by next-generation sequencing technologies, to identify patterns and trends that can inform our understanding of genomic function and disease.\nOverall, Theatre is a powerful tool for",
    "llama-2-7b-chat-hf_fact_raw": "1. Theatre is a software tool used for genomic analysis.\n2. Theatre can identify coding regions in a genomic sequence.\n3. Theatre can predict the structure of genes, including the location of introns and exons.\n4. Theatre can be used to analyze gene expression data, such as RNA-seq data.\n5. Theatre can identify regulatory elements, such as promoters, enhancers, and silencers.",
    "llama-2-7b-chat-hf_fact": [
      "Theatre is a software tool used for genomic analysis.",
      "Theatre can identify coding regions in a genomic sequence.",
      "Theatre can predict the structure of genes, including the location of introns and exons.",
      "Theatre can be used to analyze gene expression data, such as RNA-seq data.",
      "Theatre can identify regulatory elements, such as promoters, enhancers, and silencers."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The statement is too vague to determine its truthfulness without additional context. \"Theatre\" is not a commonly recognized software tool for genomic analysis. It is possible that \"Theatre\" is a misspelling or a fictional name for a genomic analysis tool. A well-known software tool for genomic analysis is \"Artemis,\" which is used for visualizing sequence features, next-generation data, and the results of analyses.\n2. UNKNOWN: Without proper context or information about the specific capabilities of \"Theatre,\" it is not possible to confirm whether it can identify coding regions in a genomic sequence.\n3. UNKNOWN: Similar to the previous statement, without specific information about \"Theatre,\" it is not possible to confirm whether it can predict the structure of genes, including the location of introns and exons.\n4. UNKNOWN: Again, without additional context or information about \"Theatre,\" it is not possible to confirm whether it can be used to analyze gene expression data, such as RNA-seq data.\n5. UNKNOWN: Without further information, it is not possible to confirm whether \"Theatre\" can identify regulatory elements, such as promoters, enhancers, and silencers.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 997,
    "user_query": "Which  is the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences is O(n^2), where n is the length of the sequences.\nThe Smith-Waterman algorithm is an efficient algorithm for finding the optimal local alignment between two sequences, and its complexity is determined by the number of elements in the sequences. Since the algorithm always finds the optimal local alignment, the time complexity is O(n^2), where n is the length of the sequences.\nThis is because the algorithm compares each element in one sequence to every element in the other sequence, which results in a total of n^2 comparisons. Therefore, the time complexity of the Smith-Waterman algorithm is O(n^2), which is a quadratic function of the length of the sequences.",
    "llama-2-7b-chat-hf_fact_raw": "1. The execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences is O(n^2).\n2. The complexity of the Smith-Waterman algorithm is determined by the number of elements in the sequences.\n3. The Smith-Waterman algorithm always finds the optimal local alignment between two sequences.\n4. The algorithm compares each element in one sequence to every element in the other sequence.\n5. The total number of comparisons made by the Smith-Waterman algorithm is n^2, where n is the length of the sequences.",
    "llama-2-7b-chat-hf_fact": [
      "The execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences is O(n^2).",
      "The complexity of the Smith-Waterman algorithm is determined by the number of elements in the sequences.",
      "The Smith-Waterman algorithm always finds the optimal local alignment between two sequences.",
      "The algorithm compares each element in one sequence to every element in the other sequence.",
      "The total number of comparisons made by the Smith-Waterman algorithm is n^2, where n is the length of the sequences."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences is indeed O(n^2), where n is the length of the longer of the two sequences being compared.\n2. TRUE: The complexity of the Smith-Waterman algorithm is determined by the number of elements in the sequences, as it involves comparing elements from one sequence to every element in the other sequence, leading to a quadratic relationship in the number of elements.\n3. TRUE: The Smith-Waterman algorithm is designed to find the optimal local alignment between two sequences using dynamic programming. It is guaranteed to find the best local alignment under the scoring system used.\n4. TRUE: The algorithm does compare each element in one sequence to every element in the other sequence as part of its dynamic programming matrix computation.\n5. FALSE [correction]: The total number of comparisons made by the Smith-Waterman algorithm is not necessarily n^2, where n is the length of the sequences. If the sequences are of different lengths, say length m and length n, the number of comparisons would be m*n. If the sequences are of the same length, then it would be n^2.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1004,
    "user_query": "Which SLC family is FLVCR1 a member of?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, FLVCR1 is a member of the SLC family of transporter proteins. Specifically, FLVCR1 is a member of the solute carrier family 39 (SLC39) subfamily, which is a subfamily of the major facilitator superfamily of transporter proteins.",
    "llama-2-7b-chat-hf_fact_raw": "1. FLVCR1 is a member of the SLC family of transporter proteins.\n2. FLVCR1 belongs to the solute carrier family 39 (SLC39) subfamily.\n3. The SLC39 subfamily is part of the major facilitator superfamily of transporter proteins.",
    "llama-2-7b-chat-hf_fact": [
      "FLVCR1 is a member of the SLC family of transporter proteins.",
      "FLVCR1 belongs to the solute carrier family 39 (SLC39) subfamily.",
      "The SLC39 subfamily is part of the major facilitator superfamily of transporter proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: FLVCR1 is not a member of the SLC family of transporter proteins; it is a member of the major facilitator superfamily (MFS).\n2. FALSE [correction]: FLVCR1 does not belong to the solute carrier family 39 (SLC39) subfamily; it is part of the major facilitator superfamily (MFS).\n3. FALSE [correction]: The SLC39 subfamily is not part of the major facilitator superfamily of transporter proteins; it is part of the ZIP (Zrt-, Irt-like Protein) family of metal ion transporters within the SLC family.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 1047,
    "user_query": "List GATA-1 interacting partners as discovered with the help of the biotinylation tagging approach.",
    "llama-2-7b-chat-hf_response": "Based on the information provided, GATA-1 interacting partners that have been discovered using the biotinylation tagging approach include:\n1. DNA binding proteins: GATA-1 binds to specific DNA sequences in the promoter and enhancer regions of target genes, regulating their expression.\n2. Transcription factors: GATA-1 interacts with other transcription factors, such as GATA-2 and GATA-3, to modulate the expression of genes involved in hematopoiesis.\n3. Cyclin-dependent kinases (CDKs): GATA-1 has been shown to interact with CDKs, which are involved in regulating the cell cycle and proliferation of hematopoietic cells.\n4. Protein kinases: GATA-1 has been reported to interact with various protein kinases, including the tyrosine kinase Src, which is involved in signaling pathways that regulate hematopoiesis.\n5. Chromatin-modifying enzymes: GATA-1 has been shown to interact with histone-modifying enzymes, such as histone acetyltransferases and histone deacetylases, which are involved in regulating chromatin structure and gene expression.\n6. Non-hematopoietic proteins: GATA-1 has been reported to interact with non-hematopoietic proteins, such as the transcription factor NF-κB, which is involved in regulating inflammation and immune responses.\nThese interactions play a crucial role in regulating the expression of genes involved in hematopoiesis and the proper functioning of the hematopoietic system. Disruption of these interactions can lead to blood disorders, such as thrombocytopenia and anemia, as mentioned in the passage.",
    "llama-2-7b-chat-hf_fact_raw": "1. GATA-1 binds to specific DNA sequences in the promoter and enhancer regions of target genes.\n2. GATA-1 interacts with other transcription factors, including GATA-2 and GATA-3.\n3. GATA-1 has been shown to interact with cyclin-dependent kinases (CDKs).\n4. GATA-1 has been reported to interact with various protein kinases, including the tyrosine kinase Src.\n5. GATA-1 has been shown to interact with histone-modifying enzymes, such as histone acetyltransferases and histone deacetylases.",
    "llama-2-7b-chat-hf_fact": [
      "GATA-1 binds to specific DNA sequences in the promoter and enhancer regions of target genes.",
      "GATA-1 interacts with other transcription factors, including GATA-2 and GATA-3.",
      "GATA-1 has been shown to interact with cyclin-dependent kinases (CDKs).",
      "GATA-1 has been reported to interact with various protein kinases, including the tyrosine kinase Src.",
      "GATA-1 has been shown to interact with histone-modifying enzymes, such as histone acetyltransferases and histone deacetylases."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: GATA-1 is a transcription factor that indeed binds to specific DNA sequences in the promoter and enhancer regions of target genes to regulate their expression.\n2. TRUE: GATA-1 can interact with other transcription factors, including other members of the GATA family such as GATA-2 and GATA-3, as part of its role in regulating gene expression.\n3. UNKNOWN: The interaction of GATA-1 with cyclin-dependent kinases (CDKs) is not commonly reported in the literature, and without specific context or references, it is difficult to confirm the accuracy of this statement.\n4. UNKNOWN: While GATA-1 is known to interact with various proteins as part of its role in gene regulation, the specific interaction with the tyrosine kinase Src is not widely established in the literature. More information would be needed to confirm this statement.\n5. TRUE: GATA-1 has been shown to interact with histone-modifying enzymes, including histone acetyltransferases (HATs) and histone deacetylases (HDACs), which play a role in chromatin remodeling and regulation of gene expression.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1072,
    "user_query": "What is the outcome of TAF10 interacting with the GATA1 transcription factor?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, TAF10 interacts with the GATA1 transcription factor and controls mouse erythropoiesis. The study found that TAF10 and GATA1 interact in vivo and in vitro, and that TAF10 is required for the proper differentiation of erythroid cells. Specifically, the study showed that TAF10-deficient mice have a severe anemia and a reduction in the expression of GATA1 target genes, indicating that TAF10 plays a critical role in regulating the activity of GATA1 during erythropoiesis.",
    "llama-2-7b-chat-hf_fact_raw": "1. TAF10 interacts with the GATA1 transcription factor in vivo and in vitro.\n2. TAF10 is required for the proper differentiation of erythroid cells.\n3. TAF10-deficient mice exhibit severe anemia.\n4. TAF10-deficient mice show a reduction in the expression of GATA1 target genes.\n5. TAF10 plays a critical role in regulating the activity of GATA1 during erythropoiesis.",
    "llama-2-7b-chat-hf_fact": [
      "TAF10 interacts with the GATA1 transcription factor in vivo and in vitro.",
      "TAF10 is required for the proper differentiation of erythroid cells.",
      "TAF10-deficient mice exhibit severe anemia.",
      "TAF10-deficient mice show a reduction in the expression of GATA1 target genes.",
      "TAF10 plays a critical role in regulating the activity of GATA1 during erythropoiesis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThese statements are consistent with scientific findings regarding the role of TAF10 (TATA-box binding protein associated factor 10) in erythropoiesis and its interaction with GATA1, a transcription factor critical for erythroid cell differentiation. TAF10's interaction with GATA1, its requirement for erythroid differentiation, the phenotype of TAF10-deficient mice, and its role in regulating GATA1 activity are supported by research in the field of molecular biology and genetics. However, without specific references to the original research or reviews, the accuracy of these statements is assumed based on general knowledge in the field up to the knowledge cutoff date.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1082,
    "user_query": "Are there any Decision support systems for chronic pain management ?",
    "llama-2-7b-chat-hf_response": "Yes, there are several decision support systems (CDSSs) available for chronic pain management. These systems use a combination of clinical guidelines, patient-reported outcomes, and machine learning algorithms to provide healthcare providers with evidence-based recommendations for managing chronic pain.\nSome examples of CDSSs for chronic pain management include:\n1. The Chronic Pain Management Decision Support System (CPM-DSS): This system was developed by the University of Washington and provides healthcare providers with real-time, evidence-based recommendations for managing chronic pain. The system takes into account patient-reported outcomes, medical history, and other relevant factors to make recommendations for pain assessment, diagnosis, and treatment.\n2. The Pain Management Decision Support System (PMDSS): This system was developed by the University of California, Los Angeles (UCLA) and provides healthcare providers with a comprehensive framework for managing chronic pain. The system includes a range of tools and resources, such as clinical guidelines, pain assessment scales, and patient education materials.\n3. The Chronic Pain Management Algorithm (CPMA): This system was developed by the University of California, San Francisco (UCSF) and provides healthcare providers with a step-by-step approach for managing chronic pain. The system includes a range of algorithms and decision support tools, such as pain assessment scales, treatment recommendations, and patient education materials.\n4. The Pain Care Network (PCN): This system was developed by the University of Washington and provides healthcare providers with a comprehensive framework for managing chronic pain. The system includes a range of tools and resources, such as clinical guidelines, pain assessment scales, and patient education materials.\nThese are just a few examples of the many CDSSs available for chronic pain management. By using these systems, healthcare providers can improve the accuracy of pain assessment, offer better support for clinical decision-making, and provide more effective treatment for patients with chronic pain.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Chronic Pain Management Decision Support System (CPM-DSS) was developed by the University of Washington.\n2. The Pain Management Decision Support System (PMDSS) was developed by the University of California, Los Angeles (UCLA).\n3. The Chronic Pain Management Algorithm (CPMA) was developed by the University of California, San Francisco (UCSF).\n4. The Pain Care Network (PCN) was developed by the University of Washington.\n5. Decision support systems for chronic pain management use clinical guidelines, patient-reported outcomes, and machine learning algorithms to provide recommendations.",
    "llama-2-7b-chat-hf_fact": [
      "The Chronic Pain Management Decision Support System (CPM-DSS) was developed by the University of Washington.",
      "The Pain Management Decision Support System (PMDSS) was developed by the University of California, Los Angeles (UCLA).",
      "The Chronic Pain Management Algorithm (CPMA) was developed by the University of California, San Francisco (UCSF).",
      "The Pain Care Network (PCN) was developed by the University of Washington.",
      "Decision support systems for chronic pain management use clinical guidelines, patient-reported outcomes, and machine learning algorithms to provide recommendations."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE\n\nThe truthfulness of statements 1, 2, 3, and 4 cannot be determined without specific information about the development of these systems and their affiliations. These details are not common knowledge and would require research or domain-specific knowledge to verify. However, statement 5 is generally true as decision support systems for chronic pain management often incorporate clinical guidelines, patient-reported outcomes, and machine learning algorithms to assist healthcare providers in making informed decisions about patient care.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1149,
    "user_query": "Which is the subcellular localization of the protein angiogenin?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, angiogenin is localized to the cytoplasm.\nAccording to Poon et al. (2003), angiogenin is involved in angiogenesis, which is the process of forming new blood vessels from pre-existing ones. This process is essential for the growth and metastatic spread of cancer cells, and gastrointestinal cancers such as stomach, liver, and colon cancer are among the leading causes of cancer deaths globally. Therefore, research on angiogenesis in gastrointestinal tumors is crucial, and angiogenin plays a key role in this process.\nSince angiogenin is involved in angiogenesis, it is likely to be localized in the cytoplasm, where it can interact with other proteins and molecules involved in this process. The cytoplasm is the region of the cell where many metabolic processes take place, including protein synthesis, folding, and degradation, and it is also the site of many cellular signaling pathways. Therefore, the cytoplasm is an appropriate location for angiogenin to carry out its functions in angiogenesis.\nIn summary, based on the information provided, angiogenin is localized to the cytoplasm, where it plays a crucial role in angiogenesis and the growth and metastatic spread of cancer cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. Angiogenin is localized to the cytoplasm.\n2. Angiogenin is involved in the process of angiogenesis.\n3. Angiogenesis is the process of forming new blood vessels from pre-existing ones.\n4. Gastrointestinal cancers such as stomach, liver, and colon cancer are among the leading causes of cancer deaths globally.\n5. The cytoplasm is the region of the cell where many metabolic processes take place, including protein synthesis, folding, and degradation.",
    "llama-2-7b-chat-hf_fact": [
      "Angiogenin is localized to the cytoplasm.",
      "Angiogenin is involved in the process of angiogenesis.",
      "Angiogenesis is the process of forming new blood vessels from pre-existing ones.",
      "Gastrointestinal cancers such as stomach, liver, and colon cancer are among the leading causes of cancer deaths globally.",
      "The cytoplasm is the region of the cell where many metabolic processes take place, including protein synthesis, folding, and degradation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1161,
    "user_query": "How does ranolazine affect kinase signaling activation in the heart?",
    "llama-2-7b-chat-hf_response": "Thank you for asking! Based on the information provided, ranolazine is a drug that has been shown to affect kinase signaling activation in the heart.\nKinase signaling is a crucial pathway involved in various cellular processes, including cell proliferation, differentiation, and survival. In the heart, kinase signaling plays a critical role in regulating cardiac function and contraction. Dysregulation of kinase signaling has been implicated in the development and progression of heart failure.\nRanolazine, a cardiovascular drug, has been shown to modulate kinase signaling in the heart. Studies have shown that ranolazine can inhibit the activity of certain kinases, such as protein kinase C (PKC) and mitogen-activated protein kinase (MAPK), which are involved in the regulation of cardiac contractility and remodeling (Chen et al., 2010; Li et al., 2013).\nBy inhibiting the activity of these kinases, ranolazine can reduce the excessive contraction and remodeling of the heart that occurs in heart failure. This can help to improve cardiac function and reduce the symptoms of heart failure.\nIn summary, ranolazine affects kinase signaling activation in the heart by inhibiting the activity of certain kinases involved in cardiac contractility and remodeling, which can help to improve cardiac function and reduce the symptoms of heart failure.\nReferences:\nChen, J., et al. (2010). Ranolazine inhibits the activity of protein kinase C and mitogen-activated protein kinase in the heart. American Journal of Physiology-Heart and Circulatory Physiology, 299(5), H1768-H1776.\nLippi, G., & Sanchis-Gomar, F. (2020). The global burden of heart failure: A review of the literature. International Journal of Cardiology, 287, 109-116.\nLi, X., et al. (2013). Ranolazine inhibits the activity of mitogen-activated protein kinase in the heart. American Journal of Physi",
    "llama-2-7b-chat-hf_fact_raw": "1. Ranolazine is a cardiovascular drug that modulates kinase signaling in the heart.\n2. Kinase signaling is involved in cell proliferation, differentiation, and survival, and plays a critical role in regulating cardiac function and contraction.\n3. Dysregulation of kinase signaling is implicated in the development and progression of heart failure.\n4. Ranolazine has been shown to inhibit the activity of protein kinase C (PKC) and mitogen-activated protein kinase (MAPK).\n5. Inhibition of these kinases by ranolazine can reduce excessive cardiac contraction and remodeling in heart failure, potentially improving cardiac function and reducing symptoms.",
    "llama-2-7b-chat-hf_fact": [
      "Ranolazine is a cardiovascular drug that modulates kinase signaling in the heart.",
      "Kinase signaling is involved in cell proliferation, differentiation, and survival, and plays a critical role in regulating cardiac function and contraction.",
      "Dysregulation of kinase signaling is implicated in the development and progression of heart failure.",
      "Ranolazine has been shown to inhibit the activity of protein kinase C (PKC) and mitogen-activated protein kinase (MAPK).",
      "Inhibition of these kinases by ranolazine can reduce excessive cardiac contraction and remodeling in heart failure, potentially improving cardiac function and reducing symptoms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Ranolazine is a cardiovascular drug that is known to inhibit late sodium current in the heart, not specifically modulate kinase signaling.\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1225,
    "user_query": "Is the regulation of Vsr endonuclease independent of the growth phase of bacteria?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, it appears that the regulation of Vsr endonuclease is not directly linked to the growth phase of bacteria. The document mentions that Vsr endonuclease recognizes a TG mismatch within the duplex DNA and initiates repair by cleaving the DNA at the position of the mismatch. The repair process is carried out by Document 0, which is not further specified in the given information.\nTherefore, it can be inferred that the regulation of Vsr endonuclease is not dependent on the growth phase of bacteria, as the enzyme is involved in the repair of DNA mismatches regardless of the growth phase.",
    "llama-2-7b-chat-hf_fact_raw": "1. The regulation of Vsr endonuclease is not directly linked to the growth phase of bacteria.\n2. Vsr endonuclease recognizes a TG mismatch within the duplex DNA.\n3. Vsr endonuclease initiates repair by cleaving the DNA at the position of the mismatch.",
    "llama-2-7b-chat-hf_fact": [
      "The regulation of Vsr endonuclease is not directly linked to the growth phase of bacteria.",
      "Vsr endonuclease recognizes a TG mismatch within the duplex DNA.",
      "Vsr endonuclease initiates repair by cleaving the DNA at the position of the mismatch."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 1233,
    "user_query": "What are the computational tools for the prediction of beta-barrel transmembrane proteins?",
    "llama-2-7b-chat-hf_response": "Thank you for asking! Based on the information provided in Document 0, there are several computational tools that can be used for the prediction of beta-barrel transmembrane proteins:\n1. Sequence alignment: This involves comparing the sequence of the protein of interest to known sequences in databases to identify similarities and differences. This can help identify potential transmembrane domains and predict the overall structure of the protein.\n2. Motif search: This involves searching for specific patterns or motifs in the protein sequence that are known to be associated with transmembrane proteins. These motifs can help identify the location of transmembrane domains and predict the structure of the protein.\n3. Functional residue identification: This involves identifying specific residues in the protein sequence that are known to be important for protein function. These residues can help identify the location of transmembrane domains and predict the structure of the protein.\n4. Transmembrane segment and protein topology predictions: These tools can predict the number and location of transmembrane segments in the protein, as well as the overall protein topology.\n5. Homology and ab initio modeling: These methods use the known structure of related proteins to predict the structure of the protein of interest. Homology modeling uses the known structure of a related protein to build a model of the protein of interest, while ab initio modeling uses a computational model to build a structure for the protein from scratch.\nOverall, these computational tools can help improve the prediction of functional and structural features of membrane proteins, although progress is hampered by the limited amount of high-quality data available.",
    "llama-2-7b-chat-hf_fact_raw": "1. Sequence alignment is used to compare the protein sequence of interest to known sequences in databases to identify potential transmembrane domains.\n2. Motif search involves looking for specific patterns in the protein sequence that are associated with transmembrane proteins.\n3. Functional residue identification is a method to identify specific residues important for protein function within the protein sequence.\n4. Transmembrane segment and protein topology predictions are tools that can predict the number and location of transmembrane segments and the overall protein topology.\n5. Homology and ab initio modeling are methods used to predict the structure of proteins, with homology modeling relying on the structure of related proteins and ab initio modeling building a structure from scratch.",
    "llama-2-7b-chat-hf_fact": [
      "Sequence alignment is used to compare the protein sequence of interest to known sequences in databases to identify potential transmembrane domains.",
      "Motif search involves looking for specific patterns in the protein sequence that are associated with transmembrane proteins.",
      "Functional residue identification is a method to identify specific residues important for protein function within the protein sequence.",
      "Transmembrane segment and protein topology predictions are tools that can predict the number and location of transmembrane segments and the overall protein topology.",
      "Homology and ab initio modeling are methods used to predict the structure of proteins, with homology modeling relying on the structure of related proteins and ab initio modeling building a structure from scratch."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1251,
    "user_query": "Galassi classification is used for which disorder?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, Galassi classification is used to classify middle cranial fossa arachnoid cysts.",
    "llama-2-7b-chat-hf_fact_raw": "1. Galassi classification is used to classify middle cranial fossa arachnoid cysts.",
    "llama-2-7b-chat-hf_fact": [
      "Galassi classification is used to classify middle cranial fossa arachnoid cysts."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 1304,
    "user_query": "List common features of Shapiro syndrome",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the common features of Shapiro syndrome are:\n1. Agenesis of the corpus callosum: This is the most typical feature of Shapiro syndrome and is best appreciated on MRI brain images 1-6.\n2. Typical features of agenesis of the corpus callosum: These features include a lack of communication between the two hemispheres of the brain, leading to cognitive and behavioral abnormalities.\n3. Treatment and prognosis: Management of Shapiro syndrome is guided by case report-level evidence, with effective agents being clonidine, clomipramine, and cyproheptadine.\nIt is important to note that Shapiro syndrome is a rare genetic disorder, and the features and treatment options may vary depending on the individual case. If you have any further questions or concerns, please feel free to ask.",
    "llama-2-7b-chat-hf_fact_raw": "1. Agenesis of the corpus callosum is the most typical feature of Shapiro syndrome.\n2. Agenesis of the corpus callosum in Shapiro syndrome can be identified on MRI brain images.\n3. Shapiro syndrome can lead to cognitive and behavioral abnormalities due to a lack of communication between the two hemispheres of the brain.\n4. Management of Shapiro syndrome may include the use of clonidine, clomipramine, and cyproheptadine.\n5. Shapiro syndrome is a rare genetic disorder.",
    "llama-2-7b-chat-hf_fact": [
      "Agenesis of the corpus callosum is the most typical feature of Shapiro syndrome.",
      "Agenesis of the corpus callosum in Shapiro syndrome can be identified on MRI brain images.",
      "Shapiro syndrome can lead to cognitive and behavioral abnormalities due to a lack of communication between the two hemispheres of the brain.",
      "Management of Shapiro syndrome may include the use of clonidine, clomipramine, and cyproheptadine.",
      "Shapiro syndrome is a rare genetic disorder."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Agenesis of the corpus callosum is not the most typical feature of Shapiro syndrome. The most typical features of Shapiro syndrome include paroxysmal hypothermia, hyperhidrosis, and agenesis of the corpus callosum is an associated but not defining feature.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1320,
    "user_query": "Which disease is linked to mutations within BRAG1?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the disease that is linked to mutations within the BRAG1 gene is X-linked intellectual disability.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutations within the BRAG1 gene are linked to X-linked intellectual disability.",
    "llama-2-7b-chat-hf_fact": [
      "Mutations within the BRAG1 gene are linked to X-linked intellectual disability."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Mutations within the ARX gene (not BRAG1) are linked to X-linked intellectual disability.",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 1362,
    "user_query": "Which protein is the main inhibitor of protein phosphatase 1 (PP1)?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the main inhibitor of protein phosphatase 1 (PP1) is Inhibitor-2 (I-2).",
    "llama-2-7b-chat-hf_fact_raw": "1. Inhibitor-2 (I-2) is the main inhibitor of protein phosphatase 1 (PP1).",
    "llama-2-7b-chat-hf_fact": [
      "Inhibitor-2 (I-2) is the main inhibitor of protein phosphatase 1 (PP1)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 1374,
    "user_query": "Which mechanisms underlie adaptive mutagenesis (stationary-phase mutagenesis) in Bacillus subtilis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the mechanisms that underlie adaptive mutagenesis (stationary-phase mutagenesis) in Bacillus subtilis are:\n1. DNA damage response: The authors of the article mention that nutrient depletion can lead to DNA damage, which can result in mutations. The DNA damage response pathways, such as the SOS response, may play a role in adaptive mutagenesis.\n2. Mutator phenotype: The authors also mention that some mutators, which are strains with a higher mutation rate than the wild type, are more likely to survive nutrient depletion. These mutators may have mutations in genes involved in DNA repair or mutation rate regulation.\n3. Genomic rearrangements: The authors suggest that genomic rearrangements, such as gene deletions or duplications, may also contribute to adaptive mutagenesis in Bacillus subtilis. These rearrangements can result in the loss or gain of function of genes involved in nutrient uptake and utilization, leading to the formation of dormant spores or metabolically quiescent cells.\n4. Epigenetic modifications: Epigenetic modifications, such as DNA methylation or histone modification, may also play a role in adaptive mutagenesis. These modifications can affect gene expression and may help cells adapt to nutrient depletion by altering the expression of genes involved in stress response and survival.\nIn summary, the mechanisms underlying adaptive mutagenesis in Bacillus subtilis include DNA damage response, mutator phenotype, genomic rearrangements, and epigenetic modifications. These mechanisms allow cells to adapt to nutrient depletion and survive in a stationary phase, which is a critical aspect of the survival strategy of this bacterium.",
    "llama-2-7b-chat-hf_fact_raw": "1. Nutrient depletion in Bacillus subtilis can lead to DNA damage, which can result in mutations.\n2. Mutator strains of Bacillus subtilis have a higher mutation rate than the wild type and are more likely to survive nutrient depletion.\n3. Genomic rearrangements, such as gene deletions or duplications, may contribute to adaptive mutagenesis in Bacillus subtilis.\n4. DNA methylation or histone modification are examples of epigenetic modifications that may play a role in adaptive mutagenesis in Bacillus subtilis.\n5. The DNA damage response pathways, including the SOS response, may be involved in adaptive mutagenesis in Bacillus subtilis.",
    "llama-2-7b-chat-hf_fact": [
      "Nutrient depletion in Bacillus subtilis can lead to DNA damage, which can result in mutations.",
      "Mutator strains of Bacillus subtilis have a higher mutation rate than the wild type and are more likely to survive nutrient depletion.",
      "Genomic rearrangements, such as gene deletions or duplications, may contribute to adaptive mutagenesis in Bacillus subtilis.",
      "DNA methylation or histone modification are examples of epigenetic modifications that may play a role in adaptive mutagenesis in Bacillus subtilis.",
      "The DNA damage response pathways, including the SOS response, may be involved in adaptive mutagenesis in Bacillus subtilis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Nutrient depletion can cause stress in bacteria like Bacillus subtilis, which can lead to DNA damage and potentially result in mutations.\n2. TRUE: Mutator strains of Bacillus subtilis do have a higher mutation rate than the wild type, which can confer a survival advantage under certain stressful conditions such as nutrient depletion.\n3. TRUE: Genomic rearrangements, including gene deletions or duplications, are mechanisms that can contribute to adaptive mutagenesis, allowing Bacillus subtilis to adapt to new environments or stressors.\n4. FALSE [correction]: DNA methylation may play a role in gene regulation in bacteria, but histone modification is not applicable to Bacillus subtilis as histones are generally associated with eukaryotic organisms, not prokaryotes like bacteria.\n5. TRUE: The DNA damage response pathways, such as the SOS response, are known to be involved in the repair of DNA damage and can be part of the adaptive mutagenesis process in bacteria, including Bacillus subtilis.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1399,
    "user_query": "What causes erucism?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, it appears that erucism is caused by the presence of Premolis larvae. These larvae are known to infect workers in contact with rubber trees in the Amazon, leading to a condition known as Pararama. This condition is characterized by progressive periarticular fibrosis, ankylosis, and the loss of articulation, which can cause significant pain and disability.\nIt is worth noting that there are other causes of erucism as well, such as bites and stings from ants and aquatic insects of the Belostomatidae family. However, based on the information provided, it seems that Premolis larvae are the primary cause of Pararama and erucism in this context.",
    "llama-2-7b-chat-hf_fact_raw": "1. Erucism is caused by the presence of Premolis larvae.\n2. Workers in contact with rubber trees in the Amazon can be infected by Premolis larvae.\n3. The condition caused by Premolis larvae is known as Pararama.\n4. Pararama is characterized by progressive periarticular fibrosis, ankylosis, and the loss of articulation.\n5. Erucism can also be caused by bites and stings from ants and aquatic insects of the Belostomatidae family.",
    "llama-2-7b-chat-hf_fact": [
      "Erucism is caused by the presence of Premolis larvae.",
      "Workers in contact with rubber trees in the Amazon can be infected by Premolis larvae.",
      "The condition caused by Premolis larvae is known as Pararama.",
      "Pararama is characterized by progressive periarticular fibrosis, ankylosis, and the loss of articulation.",
      "Erucism can also be caused by bites and stings from ants and aquatic insects of the Belostomatidae family."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Erucism is caused by contact with caterpillar bristles, not by bites and stings from ants and aquatic insects of the Belostomatidae family. The condition caused by bites and stings from ants and aquatic insects of the Belostomatidae family is known as pederism.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1413,
    "user_query": "What are the indications for hydrochlorothiazide?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the indications for hydrochlorothiazide are:\n1. Edema (fluid retention; excess fluid held in body tissues) caused by various medical problems, including:\n\t* Heart disease\n\t* Kidney disease\n\t* Liver disease\n\t* Edema caused by using certain medications, such as estrogen and corticosteroids.\nHydrochlorothiazide is a diuretic medication that helps to reduce fluid retention by increasing urine production. It is commonly used to treat edema associated with conditions such as heart failure, liver disease, and kidney disease. It may also be used to treat edema caused by certain medications, such as estrogen and corticosteroids.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hydrochlorothiazide is indicated for the treatment of edema caused by heart disease.\n2. Hydrochlorothiazide is used to treat edema associated with kidney disease.\n3. Hydrochlorothiazide is prescribed for the treatment of edema related to liver disease.\n4. Hydrochlorothiazide can be used to treat edema resulting from the use of certain medications like estrogen and corticosteroids.\n5. Hydrochlorothiazide is a diuretic that increases urine production to reduce fluid retention.",
    "llama-2-7b-chat-hf_fact": [
      "Hydrochlorothiazide is indicated for the treatment of edema caused by heart disease.",
      "Hydrochlorothiazide is used to treat edema associated with kidney disease.",
      "Hydrochlorothiazide is prescribed for the treatment of edema related to liver disease.",
      "Hydrochlorothiazide can be used to treat edema resulting from the use of certain medications like estrogen and corticosteroids.",
      "Hydrochlorothiazide is a diuretic that increases urine production to reduce fluid retention."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1447,
    "user_query": "Has silicon been used in treatment of  incontinence ?",
    "llama-2-7b-chat-hf_response": "Yes, silicon has been used in the treatment of urinary incontinence, specifically stress incontinence. Silicon-based materials have been developed and used in various medical devices, including urinary incontinence products, to help manage and treat stress incontinence.\nSilicon is a versatile material that can be molded and shaped to fit the body's contours, providing a comfortable and discreet fit for users. It is also biocompatible, meaning it is safe for use inside the body and will not cause any adverse reactions.\nSilicon-based urinary incontinence products, such as pessaries, are designed to help manage stress incontinence by providing support to the pelvic floor muscles. These products can be inserted into the vagina and can help to lift and stabilize the pelvic floor, reducing the likelihood of involuntary leakage.\nIn addition to silicon-based products, other materials such as polyurethane and polyester are also used in the treatment of urinary incontinence. These materials offer similar benefits to silicon, including comfort, discretion, and biocompatibility.\nIt is important to note that while silicon-based products can be effective in managing stress incontinence, they may not be suitable for everyone. It is important to consult with a healthcare professional to determine the best course of treatment for individual cases.",
    "llama-2-7b-chat-hf_fact_raw": "1. Silicon has been used in the treatment of urinary incontinence, specifically stress incontinence.\n2. Silicon-based materials are used in medical devices designed to manage and treat stress incontinence.\n3. Silicon is biocompatible and safe for use inside the body without causing adverse reactions.\n4. Silicon-based urinary incontinence products, such as pessaries, provide support to the pelvic floor muscles to manage stress incontinence.\n5. Other materials like polyurethane and polyester are also used in the treatment of urinary incontinence.",
    "llama-2-7b-chat-hf_fact": [
      "Silicon has been used in the treatment of urinary incontinence, specifically stress incontinence.",
      "Silicon-based materials are used in medical devices designed to manage and treat stress incontinence.",
      "Silicon is biocompatible and safe for use inside the body without causing adverse reactions.",
      "Silicon-based urinary incontinence products, such as pessaries, provide support to the pelvic floor muscles to manage stress incontinence.",
      "Other materials like polyurethane and polyester are also used in the treatment of urinary incontinence."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Silicone, not silicon, has been used in the treatment of urinary incontinence, specifically stress incontinence.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1454,
    "user_query": "What is the association between moon cycle and rupture risk of intracranial aneurysms?",
    "llama-2-7b-chat-hf_response": "Thank you for asking! Based on the information provided in Document 0, there is some evidence to suggest that there may be an association between the moon cycle and the risk of rupture of intracranial aneurysms.\nThe study found that the rupture rate of intracranial aneurysms was significantly higher during the full moon phase compared to other phases of the moon cycle. Specifically, the study found that 61% of ruptured aneurysms occurred during the full moon phase, while only 31% of unruptured aneurysms occurred during this phase.\nWhile the study did not investigate the exact mechanisms underlying this association, it is possible that the increased gravitational pull during the full moon phase may play a role in the increased risk of rupture. Additionally, the study suggests that other factors such as changes in blood flow and vessel diameter may also contribute to the association between the moon cycle and rupture risk.\nIt is important to note, however, that this study had a small sample size and further research is needed to confirm these findings and establish a clear association between the moon cycle and rupture risk of intracranial aneurysms.\nIn summary, while the evidence is limited, there is some suggestion that there may be an association between the moon cycle and the risk of rupture of intracranial aneurysms, with a higher rupture rate observed during the full moon phase. Further research is needed to fully understand the relationship between these two phenomena.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is evidence to suggest an association between the moon cycle and the risk of rupture of intracranial aneurysms.\n2. The rupture rate of intracranial aneurysms was significantly higher during the full moon phase compared to other phases of the moon cycle.\n3. The study found that 61% of ruptured aneurysms occurred during the full moon phase.\n4. Only 31% of unruptured aneurysms occurred during the full moon phase.\n5. The study mentioned had a small sample size and indicated that further research is needed to confirm the findings.",
    "llama-2-7b-chat-hf_fact": [
      "There is evidence to suggest an association between the moon cycle and the risk of rupture of intracranial aneurysms.",
      "The rupture rate of intracranial aneurysms was significantly higher during the full moon phase compared to other phases of the moon cycle.",
      "The study found that 61% of ruptured aneurysms occurred during the full moon phase.",
      "Only 31% of unruptured aneurysms occurred during the full moon phase.",
      "The study mentioned had a small sample size and indicated that further research is needed to confirm the findings."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. FALSE [correction]: There is no specific percentage provided in the context to confirm that 61% of ruptured aneurysms occurred during the full moon phase.\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1477,
    "user_query": "Does HuR protein regulate the splicing process?",
    "llama-2-7b-chat-hf_response": "Yes, HuR protein has been shown to regulate the splicing process. According to Document 0, HuR is an RNA-binding protein that can participate in regulating gene expression through various mechanisms, including the regulation of alternative splicing and alternative polyadenylation. Alternative splicing is a process by which the same gene can be expressed in different forms, depending on the splicing pattern of the RNA molecule. HuR has been shown to bind to specific splicing regulatory elements and enhance the splicing of certain exons, leading to the production of different isoforms of proteins. Therefore, HuR can regulate the splicing process by modulating the expression of specific isoforms of proteins.",
    "llama-2-7b-chat-hf_fact_raw": "1. HuR protein regulates the splicing process.\n2. HuR is an RNA-binding protein.\n3. HuR participates in regulating gene expression through various mechanisms.\n4. HuR can enhance the splicing of certain exons.\n5. HuR's regulation leads to the production of different isoforms of proteins.",
    "llama-2-7b-chat-hf_fact": [
      "HuR protein regulates the splicing process.",
      "HuR is an RNA-binding protein.",
      "HuR participates in regulating gene expression through various mechanisms.",
      "HuR can enhance the splicing of certain exons.",
      "HuR's regulation leads to the production of different isoforms of proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1492,
    "user_query": "Describe the known functions for the prothymosin alpha c-terminal peptide?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the known functions of the prothymosin alpha c-terminal peptide are:\n1. Kelch-binding: Prothymosin alpha (ProTα) and its c-terminal peptide have been shown to bind to the Kelch domain of the Keap1 protein, which is involved in regulating the activity of the Nrf2 transcription factor.\n2. Neh2 binding: ProTα and its c-terminal peptide have also been shown to bind to the Neh2 protein, which is involved in the regulation of the Keap1-Nrf2 pathway.\n3. Regulation of Nrf2 activity: ProTα has been shown to regulate the activity of the Nrf2 transcription factor by modulating its stability and localization in the cell.\n4. Antioxidant activity: ProTα has been shown to have antioxidant activity, which may contribute to its protective effects against oxidative stress.\nOverall, the c-terminal peptide of prothymosin alpha appears to play a role in regulating the Keap1-Nrf2 pathway and modulating the activity of the Nrf2 transcription factor, which is involved in the response to oxidative stress.",
    "llama-2-7b-chat-hf_fact_raw": "1. Prothymosin alpha (ProTα) and its c-terminal peptide bind to the Kelch domain of the Keap1 protein.\n2. Prothymosin alpha (ProTα) and its c-terminal peptide bind to the Neh2 protein.\n3. Prothymosin alpha (ProTα) regulates the activity of the Nrf2 transcription factor by modulating its stability and localization in the cell.\n4. Prothymosin alpha (ProTα) has antioxidant activity.\n5. The c-terminal peptide of prothymosin alpha plays a role in regulating the Keap1-Nrf2 pathway.",
    "llama-2-7b-chat-hf_fact": [
      "Prothymosin alpha (ProTα) and its c-terminal peptide bind to the Kelch domain of the Keap1 protein.",
      "Prothymosin alpha (ProTα) and its c-terminal peptide bind to the Neh2 protein.",
      "Prothymosin alpha (ProTα) regulates the activity of the Nrf2 transcription factor by modulating its stability and localization in the cell.",
      "Prothymosin alpha (ProTα) has antioxidant activity.",
      "The c-terminal peptide of prothymosin alpha plays a role in regulating the Keap1-Nrf2 pathway."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Prothymosin alpha (ProTα) and its c-terminal peptide do not bind to the Neh2 protein. Instead, the Neh2 domain is a region within the Nrf2 protein that interacts with Keap1.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1516,
    "user_query": "Which peptide plays a pivotal role in human cystatin C fibrillization?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the peptide that plays a pivotal role in human cystatin C (HCC) fibrillization is most likely the 120-amino acid segment of HCC. This is because the abstract mentions that HCC consists of 120 amino acids and that it forms amyloid fibrils in pathological conditions, such as in the brain arteries of young adults. Therefore, the 120-amino acid segment of HCC is the most likely candidate for being the pivotal peptide involved in fibrillization.",
    "llama-2-7b-chat-hf_fact_raw": "1. Human cystatin C (HCC) consists of 120 amino acids.\n2. Human cystatin C forms amyloid fibrils in pathological conditions.\n3. Amyloid fibrils of human cystatin C are found in the brain arteries of young adults.",
    "llama-2-7b-chat-hf_fact": [
      "Human cystatin C (HCC) consists of 120 amino acids.",
      "Human cystatin C forms amyloid fibrils in pathological conditions.",
      "Amyloid fibrils of human cystatin C are found in the brain arteries of young adults."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Amyloid fibrils of human cystatin C are associated with hereditary cerebral amyloid angiopathy, which typically affects older adults, not exclusively young adults.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1574,
    "user_query": "Does the concentration of protein HIF-1α increase after the administration of the cytoprotective prodrug\"amifostine\" (ethyol) ?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, it appears that the concentration of protein HIF-1α does increase after the administration of the cytoprotective prodrug \"amifostine\" (ethyol).\nThe document states that HIF-1α activation leads to a decrease in the surface expression of BCR, CD19, and B cell–activating factor receptor, as well as an increase in the expression of the proapoptotic protein BIM. When BIM deletion rescues the developmental block, it suggests that the increase in HIF-1α activity is necessary for the observed effects.\nTherefore, based on the information provided, it can be concluded that the concentration of protein HIF-1α does increase after the administration of amifostine (ethyol).",
    "llama-2-7b-chat-hf_fact_raw": "1. The concentration of protein HIF-1α increases after the administration of the cytoprotective prodrug \"amifostine\" (ethyol).\n2. HIF-1α activation leads to a decrease in the surface expression of BCR, CD19, and B cell–activating factor receptor.\n3. HIF-1α activation leads to an increase in the expression of the proapoptotic protein BIM.\n4. Deletion of BIM rescues the developmental block caused by increased HIF-1α activity.",
    "llama-2-7b-chat-hf_fact": [
      "The concentration of protein HIF-1α increases after the administration of the cytoprotective prodrug \"amifostine\" (ethyol).",
      "HIF-1α activation leads to a decrease in the surface expression of BCR, CD19, and B cell–activating factor receptor.",
      "HIF-1α activation leads to an increase in the expression of the proapoptotic protein BIM.",
      "Deletion of BIM rescues the developmental block caused by increased HIF-1α activity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The statement about the concentration of protein HIF-1α increasing after the administration of amifostine is specific and would require scientific data or research to confirm its accuracy.\n2. UNKNOWN: The effect of HIF-1α activation on the surface expression of BCR, CD19, and B cell–activating factor receptor is also specific and requires scientific evidence to validate.\n3. UNKNOWN: The statement regarding HIF-1α activation leading to an increase in the expression of the proapoptotic protein BIM is a scientific claim that needs to be supported by research data.\n4. UNKNOWN: The claim that deletion of BIM rescues the developmental block caused by increased HIF-1α activity is a scientific hypothesis or conclusion that would need to be substantiated by experimental results or studies.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1588,
    "user_query": "Which histone marks are deposited by Set7?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, Set7 deposits the histone mark H4K20 methylation.",
    "llama-2-7b-chat-hf_fact_raw": "1. Set7 deposits the histone mark H4K20 methylation.",
    "llama-2-7b-chat-hf_fact": [
      "Set7 deposits the histone mark H4K20 methylation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Set8 (also known as PR-Set7 or SETD8) is the enzyme that deposits the histone mark H4K20 methylation. Set7 (also known as SETD7) is known for methylating lysine 4 on histone H3 (H3K4).",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 1620,
    "user_query": "How many disulfide bridges has the protein hepcidin got?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the protein hepcidin has 8 disulfide bridges.",
    "llama-2-7b-chat-hf_fact_raw": "1. The protein hepcidin has 8 disulfide bridges.",
    "llama-2-7b-chat-hf_fact": [
      "The protein hepcidin has 8 disulfide bridges."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The protein hepcidin typically has 4 disulfide bridges.",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 1643,
    "user_query": "What is the localization of the protein encoded by the gene DNAJC11?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the localization of the protein encoded by the gene DNAJC11 is predicted to be internal to the cell. The document states that proteins encoded by essential genes are enriched in internal location sites and do not reside in the cell envelope. Therefore, it is likely that the protein encoded by DNAJC11 is localized within the cell, rather than on the cell surface or in the extracellular space.",
    "llama-2-7b-chat-hf_fact_raw": "1. The protein encoded by the gene DNAJC11 is predicted to be localized internally within the cell.\n2. Proteins encoded by essential genes are enriched in internal location sites.\n3. Proteins encoded by essential genes do not reside in the cell envelope.",
    "llama-2-7b-chat-hf_fact": [
      "The protein encoded by the gene DNAJC11 is predicted to be localized internally within the cell.",
      "Proteins encoded by essential genes are enriched in internal location sites.",
      "Proteins encoded by essential genes do not reside in the cell envelope."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The protein encoded by the gene DNAJC11 is indeed predicted to be localized internally within the cell, as it is a member of the DnaJ family of proteins which typically function within the cytoplasm and organelles.\n2. TRUE: Proteins encoded by essential genes are often enriched in internal location sites such as the cytoplasm, nucleus, and various organelles, where they perform critical functions for cell survival and replication.\n3. FALSE [correction]: It is not accurate to say that proteins encoded by essential genes do not reside in the cell envelope. Some essential proteins do localize to the cell envelope, where they play crucial roles in processes such as cell wall synthesis, structure, and signaling. Essential genes can encode proteins that are found in various cellular locations, including the cell envelope.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1655,
    "user_query": "Are ultraconserved elements depleted among copy number variants (CNVs)?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the answer to the user's question is: Yes, ultraconserved elements (UCEs) are depleted among copy number variants (CNVs).\nThe passage states that the number of genes containing intronic UCEs is small (123 genes, approximately 35 megabases or 1.2% of the genome), and that these genes are themselves depleted among structural variant (SD) regions (147,827 base pairs of observed overlap, P = 0.005, observed/expected = 0.10). This suggests that UCEs are underrepresented among CNVs.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ultraconserved elements (UCEs) are depleted among copy number variants (CNVs).\n2. There are 123 genes containing intronic UCEs.\n3. The total size of the genes containing intronic UCEs is approximately 35 megabases or 1.2% of the genome.\n4. The genes with intronic UCEs have a depleted presence among structural variant (SV) regions.\n5. The observed overlap between intronic UCEs and structural variant regions is 147,827 base pairs with a statistical significance of P = 0.005 and an observed/expected ratio of 0.10.",
    "llama-2-7b-chat-hf_fact": [
      "Ultraconserved elements (UCEs) are depleted among copy number variants (CNVs).",
      "There are 123 genes containing intronic UCEs.",
      "The total size of the genes containing intronic UCEs is approximately 35 megabases or 1.2% of the genome.",
      "The genes with intronic UCEs have a depleted presence among structural variant (SV) regions.",
      "The observed overlap between intronic UCEs and structural variant regions is 147,827 base pairs with a statistical significance of P = 0.005 and an observed/expected ratio of 0.10."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Ultraconserved elements (UCEs) are indeed known to be regions of the genome that are highly conserved across different species and are typically depleted among copy number variants (CNVs), which are large regions of the genome that have been deleted, duplicated, or otherwise altered.\n\n2. UNKNOWN: Without specific reference to a study or database, it is not possible to confirm the exact number of genes containing intronic UCEs. This number could vary based on the criteria used to define UCEs and the version of the human genome reference used.\n\n3. UNKNOWN: Similar to statement 2, the total size of genes containing intronic UCEs and their proportion of the genome would require specific reference data to confirm. The number provided is plausible but cannot be verified without additional context.\n\n4. TRUE: It is consistent with the nature of UCEs that the genes with intronic UCEs would have a depleted presence among structural variant (SV) regions, as structural variants can cause significant alterations in the genome, and UCEs are typically regions with low variation.\n\n5. UNKNOWN: The specific overlap between intronic UCEs and structural variant regions, along with the statistical significance and observed/expected ratio, would need to be confirmed with a specific study or dataset. Without this information, the accuracy of the statement cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1665,
    "user_query": "Which is the substrate of the haspin kinase during mitosis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the substrate of the Haspin kinase during mitosis is histone H3.",
    "llama-2-7b-chat-hf_fact_raw": "1. The substrate of the Haspin kinase during mitosis is histone H3.",
    "llama-2-7b-chat-hf_fact": [
      "The substrate of the Haspin kinase during mitosis is histone H3."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 1696,
    "user_query": "What is the mechanism of viroid replication?",
    "llama-2-7b-chat-hf_response": "Thank you for providing the information! Based on the details provided, the mechanism of viroid replication appears to involve an RNA-based rolling-circle mechanism with three steps that occur in both polarity strands.\nHere's a simplified explanation of the mechanism:\nStep 1: Synthesis of longer-than-unit strands\nViroid replication begins with the synthesis of longer-than-unit strands of RNA, catalyzed by either the nuclear RNA polymerase II or a nuclear-encoded chloroplastic RNA polymerase. These enzymes are redirected to transcribe RNA templates that are complementary to the viroid RNA.\nStep 2: Circularization of the RNA\nOnce the longer-than-unit strands are synthesized, they are circularized through an RNA-dependent RNA polymerase reaction. This results in the formation of a circular RNA molecule that serves as a template for the next step of replication.\nStep 3: Replication of the circular RNA\nThe circular RNA template is then replicated through an RNA-dependent RNA polymerase reaction, resulting in the production of additional viroid RNA molecules. This process is continuous, allowing the viroid to rapidly amplify its genetic material.\nIt's worth noting that the exact mechanisms of viroid replication can vary depending on the specific viroid and the organism in which it is found. However, the general RNA-based rolling-circle mechanism is a common feature among viroids.",
    "llama-2-7b-chat-hf_fact_raw": "1. Viroid replication involves an RNA-based rolling-circle mechanism.\n2. The replication begins with the synthesis of longer-than-unit strands of RNA.\n3. The synthesis of longer-than-unit strands is catalyzed by either the nuclear RNA polymerase II or a nuclear-encoded chloroplastic RNA polymerase.\n4. The longer-than-unit strands are circularized through an RNA-dependent RNA polymerase reaction.\n5. The circular RNA template is replicated to produce additional viroid RNA molecules.",
    "llama-2-7b-chat-hf_fact": [
      "Viroid replication involves an RNA-based rolling-circle mechanism.",
      "The replication begins with the synthesis of longer-than-unit strands of RNA.",
      "The synthesis of longer-than-unit strands is catalyzed by either the nuclear RNA polymerase II or a nuclear-encoded chloroplastic RNA polymerase.",
      "The longer-than-unit strands are circularized through an RNA-dependent RNA polymerase reaction.",
      "The circular RNA template is replicated to produce additional viroid RNA molecules."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The longer-than-unit strands are cleaved and circularized through host cell enzymes, not an RNA-dependent RNA polymerase reaction.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1723,
    "user_query": "Does fibronectin constitute a serum biomarker for Duchenne muscular dystrophy?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, fibronectin does not constitute a serum biomarker for Duchenne muscular dystrophy. The document focuses on molecular biomarkers linked to inflammation and oxidative damage, but does not mention fibronectin as a biomarker for Duchenne muscular dystrophy.\nFibronectin is a protein that plays a crucial role in cell adhesion, migration, and signaling, and has been implicated in various diseases, including cancer and cardiovascular disease. However, there is limited information available on its use as a biomarker for Duchenne muscular dystrophy.\nThe document highlights protein thiol oxidation and neutrophils as potential biomarkers for Duchenne muscular dystrophy, but does not mention fibronectin. Therefore, based on the information provided, fibronectin is not a serum biomarker for Duchenne muscular dystrophy.",
    "llama-2-7b-chat-hf_fact_raw": "1. Fibronectin is a protein that plays a role in cell adhesion, migration, and signaling.\n2. Fibronectin has been implicated in various diseases, including cancer and cardiovascular disease.\n3. The document reviewed does not mention fibronectin as a biomarker for Duchenne muscular dystrophy.\n4. Protein thiol oxidation and neutrophils are highlighted as potential biomarkers for Duchenne muscular dystrophy in the document.\n5. Based on the provided information, fibronectin is not considered a serum biomarker for Duchenne muscular dystrophy.",
    "llama-2-7b-chat-hf_fact": [
      "Fibronectin is a protein that plays a role in cell adhesion, migration, and signaling.",
      "Fibronectin has been implicated in various diseases, including cancer and cardiovascular disease.",
      "The document reviewed does not mention fibronectin as a biomarker for Duchenne muscular dystrophy.",
      "Protein thiol oxidation and neutrophils are highlighted as potential biomarkers for Duchenne muscular dystrophy in the document.",
      "Based on the provided information, fibronectin is not considered a serum biomarker for Duchenne muscular dystrophy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout the actual document for review, it is impossible to confirm the specific content regarding fibronectin, protein thiol oxidation, neutrophils, or their relation to Duchenne muscular dystrophy. Therefore, statements 3, 4, and 5 are marked as UNKNOWN.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1763,
    "user_query": "Data from which major epigenome projects are contained in the DeepBlue epigenomic data server?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the major epigenome projects whose data are contained in the DeepBlue epigenomic data server are:\n1. ENCODE (Encyclopedia of DNA Elements)\n2. ROADMAP (Roadmap Epigenomics Consortium)\n3. BLUEPRINT (Blueprint Epigenomics Project)\n4. DEEP (Deep Epigenomics Project)\nThese projects are some of the largest and most comprehensive epigenomics initiatives to date, and their data are widely used in the field of epigenomics research. The DeepBlue data server provides a centralized repository for these data, making it easier for researchers to access and analyze the data from these projects.",
    "llama-2-7b-chat-hf_fact_raw": "1. The DeepBlue epigenomic data server contains data from the ENCODE project.\n2. The DeepBlue epigenomic data server contains data from the ROADMAP Epigenomics Consortium.\n3. The DeepBlue epigenomic data server contains data from the BLUEPRINT Epigenomics Project.\n4. The DeepBlue epigenomic data server contains data from the DEEP Epigenomics Project.",
    "llama-2-7b-chat-hf_fact": [
      "The DeepBlue epigenomic data server contains data from the ENCODE project.",
      "The DeepBlue epigenomic data server contains data from the ROADMAP Epigenomics Consortium.",
      "The DeepBlue epigenomic data server contains data from the BLUEPRINT Epigenomics Project.",
      "The DeepBlue epigenomic data server contains data from the DEEP Epigenomics Project."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n\nThe DeepBlue epigenomic data server is designed to provide access to a variety of epigenomic data, including data from projects such as ENCODE (Encyclopedia of DNA Elements), ROADMAP Epigenomics Consortium, BLUEPRINT Epigenomics, and DEEP (Deutsches Epigenom Programm). These projects aim to map the human epigenome and provide insights into the regulation of gene expression.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1792,
    "user_query": "Which tool employs self organizing maps for analyzing synonymous codon usage?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the tool that employs self-organizing maps for analyzing synonymous codon usage is called \"CodonUsage\".",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 1793,
    "user_query": "What is MINDY-1?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, MINDY-1 appears to be a television show. Specifically, it is a comedy series created by Mindy Kaling and starring Kaling as a young Ob/Gyn doctor. The show follows the personal and professional life of the doctor and her quirky co-workers in a small office. The show has six seasons available to stream on various platforms, including IMDbPro.",
    "llama-2-7b-chat-hf_fact_raw": "1. MINDY-1 is a television show.\n2. Mindy Kaling created the MINDY-1 series.\n3. Mindy Kaling stars in the MINDY-1 series as a young Ob/Gyn doctor.\n4. The show MINDY-1 has six seasons.\n5. MINDY-1 is available to stream on various platforms, including IMDbPro.",
    "llama-2-7b-chat-hf_fact": [
      "MINDY-1 is a television show.",
      "Mindy Kaling created the MINDY-1 series.",
      "Mindy Kaling stars in the MINDY-1 series as a young Ob/Gyn doctor.",
      "The show MINDY-1 has six seasons.",
      "MINDY-1 is available to stream on various platforms, including IMDbPro."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The television show is called \"The Mindy Project,\" not MINDY-1.\n2. TRUE (Assuming the statement refers to \"The Mindy Project,\" which was created by Mindy Kaling.)\n3. TRUE (Again, assuming the statement refers to \"The Mindy Project,\" in which Mindy Kaling stars as a young Ob/Gyn doctor.)\n4. FALSE [correction]: \"The Mindy Project\" has six seasons.\n5. UNKNOWN (While \"The Mindy Project\" is available to stream on various platforms, without current data, it's unclear if IMDbPro is one of them, as platforms' offerings can change.)",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1810,
    "user_query": "Which software package is available for the analysis of conserved genomic loci?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the software package available for the analysis of conserved genomic loci is PHYLUCE. According to the document, PHYLUCE is a software package for the analysis of conserved genomic loci, and targeted enrichment of conserved and ultraconserved genomic elements allows for universal collection of genomic DNA samples. This suggests that PHYLUCE is specifically designed for the analysis of conserved genomic regions, which are often associated with functional elements such as genes, regulatory elements, and other important features.",
    "llama-2-7b-chat-hf_fact_raw": "1. PHYLUCE is a software package available for the analysis of conserved genomic loci.\n2. PHYLUCE is designed for targeted enrichment of conserved and ultraconserved genomic elements.\n3. PHYLUCE allows for the universal collection of genomic DNA samples.",
    "llama-2-7b-chat-hf_fact": [
      "PHYLUCE is a software package available for the analysis of conserved genomic loci.",
      "PHYLUCE is designed for targeted enrichment of conserved and ultraconserved genomic elements.",
      "PHYLUCE allows for the universal collection of genomic DNA samples."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: PHYLUCE is designed for the analysis of conserved genomic loci, particularly from ultraconserved elements, but it does not collect genomic DNA samples. The collection of samples is a separate process that must be done before using software like PHYLUCE for analysis.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1860,
    "user_query": "Please list 3 diseases associated with the PIEZO2 gene.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the three diseases associated with the PIEZO2 gene are:\n1. Distal arthrogryposis with impaired proprioception and touch (DAIPT)\n2. Impaired proprioception and touch\n3. Recessive PIEZO2 loss-of-function pathogenic variants\nPlease note that these are the diseases associated with the PIEZO2 gene based on the information provided in the document, and there may be other diseases associated with this gene that are not mentioned in the document.",
    "llama-2-7b-chat-hf_fact_raw": "1. Distal arthrogryposis with impaired proprioception and touch (DAIPT) is associated with the PIEZO2 gene.\n2. Impaired proprioception and touch is associated with the PIEZO2 gene.\n3. Recessive PIEZO2 loss-of-function pathogenic variants are associated with disease.",
    "llama-2-7b-chat-hf_fact": [
      "Distal arthrogryposis with impaired proprioception and touch (DAIPT) is associated with the PIEZO2 gene.",
      "Impaired proprioception and touch is associated with the PIEZO2 gene.",
      "Recessive PIEZO2 loss-of-function pathogenic variants are associated with disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1867,
    "user_query": "What is promoted by ERAP1-ERAP2 dimerization?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, ERAP1-ERAP2 dimerization is promoted by the induction of ERAP1 and ERAP2 proteins after treatment of HeLa cells with interferon-gamma (IFN-γ). The mRNA induction of ERAP1 and ERAP2 was found to be 10.5-fold and 7.2-fold, respectively, after treatment with IFN-γ. This suggests that the dimerization of ERAP1 and ERAP2 is enhanced after the induction of these proteins, which is likely to play a role in the processing and presentation of exogenous antigens to T cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. ERAP1-ERAP2 dimerization is promoted by the induction of ERAP1 and ERAP2 proteins.\n2. Treatment of HeLa cells with interferon-gamma (IFN-γ) induces ERAP1 and ERAP2 proteins.\n3. The mRNA induction of ERAP1 was found to be 10.5-fold after treatment with IFN-γ.\n4. The mRNA induction of ERAP2 was found to be 7.2-fold after treatment with IFN-γ.\n5. The dimerization of ERAP1 and ERAP2 is suggested to play a role in the processing and presentation of exogenous antigens to T cells.",
    "llama-2-7b-chat-hf_fact": [
      "ERAP1-ERAP2 dimerization is promoted by the induction of ERAP1 and ERAP2 proteins.",
      "Treatment of HeLa cells with interferon-gamma (IFN-γ) induces ERAP1 and ERAP2 proteins.",
      "The mRNA induction of ERAP1 was found to be 10.5-fold after treatment with IFN-γ.",
      "The mRNA induction of ERAP2 was found to be 7.2-fold after treatment with IFN-γ.",
      "The dimerization of ERAP1 and ERAP2 is suggested to play a role in the processing and presentation of exogenous antigens to T cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: The dimerization of ERAP1 and ERAP2 is suggested to play a role in the processing and presentation of endogenous antigens to T cells.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 1890,
    "user_query": "What is the function of R-spondin 1 and noggin in non-damaged gallbladders?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, R-spondin 1 and Noggin are growth factors that play a crucial role in the growth and development of organoids derived from various epithelial tissues, including the gallbladder. In non-damaged gallbladders, these factors are essential for the proper formation and maintenance of gallbladder tissue.\nR-spondin 1 is a secreted protein that belongs to the R-spondin family of growth factors. It is a key regulator of cell fate decisions during embryonic development and tissue repair, and it has been shown to play a role in the regulation of gallbladder development and function.\nNoggin, on the other hand, is a BMP (Bone Morphogenetic Protein) inhibitor that is also essential for the growth and development of organoids derived from various epithelial tissues. BMPs are a family of growth factors that play a crucial role in the regulation of cell fate decisions and tissue development, and Noggin inhibits the activity of BMPs, thereby regulating their downstream effects.\nIn non-damaged gallbladders, R-spondin 1 and Noggin work together to regulate the growth and development of gallbladder tissue, ensuring that it functions properly and efficiently. Without these factors, the gallbladder may not develop or function properly, leading to a range of health problems.\nIn summary, R-spondin 1 and Noggin are essential growth factors in non-damaged gallbladders, and their dysregulation can lead to problems with gallbladder development and function.",
    "llama-2-7b-chat-hf_fact_raw": "1. R-spondin 1 is a secreted protein that is part of the R-spondin family of growth factors.\n2. R-spondin 1 plays a role in cell fate decisions during embryonic development and tissue repair.\n3. R-spondin 1 is involved in the regulation of gallbladder development and function.\n4. Noggin is a BMP inhibitor that is involved in the growth and development of organoids derived from various epithelial tissues.\n5. BMPs are a family of growth factors that are involved in the regulation of cell fate decisions and tissue development.",
    "llama-2-7b-chat-hf_fact": [
      "R-spondin 1 is a secreted protein that is part of the R-spondin family of growth factors.",
      "R-spondin 1 plays a role in cell fate decisions during embryonic development and tissue repair.",
      "R-spondin 1 is involved in the regulation of gallbladder development and function.",
      "Noggin is a BMP inhibitor that is involved in the growth and development of organoids derived from various epithelial tissues.",
      "BMPs are a family of growth factors that are involved in the regulation of cell fate decisions and tissue development."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: R-spondin 1 is involved in the regulation of Wnt signaling, which is important for various developmental processes, but there is no specific evidence provided here that it is involved in gallbladder development and function. This role is more commonly associated with R-spondin 2.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1937,
    "user_query": "Does NADPH oxidase 5 require any subunit for function?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, it appears that NOX5, also known as NADPH oxidase 5, does require a subunit for function. The document states that NOX5 contains four Ca2+ binding domains at the N-terminus, which suggests that it may be a multi-subunit enzyme. Additionally, the document states that the activity of NOX5 is regulated by the intracellular concentration of Ca2+, which further supports the idea that NOX5 is a multi-subunit enzyme.\nTherefore, based on the information provided in Document 0, the answer to the user's question is yes, NOX5 requires a subunit for function.",
    "llama-2-7b-chat-hf_fact_raw": "1. NADPH oxidase 5 (NOX5) requires a subunit for function.\n2. NOX5 contains four Ca2+ binding domains at the N-terminus.\n3. The activity of NOX5 is regulated by the intracellular concentration of Ca2+.",
    "llama-2-7b-chat-hf_fact": [
      "NADPH oxidase 5 (NOX5) requires a subunit for function.",
      "NOX5 contains four Ca2+ binding domains at the N-terminus.",
      "The activity of NOX5 is regulated by the intracellular concentration of Ca2+."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: NADPH oxidase 5 (NOX5) does not require a subunit for function; it is calcium-dependent and functions independently of cytosolic subunits.\n2. TRUE\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1944,
    "user_query": "What is the connection between furin and hepcidin?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there appears to be a connection between the protein furin and the peptide hepcidin. According to the document, hepcidin is synthesized in hepatocytes as a larger, inactive pre-prohepcidin, which is then cleaved by the prohormone convertase furin to generate mature hepcidin. In other words, furin plays a role in the processing and activation of hepcidin.\nFurin is a prohormone convertase that is involved in the post-translational modification of many proteins, including hormones, neurotransmitters, and growth factors. It is a key enzyme in the processing of many proteins, and is involved in a wide range of cellular processes, including protein secretion, cell signaling, and immune response.\nIn the case of hepcidin, furin is responsible for cleaving the larger pre-prohepcidin molecule into the active mature hepcidin peptide. This processing step is important for the proper functioning of hepcidin, as it allows the peptide to interact with its target proteins and perform its antimicrobial and iron-regulatory functions.\nIn summary, the connection between furin and hepcidin is that furin is involved in the processing and activation of hepcidin, converting the larger pre-prohepcidin molecule into the active mature hepcidin peptide.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hepcidin is synthesized in hepatocytes as a larger, inactive pre-prohepcidin.\n2. The prohormone convertase furin cleaves pre-prohepcidin to generate mature hepcidin.\n3. Furin is involved in the post-translational modification of many proteins, including hormones, neurotransmitters, and growth factors.\n4. Furin plays a role in cellular processes such as protein secretion, cell signaling, and immune response.\n5. The active mature hepcidin peptide performs antimicrobial and iron-regulatory functions.",
    "llama-2-7b-chat-hf_fact": [
      "Hepcidin is synthesized in hepatocytes as a larger, inactive pre-prohepcidin.",
      "The prohormone convertase furin cleaves pre-prohepcidin to generate mature hepcidin.",
      "Furin is involved in the post-translational modification of many proteins, including hormones, neurotransmitters, and growth factors.",
      "Furin plays a role in cellular processes such as protein secretion, cell signaling, and immune response.",
      "The active mature hepcidin peptide performs antimicrobial and iron-regulatory functions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1956,
    "user_query": "Which is the largest metabolic gene cluster in yeast?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the largest metabolic gene cluster in yeast is the DAL cluster.",
    "llama-2-7b-chat-hf_fact_raw": "1. The largest metabolic gene cluster in yeast is the DAL cluster.",
    "llama-2-7b-chat-hf_fact": [
      "The largest metabolic gene cluster in yeast is the DAL cluster."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 1967,
    "user_query": "What is the role of LIMT lncRNA?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the role of the long non-coding RNA (lncRNA) LIMT in hepatocellular carcinoma (HCC) is not well understood. The study aims to explore the biological role of LIMT in HCC by evaluating its expression in HCC tissue using quantitative real-time PCR. The study found that the expression of LIMT was significantly lower in HCC tissue compared to normal liver tissue, suggesting that LIMT may play a tumor suppressor role in HCC. Further research is needed to confirm this finding and to determine the underlying mechanisms by which LIMT regulates HCC development and progression.",
    "llama-2-7b-chat-hf_fact_raw": "1. LIMT is a long non-coding RNA (lncRNA).\n2. The role of LIMT in hepatocellular carcinoma (HCC) is not well understood.\n3. The study mentioned aimed to explore the biological role of LIMT in HCC.\n4. The expression of LIMT was found to be significantly lower in HCC tissue compared to normal liver tissue.\n5. The study suggests that LIMT may play a tumor suppressor role in hepatocellular carcinoma.",
    "llama-2-7b-chat-hf_fact": [
      "LIMT is a long non-coding RNA (lncRNA).",
      "The role of LIMT in hepatocellular carcinoma (HCC) is not well understood.",
      "The study mentioned aimed to explore the biological role of LIMT in HCC.",
      "The expression of LIMT was found to be significantly lower in HCC tissue compared to normal liver tissue.",
      "The study suggests that LIMT may play a tumor suppressor role in hepatocellular carcinoma."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nWithout additional context or specific details from the study, it is difficult to provide corrections for any of the statements. The statements provided are consistent with common scientific reporting where a study might explore the role of a particular lncRNA in a type of cancer, findings could indicate differential expression, and implications of such findings could suggest a potential role in cancer biology.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1984,
    "user_query": "Which R / bioconductor package is used for performing SNP enrichment analysis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the R/Bioconductor package used for performing SNP enrichment analysis is \"gprofiler2\".",
    "llama-2-7b-chat-hf_fact_raw": "1. The R/Bioconductor package \"gprofiler2\" is used for performing SNP enrichment analysis.",
    "llama-2-7b-chat-hf_fact": [
      "The R/Bioconductor package \"gprofiler2\" is used for performing SNP enrichment analysis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The R/Bioconductor package \"gprofiler2\" is used for gene set enrichment analysis, not specifically SNP enrichment analysis. It provides functions for querying gene sets against various biological databases to understand the functional profiles of gene lists.",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 2015,
    "user_query": "Which are the key players on radial glial specification to ependymal cells?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the key players in radial glial specification to ependymal cells are:\n1. Radial glia (Gfap+ cluster): These are the immature ependymal cell precursor cells that give rise to mature ependymal cells through an ordered process.\n2. Foxj1+ cells: These are the cells that are expressed in the ependymal cells (Foxj1+ cluster) and are involved in the specification of ependymal cells from radial glia.\nThe information provided in Document 0 suggests that there is a pseudotime ordering of the cells in the neonatal dataset, where radial glia give rise to mature ependymal cells through a curved trajectory. The use of Slingshot for pseudotime ordering suggests that the cells are ordered in a specific manner, with radial glia being the immature ependymal cell precursor cells and mature ependymal cells being the final product of the process.\nTherefore, the key players in radial glial specification to ependymal cells are the radial glia and Foxj1+ cells, as they are involved in the process of specification and differentiation of ependymal cells from radial glia.",
    "llama-2-7b-chat-hf_fact_raw": "1. Radial glia are precursor cells that give rise to mature ependymal cells.\n2. Foxj1+ cells are expressed in ependymal cells and are involved in their specification from radial glia.\n3. There is a pseudotime ordering of cells in the neonatal dataset, where radial glia develop into mature ependymal cells.\n4. The Slingshot method is used for pseudotime ordering of cells.\n5. The process of radial glia developing into mature ependymal cells follows a curved trajectory.",
    "llama-2-7b-chat-hf_fact": [
      "Radial glia are precursor cells that give rise to mature ependymal cells.",
      "Foxj1+ cells are expressed in ependymal cells and are involved in their specification from radial glia.",
      "There is a pseudotime ordering of cells in the neonatal dataset, where radial glia develop into mature ependymal cells.",
      "The Slingshot method is used for pseudotime ordering of cells.",
      "The process of radial glia developing into mature ependymal cells follows a curved trajectory."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nThe first four statements are consistent with known biological processes and methods used in cell biology research. Radial glia are indeed precursor cells that can differentiate into various cell types, including ependymal cells. Foxj1 is a transcription factor known to be involved in the specification of ependymal cells. Pseudotime ordering is a concept used in single-cell analyses to infer the developmental trajectory of cells, and the Slingshot method is one of the computational approaches used for this purpose.\n\nThe fifth statement is more ambiguous without additional context. The term \"curved trajectory\" is not standard in describing cell differentiation pathways, and without specific data or a source, it's unclear whether this refers to a literal spatial trajectory or a more abstract developmental pathway. Therefore, the truth of this statement cannot be determined with the information provided.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2065,
    "user_query": "How are triple negative gliomas characterized?",
    "llama-2-7b-chat-hf_response": "Thank you for asking! Based on the information provided, triple negative gliomas are characterized as having a specific genomic landscape. According to Document 0, lower-grade gliomas, including triple negative gliomas, have been investigated in \"multi-omic\" analyses that have revealed molecular subgroups with prognostic relevance. Specifically, these analyses have found that triple negative gliomas have a distinct genomic profile, including the presence of certain genetic mutations and copy number alterations. These findings have important implications for the diagnosis and prognosis of triple negative gliomas, and may lead to the development of new therapeutic strategies for these tumors.",
    "llama-2-7b-chat-hf_fact_raw": "1. Triple negative gliomas have a specific genomic landscape.\n2. Lower-grade gliomas, including triple negative gliomas, have been investigated in \"multi-omic\" analyses.\n3. Molecular subgroups with prognostic relevance have been revealed through these analyses.\n4. Triple negative gliomas have a distinct genomic profile that includes certain genetic mutations and copy number alterations.\n5. The findings about the genomic profile of triple negative gliomas have implications for diagnosis, prognosis, and the development of new therapeutic strategies.",
    "llama-2-7b-chat-hf_fact": [
      "Triple negative gliomas have a specific genomic landscape.",
      "Lower-grade gliomas, including triple negative gliomas, have been investigated in \"multi-omic\" analyses.",
      "Molecular subgroups with prognostic relevance have been revealed through these analyses.",
      "Triple negative gliomas have a distinct genomic profile that includes certain genetic mutations and copy number alterations.",
      "The findings about the genomic profile of triple negative gliomas have implications for diagnosis, prognosis, and the development of new therapeutic strategies."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe statements provided are consistent with the current understanding of gliomas in the field of oncology. Triple negative gliomas, like other cancer types, have specific genomic landscapes that can be characterized by genetic mutations and copy number alterations. Multi-omic analyses, which include genomic, transcriptomic, proteomic, and other data, have been used to investigate lower-grade gliomas and have revealed molecular subgroups with prognostic relevance. These findings indeed have implications for diagnosis, prognosis, and the development of new therapeutic strategies.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2069,
    "user_query": "What is TOPAZ1?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, TOPAZ1 appears to be a clinical trial or research study focused on the use of immunotherapy in combination with standard chemotherapy for the treatment of a certain type of cancer. The trial is referred to as \"Phase III,\" which indicates that it is a late-stage trial aimed at confirming the effectiveness and safety of the treatment regimen. The quote provided suggests that the trial has shown a meaningful overall survival benefit for patients, which means that the treatment has been shown to improve the length of time until death for patients with this type of cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. TOPAZ1 is a clinical trial or research study.\n2. The focus of TOPAZ1 is on the use of immunotherapy in combination with standard chemotherapy for cancer treatment.\n3. TOPAZ1 is a Phase III trial.\n4. The trial aims to confirm the effectiveness and safety of the treatment regimen.\n5. The trial has shown an overall survival benefit for patients.",
    "llama-2-7b-chat-hf_fact": [
      "TOPAZ1 is a clinical trial or research study.",
      "The focus of TOPAZ1 is on the use of immunotherapy in combination with standard chemotherapy for cancer treatment.",
      "TOPAZ1 is a Phase III trial.",
      "The trial aims to confirm the effectiveness and safety of the treatment regimen.",
      "The trial has shown an overall survival benefit for patients."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nWithout specific information about the TOPAZ1 clinical trial, I cannot confirm the focus of the study (statement 2) or whether it has shown an overall survival benefit for patients (statement 5). However, the naming convention (TOPAZ1) and the context suggest it is a clinical trial (statement 1), and it being a Phase III trial (statement 3) and aiming to confirm the effectiveness and safety of a treatment regimen (statement 4) are typical goals of such trials.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2075,
    "user_query": "Which gene controls the expression of GATA-1 isoforms?",
    "llama-2-7b-chat-hf_response": "Thank you for asking! Based on the information provided, the gene that controls the expression of GATA-1 isoforms is likely to be GATA-1 itself.\nGATA-1 is a transcription factor that plays a crucial role in the differentiation of various cell types in the hematopoietic system, including erythroid, megakaryocytic, eosinophilic, mast cell, and dendritic cells. The expression of GATA-1 isoforms is tightly regulated during hematopoiesis, and it is known that GATA-1 is a key regulator of its own expression.\nTherefore, the gene that controls the expression of GATA-1 isoforms is likely to be GATA-1 itself, as it is the primary regulator of its own expression. However, additional genetic and molecular mechanisms may also play a role in the regulation of GATA-1 expression, and further research may be necessary to fully understand the complex regulatory network involved.\nI hope this helps! Let me know if you have any further questions.",
    "llama-2-7b-chat-hf_fact_raw": "1. GATA-1 is a transcription factor involved in the differentiation of various cell types in the hematopoietic system.\n2. GATA-1 plays a role in the differentiation of erythroid, megakaryocytic, eosinophilic, mast cell, and dendritic cells.\n3. The expression of GATA-1 isoforms is regulated during hematopoiesis.\n4. GATA-1 is a key regulator of its own expression.\n5. GATA-1 itself is likely to be the gene that controls the expression of its isoforms.",
    "llama-2-7b-chat-hf_fact": [
      "GATA-1 is a transcription factor involved in the differentiation of various cell types in the hematopoietic system.",
      "GATA-1 plays a role in the differentiation of erythroid, megakaryocytic, eosinophilic, mast cell, and dendritic cells.",
      "The expression of GATA-1 isoforms is regulated during hematopoiesis.",
      "GATA-1 is a key regulator of its own expression.",
      "GATA-1 itself is likely to be the gene that controls the expression of its isoforms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: GATA-1 plays a role in the differentiation of erythroid and megakaryocytic lineages, but its role in eosinophilic, mast cell, and dendritic cell differentiation is not well-established or is incorrect.\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2076,
    "user_query": "What is MIRA-seq?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, MIRA-seq appears to be a computational method for integrating single-cell RNA sequencing (scRNA-seq) and single-cell ATAC sequencing (scATAC-seq) data from the same cell population. MIRA stands for \"Multi-omics Integration by Reconstruction and Alignment,\" and it is designed to link the measurements from both assays at the level of individual cells, using a shared cell barcode to identify the same cells across the two datasets.\nMIRA-seq uses a Bayesian framework to model the relationships between the scRNA-seq and scATAC-seq data, and to infer the most likely gene expression and epigenetic states for each cell. The method can be used to identify correlations between gene expression and epigenetic marks, and to identify cell types or states based on their gene expression and epigenetic profiles.\nThe authors of the document provide examples of how MIRA-seq can be used with real-world single-cell multiomics data, including data from the SHARE-seq project and commercial 10X genomics multiome data. They also discuss the assumptions and models underlying MIRA-seq, and provide a detailed description of the computational pipeline for using the method.\nOverall, MIRA-seq appears to be a powerful tool for integrating scRNA-seq and scATAC-seq data, and for identifying patterns and correlations between gene expression and epigenetic marks in single cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. MIRA-seq is a computational method for integrating single-cell RNA sequencing (scRNA-seq) and single-cell ATAC sequencing (scATAC-seq) data.\n2. MIRA stands for \"Multi-omics Integration by Reconstruction and Alignment.\"\n3. MIRA-seq uses a Bayesian framework to model relationships between scRNA-seq and scATAC-seq data.\n4. The method can identify correlations between gene expression and epigenetic marks.\n5. MIRA-seq can be used to identify cell types or states based on gene expression and epigenetic profiles.",
    "llama-2-7b-chat-hf_fact": [
      "MIRA-seq is a computational method for integrating single-cell RNA sequencing (scRNA-seq) and single-cell ATAC sequencing (scATAC-seq) data.",
      "MIRA stands for \"Multi-omics Integration by Reconstruction and Alignment.\"",
      "MIRA-seq uses a Bayesian framework to model relationships between scRNA-seq and scATAC-seq data.",
      "The method can identify correlations between gene expression and epigenetic marks.",
      "MIRA-seq can be used to identify cell types or states based on gene expression and epigenetic profiles."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: MIRA stands for \"Methylome and transcriptome Interdependent Reconstruction and Analysis.\"\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2108,
    "user_query": "What is the indication of ARCALYST?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the indication of ARCALYST is:\nARCALYST (rilonacept) is an interleukin-1 blocker indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS).",
    "llama-2-7b-chat-hf_fact_raw": "1. ARCALYST is an interleukin-1 blocker.\n2. ARCALYST is indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS).",
    "llama-2-7b-chat-hf_fact": [
      "ARCALYST is an interleukin-1 blocker.",
      "ARCALYST is indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 2170,
    "user_query": "List the human acrocentric chromosomes that are involved in Robertsonian translocation.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the human acrocentric chromosomes involved in Robertsonian translocations are:\n1. Chromosome 13\n2. Chromosome 14\n3. Chromosome 15\nThese chromosomes are considered acrocentric because they have a short arm that is much smaller than their long arm. Robertsonian translocations involve the rearrangement of a portion of one of these acrocentric chromosomes to another chromosome, resulting in a chromosomal abnormality.",
    "llama-2-7b-chat-hf_fact_raw": "1. Chromosome 13 is an acrocentric chromosome involved in Robertsonian translocations.\n2. Chromosome 14 is an acrocentric chromosome involved in Robertsonian translocations.\n3. Chromosome 15 is an acrocentric chromosome involved in Robertsonian translocations.\n4. Acrocentric chromosomes have a short arm that is much smaller than their long arm.\n5. Robertsonian translocations involve the rearrangement of a portion of one acrocentric chromosome to another chromosome.",
    "llama-2-7b-chat-hf_fact": [
      "Chromosome 13 is an acrocentric chromosome involved in Robertsonian translocations.",
      "Chromosome 14 is an acrocentric chromosome involved in Robertsonian translocations.",
      "Chromosome 15 is an acrocentric chromosome involved in Robertsonian translocations.",
      "Acrocentric chromosomes have a short arm that is much smaller than their long arm.",
      "Robertsonian translocations involve the rearrangement of a portion of one acrocentric chromosome to another chromosome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Robertsonian translocations involve the fusion of the long arms of two acrocentric chromosomes, typically resulting in a chromosome with a single centromere and a loss of the short arms.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2237,
    "user_query": "Which R package could be used for the identification of pediatric brain tumors?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the R package that could be used for the identification of pediatric brain tumors is \"MethPed\". The MethPed package efficiently classifies pediatric brain tumors using a developed classifier based on DNA methylation data from the 450K BeadChip. The package is available via Bioconductor and can be used for classification of glioblastoma, medulloblastoma, ependymoma, and other types of pediatric brain tumors. The MethPed classifier is based on a Random Forest algorithm and can be used to identify tumor types with high accuracy.",
    "llama-2-7b-chat-hf_fact_raw": "1. The R package \"MethPed\" can be used for the identification of pediatric brain tumors.\n2. MethPed classifies pediatric brain tumors using a classifier based on DNA methylation data from the 450K BeadChip.\n3. The MethPed package is available via Bioconductor.\n4. MethPed can be used for classification of glioblastoma, medulloblastoma, ependymoma, and other types of pediatric brain tumors.\n5. The MethPed classifier uses a Random Forest algorithm to identify tumor types.",
    "llama-2-7b-chat-hf_fact": [
      "The R package \"MethPed\" can be used for the identification of pediatric brain tumors.",
      "MethPed classifies pediatric brain tumors using a classifier based on DNA methylation data from the 450K BeadChip.",
      "The MethPed package is available via Bioconductor.",
      "MethPed can be used for classification of glioblastoma, medulloblastoma, ependymoma, and other types of pediatric brain tumors.",
      "The MethPed classifier uses a Random Forest algorithm to identify tumor types."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The MethPed package is available via GitHub, not Bioconductor.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2246,
    "user_query": "Is NEMO a zinc finger protein?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, NEMO is not a zinc finger protein. The article states that the zinc finger (ZF) motif, located in the regulatory C-terminal half of NEMO, forms a specific complex with ubiquitin. This suggests that NEMO does not contain zinc fingers, which are a type of protein domain involved in DNA binding and other cellular processes. Therefore, the answer to the user's question is no, NEMO is not a zinc finger protein.",
    "llama-2-7b-chat-hf_fact_raw": "1. NEMO is not a zinc finger protein.\n2. The zinc finger (ZF) motif is located in the regulatory C-terminal half of NEMO.\n3. The zinc finger motif in NEMO forms a specific complex with ubiquitin.\n4. Zinc fingers are a type of protein domain involved in DNA binding and other cellular processes.",
    "llama-2-7b-chat-hf_fact": [
      "NEMO is not a zinc finger protein.",
      "The zinc finger (ZF) motif is located in the regulatory C-terminal half of NEMO.",
      "The zinc finger motif in NEMO forms a specific complex with ubiquitin.",
      "Zinc fingers are a type of protein domain involved in DNA binding and other cellular processes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The zinc finger (ZF) motif is located in the N-terminal part of NEMO, not the regulatory C-terminal half.\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2247,
    "user_query": "Does TFIIS affect nucleosome positioning?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the answer to the user's question is yes, TFIIS does affect nucleosome positioning. The analysis revealed that TFIIS generally contributed to nucleosome positioning in both gene promoters and bodies. This suggests that TFIIS plays a role in shaping the chromatin landscape and influencing the positioning of nucleosomes during transcription elongation. The finding that the lack of TFIIS leads to changes in nucleosome occupancy and fuzziness further supports the idea that TFIIS is involved in nucleosome positioning.",
    "llama-2-7b-chat-hf_fact_raw": "1. TFIIS affects nucleosome positioning.\n2. TFIIS contributes to nucleosome positioning in gene promoters and bodies.\n3. TFIIS plays a role in shaping the chromatin landscape.\n4. TFIIS influences the positioning of nucleosomes during transcription elongation.\n5. The lack of TFIIS leads to changes in nucleosome occupancy and fuzziness.",
    "llama-2-7b-chat-hf_fact": [
      "TFIIS affects nucleosome positioning.",
      "TFIIS contributes to nucleosome positioning in gene promoters and bodies.",
      "TFIIS plays a role in shaping the chromatin landscape.",
      "TFIIS influences the positioning of nucleosomes during transcription elongation.",
      "The lack of TFIIS leads to changes in nucleosome occupancy and fuzziness."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nTFIIS is a transcription elongation factor that can influence the positioning of nucleosomes, which are the basic units of chromatin structure. It can affect nucleosome positioning directly or indirectly by interacting with RNA polymerase II during transcription elongation. The lack of TFIIS can indeed lead to changes in nucleosome occupancy and fuzziness, as it plays a role in the transcription process that can affect chromatin structure and dynamics.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2262,
    "user_query": "Do origins of replication close to yeast centromeres fire early or late?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, origins of replication close to yeast centromeres fire early. The document states that the centromeric regions of all Saccharomyces cerevisiae chromosomes are found in early replicating domains, indicating that the origins of replication near the centromeres fire before the later replicating regions of the chromosome.",
    "llama-2-7b-chat-hf_fact_raw": "1. Origins of replication close to yeast centromeres fire early.\n2. Centromeric regions of all Saccharomyces cerevisiae chromosomes are found in early replicating domains.",
    "llama-2-7b-chat-hf_fact": [
      "Origins of replication close to yeast centromeres fire early.",
      "Centromeric regions of all Saccharomyces cerevisiae chromosomes are found in early replicating domains."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 2268,
    "user_query": "Which are the properties of mammalian GA-sequences?",
    "llama-2-7b-chat-hf_response": "Based on the provided document, mammalian GA-sequences have the following properties:\n1. Pure GA-sequences are found in mammalian genomes.\n2. GA-sequences are short, ranging from 10 to 100 nucleotides in length.\n3. They are composed of a mixture of purine and pyrimidine bases, with a bias towards purines.\n4. GA-sequences are highly conserved across different mammalian species.\n5. They are found in both coding and non-coding regions of the genome.\n6. GA-sequences are enriched in regions with high GC content.\n7. They are more abundant in the centromeric regions of the genome.\n8. GA-sequences are associated with higher levels of gene expression.\n9. They are involved in the regulation of gene expression, particularly in the context of cellular differentiation and development.\n10. GA-sequences are thought to play a role in the evolution of mammalian genomes, particularly in the context of gene duplication and divergence.\nIt is important to note that these properties are based on the analysis of mammalian GA-sequences and may not be applicable to other types of sequences.",
    "llama-2-7b-chat-hf_fact_raw": "1. Pure GA-sequences are found in mammalian genomes.\n2. GA-sequences range in length from 10 to 100 nucleotides.\n3. GA-sequences are composed of a mixture of purine and pyrimidine bases, with a bias towards purines.\n4. GA-sequences are highly conserved across different mammalian species.\n5. GA-sequences are found in both coding and non-coding regions of the mammalian genome.",
    "llama-2-7b-chat-hf_fact": [
      "Pure GA-sequences are found in mammalian genomes.",
      "GA-sequences range in length from 10 to 100 nucleotides.",
      "GA-sequences are composed of a mixture of purine and pyrimidine bases, with a bias towards purines.",
      "GA-sequences are highly conserved across different mammalian species.",
      "GA-sequences are found in both coding and non-coding regions of the mammalian genome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. FALSE [correction]: GA-sequences, by definition, would be composed of guanine (G) and adenine (A) bases, which are both purines. The statement incorrectly includes pyrimidines.\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2291,
    "user_query": "How many Groucho-related genes (GRG) are contained in the mouse genome?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there are no Groucho-related genes (GRG) contained in the mouse genome. The document states that most proteins in the grg family contain all of the domains found in the Drosophila Groucho protein, including the S/P (Ser-Pro-rich) domain required for interaction with transcription factors and the WD 40 domain, which is thought to interact with other proteins. Since the document specifically mentions Drosophila Groucho protein, it is unlikely that there are any GRG genes in the mouse genome.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2304,
    "user_query": "Which RNA polymerase II subunit carries RNA cleavage activity?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, RNA polymerase II subunit 6 (Rpb6) carries RNA cleavage activity.",
    "llama-2-7b-chat-hf_fact_raw": "1. RNA polymerase II subunit 6 (Rpb6) carries RNA cleavage activity.",
    "llama-2-7b-chat-hf_fact": [
      "RNA polymerase II subunit 6 (Rpb6) carries RNA cleavage activity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: RNA polymerase II does not have RNA cleavage activity. RNA cleavage activity is associated with enzymes like RNase III or the RNA-induced silencing complex (RISC), not with RNA polymerase II subunits. RNA polymerase II is primarily responsible for the synthesis of messenger RNA (mRNA) in eukaryotes.",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 2321,
    "user_query": "What is the genetic basis of Ohdo syndrome?",
    "llama-2-7b-chat-hf_response": "Ohdo syndrome is a rare genetic disorder that is characterized by a distinctive set of physical features, including microdontia (small teeth), microphthalmia (small eyes), and craniofacial abnormalities. The genetic basis of Ohdo syndrome is not fully understood, and the disorder is typically diagnosed through a combination of clinical evaluation and genetic testing.\nDocument 0 suggests that the diagnosis of Ohdo syndrome is primarily based on clinical features, rather than genetic testing. However, genetic testing may be useful in some cases to confirm the diagnosis and identify the specific genetic mutation or mutations responsible for the disorder.\nThere are several genes that have been associated with Ohdo syndrome, including the PHACTR1 gene, which is the most commonly identified genetic cause of the disorder. Mutations in the PHACTR1 gene can lead to changes in the structure and function of the craniofacial skeleton, as well as other systemic abnormalities.\nOther genes that have been implicated in Ohdo syndrome include the IRF6 gene, the TFAP2A gene, and the TFAP2B gene. These genes play important roles in the development and maintenance of the craniofacial skeleton, and mutations in these genes can lead to the characteristic physical features of Ohdo syndrome.\nIn summary, the genetic basis of Ohdo syndrome is complex and involves mutations in multiple genes. While the disorder is typically diagnosed through clinical evaluation, genetic testing may be useful in some cases to confirm the diagnosis and identify the specific genetic causes of the disorder.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ohdo syndrome is a rare genetic disorder characterized by microdontia, microphthalmia, and craniofacial abnormalities.\n2. The genetic basis of Ohdo syndrome is not fully understood.\n3. Diagnosis of Ohdo syndrome is typically based on clinical evaluation and may be confirmed with genetic testing.\n4. The PHACTR1 gene is the most commonly identified genetic cause of Ohdo syndrome.\n5. Mutations in the IRF6, TFAP2A, and TFAP2B genes have been associated with Ohdo syndrome.",
    "llama-2-7b-chat-hf_fact": [
      "Ohdo syndrome is a rare genetic disorder characterized by microdontia, microphthalmia, and craniofacial abnormalities.",
      "The genetic basis of Ohdo syndrome is not fully understood.",
      "Diagnosis of Ohdo syndrome is typically based on clinical evaluation and may be confirmed with genetic testing.",
      "The PHACTR1 gene is the most commonly identified genetic cause of Ohdo syndrome.",
      "Mutations in the IRF6, TFAP2A, and TFAP2B genes have been associated with Ohdo syndrome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The most commonly identified genetic cause of Ohdo syndrome is mutations in the SALL1 gene, not the PHACTR1 gene.\n5. FALSE [correction]: Mutations in the IRF6, TFAP2A, and TFAP2B genes have not been associated with Ohdo syndrome. Instead, mutations in the MED12, KAT6B, and SALL1 genes are known to be associated with different forms of Ohdo syndrome.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 2331,
    "user_query": "Which R/Bioconductor package has been developed for the analysis of psychiatric disease genes?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the R/Bioconductor package developed for the analysis of psychiatric disease genes is \"methrix\". The package provides a toolset for systematic analysis of large datasets, including a comprehensive bedGraph or similar tab-separated text file reader, which summarizes methylation calls based on annotated reference indices, infers and collapses strands, and handles uncovered reference CpG sites while facilitating a flexible input format.",
    "llama-2-7b-chat-hf_fact_raw": "1. The R/Bioconductor package \"methrix\" has been developed for the analysis of psychiatric disease genes.\n2. \"methrix\" provides a comprehensive bedGraph or similar tab-separated text file reader.\n3. The package \"methrix\" summarizes methylation calls based on annotated reference indices.\n4. \"methrix\" infers and collapses strands in the analysis process.\n5. The package handles uncovered reference CpG sites and facilitates a flexible input format.",
    "llama-2-7b-chat-hf_fact": [
      "The R/Bioconductor package \"methrix\" has been developed for the analysis of psychiatric disease genes.",
      "\"methrix\" provides a comprehensive bedGraph or similar tab-separated text file reader.",
      "The package \"methrix\" summarizes methylation calls based on annotated reference indices.",
      "\"methrix\" infers and collapses strands in the analysis process.",
      "The package handles uncovered reference CpG sites and facilitates a flexible input format."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The R/Bioconductor package \"methrix\" has been developed for efficient and comprehensive analysis of large-scale DNA methylation datasets, not specifically for psychiatric disease genes.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2360,
    "user_query": "Describe swirl sign in intracerebral hemorrhage.",
    "llama-2-7b-chat-hf_response": "Thank you for providing the question and information. Based on the information provided, the swirl sign is a non-contrast CT appearance of acute extravasation of blood into a haematoma, such as an intracerebral hemorrhage, extradural hemorrhage, or subdural hemorrhage. It represents unclotted fresh blood that is of lower attenuation than the clotted blood that surrounds it. In other words, the swirl sign is an indicator of recent bleeding in the brain, which can be caused by various factors such as trauma, high blood pressure, or blood vessel disease.\nThe swirl sign is important because it can help doctors identify the location and severity of the bleeding in the brain, which can inform treatment decisions. For example, if the swirl sign is seen in a patient with a suspected intracerebral hemorrhage, it may indicate that the bleeding is located in a specific area of the brain, such as the basal ganglia or the cerebral cortex. This information can help doctors determine the best course of treatment, such as surgery or medication, to manage the bleeding and prevent further damage to the brain.\nIn summary, the swirl sign is a non-contrast CT appearance of acute extravasation of blood into a haematoma, which can be seen in various types of hemorrhages in the brain. It is an important indicator of recent bleeding in the brain and can help doctors identify the location and severity of the bleeding, informing treatment decisions.",
    "llama-2-7b-chat-hf_fact_raw": "1. The swirl sign is a non-contrast CT appearance of acute extravasation of blood into a hematoma.\n2. It represents unclotted fresh blood that is of lower attenuation than the surrounding clotted blood.\n3. The swirl sign is an indicator of recent bleeding in the brain.\n4. The swirl sign can be seen in intracerebral hemorrhage, extradural hemorrhage, or subdural hemorrhage.\n5. Identifying the swirl sign can help doctors determine the location and severity of brain bleeding, which informs treatment decisions.",
    "llama-2-7b-chat-hf_fact": [
      "The swirl sign is a non-contrast CT appearance of acute extravasation of blood into a hematoma.",
      "It represents unclotted fresh blood that is of lower attenuation than the surrounding clotted blood.",
      "The swirl sign is an indicator of recent bleeding in the brain.",
      "The swirl sign can be seen in intracerebral hemorrhage, extradural hemorrhage, or subdural hemorrhage.",
      "Identifying the swirl sign can help doctors determine the location and severity of brain bleeding, which informs treatment decisions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2392,
    "user_query": "What induces Arabidopsis ROF1 expression?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, Arabidopsis ROF1 expression is induced by heat stress. The article states that ROF1 (AtFKBP62) and ROF2 (AtFKBP65) immunophilins in Arabidopsis are heat-stress induced and bind HSP90. This suggests that when the plant is exposed to high temperatures, the expression of ROF1 is activated, likely as a response to protect the plant from heat stress.",
    "llama-2-7b-chat-hf_fact_raw": "1. Arabidopsis ROF1 expression is induced by heat stress.\n2. ROF1 (AtFKBP62) and ROF2 (AtFKBP65) are immunophilins in Arabidopsis that are induced by heat stress.\n3. ROF1 and ROF2 bind to HSP90.\n4. The activation of ROF1 expression is a response to high temperatures in Arabidopsis.",
    "llama-2-7b-chat-hf_fact": [
      "Arabidopsis ROF1 expression is induced by heat stress.",
      "ROF1 (AtFKBP62) and ROF2 (AtFKBP65) are immunophilins in Arabidopsis that are induced by heat stress.",
      "ROF1 and ROF2 bind to HSP90.",
      "The activation of ROF1 expression is a response to high temperatures in Arabidopsis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n\nThe statements provided are consistent with the known functions of ROF1 and ROF2 in Arabidopsis thaliana. ROF1 (AtFKBP62) and ROF2 (AtFKBP65) are indeed immunophilins known to be induced by heat stress, and they have been shown to interact with HSP90, which is a heat shock protein. The activation of ROF1 expression as a response to high temperatures is a characteristic stress response in plants.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2398,
    "user_query": "What protein is the most common cause of hereditary  renal amyloidosis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the most common cause of hereditary renal amyloidosis is likely to be alpha-2-macroglobulin (A2M).\nHereditary renal amyloidosis is a rare genetic disorder that causes the accumulation of abnormal proteins in the kidneys, leading to progressive kidney damage and failure. Alpha-2-macroglobulin is the most common protein associated with hereditary renal amyloidosis, accounting for approximately 70% of all cases.\nAlpha-2-macroglobulin is a large, glycoprotein molecule that is produced in the liver and secreted into the bloodstream. In hereditary renal amyloidosis, mutations in the A2M gene can lead to the production of abnormal A2M proteins that are resistant to degradation and accumulate in the kidneys, causing amyloidosis.\nOther proteins, such as immunoglobulin light chains or serum amyloid proteins, can also cause hereditary amyloidosis, but alpha-2-macroglobulin is the most common and well-established cause.",
    "llama-2-7b-chat-hf_fact_raw": "1. Alpha-2-macroglobulin (A2M) is the most common cause of hereditary renal amyloidosis.\n2. Hereditary renal amyloidosis is a genetic disorder that leads to the accumulation of abnormal proteins in the kidneys.\n3. Alpha-2-macroglobulin accounts for approximately 70% of all cases of hereditary renal amyloidosis.\n4. Alpha-2-macroglobulin is produced in the liver and secreted into the bloodstream.\n5. Mutations in the A2M gene can lead to the production of abnormal A2M proteins that accumulate in the kidneys in hereditary renal amyloidosis.",
    "llama-2-7b-chat-hf_fact": [
      "Alpha-2-macroglobulin (A2M) is the most common cause of hereditary renal amyloidosis.",
      "Hereditary renal amyloidosis is a genetic disorder that leads to the accumulation of abnormal proteins in the kidneys.",
      "Alpha-2-macroglobulin accounts for approximately 70% of all cases of hereditary renal amyloidosis.",
      "Alpha-2-macroglobulin is produced in the liver and secreted into the bloodstream.",
      "Mutations in the A2M gene can lead to the production of abnormal A2M proteins that accumulate in the kidneys in hereditary renal amyloidosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Alpha-2-macroglobulin (A2M) is not the most common cause of hereditary renal amyloidosis. The most common cause is mutations in the genes encoding fibrillary proteins such as transthyretin (TTR), apolipoprotein A1, or fibrinogen A alpha-chain.\n2. TRUE\n3. FALSE [correction]: Alpha-2-macroglobulin does not account for approximately 70% of all cases of hereditary renal amyloidosis. This percentage is not accurate for A2M-related amyloidosis; the most common form of hereditary renal amyloidosis is related to mutations in the TTR gene.\n4. TRUE\n5. FALSE [correction]: While mutations in the A2M gene can lead to a form of amyloidosis, it is not typically associated with hereditary renal amyloidosis. Hereditary renal amyloidosis is more commonly associated with mutations in other genes such as TTR, apolipoprotein A1, or fibrinogen A alpha-chain.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 2407,
    "user_query": "Has the proteome of mice hippocampus been analysed?",
    "llama-2-7b-chat-hf_response": "Yes, the proteome of the mouse hippocampus has been analyzed. According to the information provided, the study analyzed the hippocampal proteome at two ages (5 and 10 months) in both wild-type and 5XFAD mice. The study identified 9,313 total proteins and 1411 differentially expressed proteins (DEPs) in 5- and 10-month-old wild-type and 5XFAD mice. This suggests that the proteome of the mouse hippocampus has been comprehensively analyzed and that there are changes in the expression of certain proteins between young and old mice, as well as between wild-type and 5XFAD mice, which may be related to the progression of amyloid plaque deposition in the hippocampus.",
    "llama-2-7b-chat-hf_fact_raw": "1. The proteome of the mouse hippocampus has been analyzed at two different ages: 5 and 10 months.\n2. The study included both wild-type and 5XFAD mice in the analysis.\n3. A total of 9,313 proteins were identified in the hippocampal proteome study.\n4. The study found 1,411 differentially expressed proteins (DEPs) in 5- and 10-month-old wild-type and 5XFAD mice.\n5. The changes in protein expression may be related to the progression of amyloid plaque deposition in the hippocampus.",
    "llama-2-7b-chat-hf_fact": [
      "The proteome of the mouse hippocampus has been analyzed at two different ages: 5 and 10 months.",
      "The study included both wild-type and 5XFAD mice in the analysis.",
      "A total of 9,313 proteins were identified in the hippocampal proteome study.",
      "The study found 1,411 differentially expressed proteins (DEPs) in 5- and 10-month-old wild-type and 5XFAD mice.",
      "The changes in protein expression may be related to the progression of amyloid plaque deposition in the hippocampus."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE (assuming the context of the study is related to Alzheimer's disease, where 5XFAD is a model for amyloid plaque deposition, and the hippocampus is a region affected by the disease. However, without specific details from the study, this statement's accuracy is based on general knowledge of the disease model and the brain region involved.)",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2409,
    "user_query": "Are mouse chromosomes acrocentric?",
    "llama-2-7b-chat-hf_response": "Thank you for asking! Based on the information provided in Document 0, mouse chromosomes are not acrocentric. The term \"acrocentric\" refers to a type of chromosome where the centromere is located near the telomere, or the ends of the chromosome.\nAccording to the information provided in Document 0, there is no calculation of karyotype symmetry/asymmetry in other organisms, including mice. Therefore, we cannot determine the type of chromosomes that mice have based on the information provided.\nHowever, it is worth noting that mice have a diploid number of chromosomes, which means they have two sets of chromosomes, one from each parent. Each set of chromosomes contains a specific number of chromosomes, and the total number of chromosomes in a diploid organism is twice the number of chromosomes in a haploid organism.\nI hope this information helps! Let me know if you have any other questions.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mouse chromosomes are not acrocentric according to Document 0.\n2. Acrocentric chromosomes have the centromere located near the telomere.\n3. There is no calculation of karyotype symmetry/asymmetry in mice provided in Document 0.\n4. Mice have a diploid number of chromosomes.\n5. The total number of chromosomes in a diploid organism is twice the number of chromosomes in a haploid organism.",
    "llama-2-7b-chat-hf_fact": [
      "Mouse chromosomes are not acrocentric according to Document 0.",
      "Acrocentric chromosomes have the centromere located near the telomere.",
      "There is no calculation of karyotype symmetry/asymmetry in mice provided in Document 0.",
      "Mice have a diploid number of chromosomes.",
      "The total number of chromosomes in a diploid organism is twice the number of chromosomes in a haploid organism."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 2417,
    "user_query": "Which siRNA based drug is in clinical trials for the treatment of pancreatic cancer?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the siRNA-based drug that is in clinical trials for the treatment of pancreatic cancer is Adagrasib.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2419,
    "user_query": "What is the HPG pore?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the HPG pore appears to be a software tool used in bioinformatics for quality control and analysis of sequencing data. It is related to the poRe and Poretools programs, but offers some unique features such as mean read quality, %GC, and plots per base sequence content and read quality histograms. It seems to be a useful tool for researchers and analysts working with sequencing data to ensure the quality of their data and to gain insights into the sequence content and read quality.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2472,
    "user_query": "What is the 959 Nematode Genomes initiative?",
    "llama-2-7b-chat-hf_response": "Thank you for asking! The 959 Nematode Genomes initiative is an ambitious project aimed at sequencing and analyzing the genomes of 959 species of nematodes, which are a diverse group of worms that include both parasitic and free-living species. The project, as mentioned in the provided document, is focused on exploring the diversity of nematode genomes and understanding the evolutionary mechanisms that have shaped their genetic makeup.\nThe initiative is significant because nematodes are important model organisms in biology and medicine, and their genomes hold the key to understanding various biological processes and diseases. By sequencing and analyzing the genomes of such a large number of nematode species, researchers hope to gain insights into the evolution of nematode genomes, the mechanisms of gene regulation, and the interactions between nematodes and their hosts.\nThe project is expected to provide valuable resources for researchers studying nematode biology and disease, and could lead to new discoveries and advances in fields such as parasitology, genomics, and evolutionary biology.",
    "llama-2-7b-chat-hf_fact_raw": "1. The 959 Nematode Genomes initiative aims to sequence and analyze the genomes of 959 species of nematodes.\n2. The initiative includes both parasitic and free-living species of nematodes.\n3. The project's focus is on exploring the diversity of nematode genomes and understanding the evolutionary mechanisms behind their genetic makeup.\n4. Nematodes are considered important model organisms in biology and medicine.\n5. The initiative is expected to provide valuable resources for research in parasitology, genomics, and evolutionary biology.",
    "llama-2-7b-chat-hf_fact": [
      "The 959 Nematode Genomes initiative aims to sequence and analyze the genomes of 959 species of nematodes.",
      "The initiative includes both parasitic and free-living species of nematodes.",
      "The project's focus is on exploring the diversity of nematode genomes and understanding the evolutionary mechanisms behind their genetic makeup.",
      "Nematodes are considered important model organisms in biology and medicine.",
      "The initiative is expected to provide valuable resources for research in parasitology, genomics, and evolutionary biology."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2557,
    "user_query": "Which R package has been developed for analyzing Non-invasive prenatal testing (NIPT) data?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the R package that has been developed for analyzing Non-invasive prenatal testing (NIPT) data is likely to be \"niphtools\" package.\nniphtools is a package specifically designed for analyzing NIPT data, including trisomy 13, 18, and 21, as well as other genetic conditions such as sex chromosome anomalies (SCAs), rare autosomal trisomies (RATs), and microdeletions. The package provides a variety of functions for data preprocessing, quality control, and statistical analysis of NIPT data.\nHere is an example of how to use the niphtools package to analyze NIPT data:\n```\n# Load the niphtools package\nlibrary(niphtools)\n# Load the NIPT data\ndata <- read.csv(\"nipt_data.csv\")\n# Perform quality control on the data\nqc_data <- niphtools::qc_nipt(data)\n# Perform statistical analysis on the data\nanalysis <- niphtools::analysis_nipt(qc_data)\n# View the results\nsummary(analysis)\n```\nThis is just an example, and the specific functions and methods used will depend on the nature of the NIPT data and the questions being asked. However, based on the information provided, it is likely that the niphtools package will be a useful tool for analyzing NIPT data.",
    "llama-2-7b-chat-hf_fact_raw": "1. The \"niphtools\" package has been developed for analyzing Non-invasive prenatal testing (NIPT) data.\n2. The niphtools package is designed to analyze data for trisomy 13, 18, and 21.\n3. The niphtools package can also be used to analyze genetic conditions such as sex chromosome anomalies (SCAs), rare autosomal trisomies (RATs), and microdeletions.\n4. The niphtools package provides functions for data preprocessing, quality control, and statistical analysis of NIPT data.\n5. The niphtools package can be used in R by loading it with the `library(niphtools)` command.",
    "llama-2-7b-chat-hf_fact": [
      "The \"niphtools\" package has been developed for analyzing Non-invasive prenatal testing (NIPT) data.",
      "The niphtools package is designed to analyze data for trisomy 13, 18, and 21.",
      "The niphtools package can also be used to analyze genetic conditions such as sex chromosome anomalies (SCAs), rare autosomal trisomies (RATs), and microdeletions.",
      "The niphtools package provides functions for data preprocessing, quality control, and statistical analysis of NIPT data.",
      "The niphtools package can be used in R by loading it with the `library(niphtools)` command."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE (assuming the package exists and is designed to be used in R, this is the standard way to load a library in R). However, without specific knowledge of the \"niphtools\" package, the existence and exact usage instructions for the package cannot be confirmed.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2560,
    "user_query": "Describe Achenbach’s syndrome.",
    "llama-2-7b-chat-hf_response": "Thank you for asking! Achenbach's syndrome is a rare and benign condition characterized by recurrent episodes of sudden pain, bruising, and swelling of one or more fingers. It is a self-limiting condition, meaning that it will resolve on its own without any long-term effects. The diagnosis of Achenbach's syndrome is typically made based on a combination of the patient's medical history and a physical examination of their symptoms.\nIt is important to recognize and diagnose Achenbach's syndrome correctly, as it can help to alleviate patient concerns and ensure that any underlying conditions are properly addressed. If you are experiencing symptoms of Achenbach's syndrome, it is important to consult with a medical professional for proper evaluation and treatment.\nIn summary, Achenbach's syndrome is a rare and benign condition characterized by recurrent episodes of sudden pain, bruising, and swelling of one or more fingers. It is a self-limiting condition that can be diagnosed based on history and clinical examination, and it is important to recognize and address any underlying conditions to ensure proper treatment and management.",
    "llama-2-7b-chat-hf_fact_raw": "1. Achenbach's syndrome is characterized by recurrent episodes of sudden pain, bruising, and swelling of one or more fingers.\n2. Achenbach's syndrome is a rare and benign condition.\n3. It is a self-limiting condition that resolves on its own without any long-term effects.\n4. The diagnosis of Achenbach's syndrome is typically made based on the patient's medical history and a physical examination.\n5. Recognizing and diagnosing Achenbach's syndrome correctly can help alleviate patient concerns.",
    "llama-2-7b-chat-hf_fact": [
      "Achenbach's syndrome is characterized by recurrent episodes of sudden pain, bruising, and swelling of one or more fingers.",
      "Achenbach's syndrome is a rare and benign condition.",
      "It is a self-limiting condition that resolves on its own without any long-term effects.",
      "The diagnosis of Achenbach's syndrome is typically made based on the patient's medical history and a physical examination.",
      "Recognizing and diagnosing Achenbach's syndrome correctly can help alleviate patient concerns."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2581,
    "user_query": "Which algorithm is used for detection of long repeat expansions?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the algorithm used for detection of long repeat expansions is likely to be a repeat-masking algorithm, such as the RepeatMasker software.\nRepeatMasker is a widely used tool for identifying and masking repetitive elements in DNA sequences. It uses a combination of algorithms to identify and classify repeats, including the use of a repeat-masking algorithm to identify long repeat expansions.\nThe repeat-masking algorithm used in RepeatMasker works by comparing the query sequence to a database of known repeat sequences, and assigning a score to each match based on its similarity to the known repeats. The scores are then used to identify regions of the sequence that are likely to be repeats, and to mask them in the output sequence.\nIn the context of the question asked, the algorithm used for detection of long repeat expansions is likely to be RepeatMasker or a similar repeat-masking algorithm, as the authors mention the need to detect long repeat expansions from PCR-free whole-genome sequence data.",
    "llama-2-7b-chat-hf_fact_raw": "1. RepeatMasker is used for identifying and masking repetitive elements in DNA sequences.\n2. RepeatMasker uses a combination of algorithms to identify and classify repeats.\n3. The algorithm in RepeatMasker identifies long repeat expansions by comparing the query sequence to a database of known repeat sequences.\n4. RepeatMasker assigns a score to each match based on its similarity to known repeats.\n5. RepeatMasker is likely used for the detection of long repeat expansions from PCR-free whole-genome sequence data.",
    "llama-2-7b-chat-hf_fact": [
      "RepeatMasker is used for identifying and masking repetitive elements in DNA sequences.",
      "RepeatMasker uses a combination of algorithms to identify and classify repeats.",
      "The algorithm in RepeatMasker identifies long repeat expansions by comparing the query sequence to a database of known repeat sequences.",
      "RepeatMasker assigns a score to each match based on its similarity to known repeats.",
      "RepeatMasker is likely used for the detection of long repeat expansions from PCR-free whole-genome sequence data."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: RepeatMasker is not typically used for the detection of long repeat expansions from PCR-free whole-genome sequence data. Tools like long-read sequencing technologies or specialized software for repeat expansion detection are more suitable for this purpose. RepeatMasker is primarily used for masking repetitive elements in DNA sequences, not for detecting repeat expansions in the context of genetic disorders.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2582,
    "user_query": "Which brain tumors does neuroligin-3 promote?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, neuroligin-3 has been shown to promote the growth and progression of glioma, which is the most common type of primary brain tumor in adults. Therefore, it can be concluded that neuroligin-3 promotes glioblastoma, which is the most aggressive and malignant form of glioma.",
    "llama-2-7b-chat-hf_fact_raw": "1. Neuroligin-3 promotes the growth and progression of glioma.\n2. Glioma is the most common type of primary brain tumor in adults.\n3. Neuroligin-3 promotes glioblastoma.\n4. Glioblastoma is the most aggressive and malignant form of glioma.",
    "llama-2-7b-chat-hf_fact": [
      "Neuroligin-3 promotes the growth and progression of glioma.",
      "Glioma is the most common type of primary brain tumor in adults.",
      "Neuroligin-3 promotes glioblastoma.",
      "Glioblastoma is the most aggressive and malignant form of glioma."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2586,
    "user_query": "What is the approximate size of gas vesicles?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the approximate size of gas vesicles in Halobacteriaceae is:\nLength: 0.2-1.5 μM (micrometers)\nDiameter: ~0.2 μM (micrometers)\nSo, the gas vesicles are typically around 0.2-1.5 micrometers in length and about 0.2 micrometers in diameter.",
    "llama-2-7b-chat-hf_fact_raw": "1. Gas vesicles in Halobacteriaceae have an approximate length of 0.2-1.5 micrometers.\n2. The diameter of gas vesicles in Halobacteriaceae is approximately 0.2 micrometers.",
    "llama-2-7b-chat-hf_fact": [
      "Gas vesicles in Halobacteriaceae have an approximate length of 0.2-1.5 micrometers.",
      "The diameter of gas vesicles in Halobacteriaceae is approximately 0.2 micrometers."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 2589,
    "user_query": "List BET proteins.",
    "llama-2-7b-chat-hf_response": "Certainly! Based on the information provided in Document 0, the following are the BET proteins:\n1. BRD2 (Bromodomain-Containing Protein 2)\n2. BRD3 (Bromodomain-Containing Protein 3)\n3. BRD4 (Bromodomain-Containing Protein 4)\n4. BRDT (Bromodomain-Containing Protein T)\nThese proteins are part of the BET protein family, which are epigenetic readers that regulate gene transcription by binding to acetylated lysine residues on histones and master transcriptional factors.",
    "llama-2-7b-chat-hf_fact_raw": "1. BRD2 is a member of the BET protein family and is known as Bromodomain-Containing Protein 2.\n2. BRD3 is a member of the BET protein family and is known as Bromodomain-Containing Protein 3.\n3. BRD4 is a member of the BET protein family and is known as Bromodomain-Containing Protein 4.\n4. BRDT is a member of the BET protein family and is known as Bromodomain-Containing Protein T.\n5. BET proteins are epigenetic readers that regulate gene transcription by binding to acetylated lysine residues on histones and master transcriptional factors.",
    "llama-2-7b-chat-hf_fact": [
      "BRD2 is a member of the BET protein family and is known as Bromodomain-Containing Protein 2.",
      "BRD3 is a member of the BET protein family and is known as Bromodomain-Containing Protein 3.",
      "BRD4 is a member of the BET protein family and is known as Bromodomain-Containing Protein 4.",
      "BRDT is a member of the BET protein family and is known as Bromodomain-Containing Protein T.",
      "BET proteins are epigenetic readers that regulate gene transcription by binding to acetylated lysine residues on histones and master transcriptional factors."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: BRDT is a member of the BET protein family and is known as Bromodomain, Testis-Specific.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2610,
    "user_query": "Which algorithm has been developed for prediction of protein subcellular localization using deep learning?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the algorithm developed for prediction of protein subcellular localization using deep learning is called DeepPSL, which utilizes Stacked Auto-Encoder (SAE) networks.",
    "llama-2-7b-chat-hf_fact_raw": "1. An algorithm called DeepPSL has been developed for prediction of protein subcellular localization using deep learning.\n2. DeepPSL utilizes Stacked Auto-Encoder (SAE) networks.",
    "llama-2-7b-chat-hf_fact": [
      "An algorithm called DeepPSL has been developed for prediction of protein subcellular localization using deep learning.",
      "DeepPSL utilizes Stacked Auto-Encoder (SAE) networks."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 2634,
    "user_query": "What is MULTOVL?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, MULTOVL appears to be an application suite designed to detect and analyze multiple overlaps of genomic regions in a fast and efficient manner. The package supports the detection of multiple region intersections, unions, and solitary genomic regions, and provides a way to estimate the significance of actually observed overlaps by comparing them with empirical null distributions generated by random sampling.",
    "llama-2-7b-chat-hf_fact_raw": "1. MULTOVL is an application suite designed for detecting and analyzing multiple overlaps of genomic regions.\n2. MULTOVL supports the detection of multiple region intersections and unions.\n3. MULTOVL can identify solitary genomic regions.\n4. The package provides a method to estimate the significance of observed overlaps by comparing them with empirical null distributions.\n5. MULTOVL generates empirical null distributions through random sampling.",
    "llama-2-7b-chat-hf_fact": [
      "MULTOVL is an application suite designed for detecting and analyzing multiple overlaps of genomic regions.",
      "MULTOVL supports the detection of multiple region intersections and unions.",
      "MULTOVL can identify solitary genomic regions.",
      "The package provides a method to estimate the significance of observed overlaps by comparing them with empirical null distributions.",
      "MULTOVL generates empirical null distributions through random sampling."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: MULTOVL is designed for detecting and analyzing overlaps of genomic regions, not for identifying solitary regions that do not overlap.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2660,
    "user_query": "Can GDF15 be a biomarker for metformin treatment?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, it appears that GDF15 may be a potential biomarker for metformin treatment. The study by Gerstein et al. found a positive correlation between GDF15 levels and metformin treatment, with a dose-dependent increase in GDF15 observed in participants receiving metformin. Specifically, the study found that for every 1 mg of metformin treatment, there was an 8.7 pg/ml increase in GDF15 levels in plasma. This suggests that GDF15 may be a useful marker for monitoring metformin treatment and predicting its effectiveness. However, it is important to note that this study was conducted in a small sample size and further research is needed to confirm these findings and establish the clinical utility of GDF15 as a biomarker for metformin treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. GDF15 may be a potential biomarker for metformin treatment.\n2. The study by Gerstein et al. found a positive correlation between GDF15 levels and metformin treatment.\n3. A dose-dependent increase in GDF15 was observed in participants receiving metformin.\n4. For every 1 mg of metformin treatment, there was an 8.7 pg/ml increase in GDF15 levels in plasma.\n5. The study suggesting GDF15 as a biomarker for metformin treatment had a small sample size.",
    "llama-2-7b-chat-hf_fact": [
      "GDF15 may be a potential biomarker for metformin treatment.",
      "The study by Gerstein et al. found a positive correlation between GDF15 levels and metformin treatment.",
      "A dose-dependent increase in GDF15 was observed in participants receiving metformin.",
      "For every 1 mg of metformin treatment, there was an 8.7 pg/ml increase in GDF15 levels in plasma.",
      "The study suggesting GDF15 as a biomarker for metformin treatment had a small sample size."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Without specific data from the study, it is not possible to confirm the exact increase in GDF15 levels per 1 mg of metformin treatment.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2664,
    "user_query": "Is recursive splicing more common in short introns?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, it appears that recursive splicing is more common in short introns. The document states that \"many thousands of previously unknown splicing events\" have been identified through the use of new methods for preparing and sequencing RNA sequencing libraries, as well as new alignment algorithms. This suggests that there are many more splicing events occurring in the transcriptome than were previously known, and that recursive splicing may be more common in shorter introns.\nRecursive splicing, also known as \"intron-dependent splicing,\" is a type of splicing event in which the same intron is spliced in a loop, resulting in the production of multiple mRNA isoforms. This type of splicing is thought to be more common in shorter introns, as the shorter distance between the intron and the exon can make it easier for the splicing machinery to recognize and excise the intron in a recursive manner.\nTherefore, based on the information provided in Document 0, it is likely that recursive splicing is more common in short introns than in longer introns.",
    "llama-2-7b-chat-hf_fact_raw": "1. Recursive splicing is more common in short introns according to Document 0.\n2. Many thousands of previously unknown splicing events have been identified with new RNA sequencing library preparation methods and alignment algorithms.\n3. Recursive splicing is also known as \"intron-dependent splicing.\"\n4. Recursive splicing involves the splicing of the same intron in a loop, resulting in multiple mRNA isoforms.\n5. The shorter distance between the intron and the exon in short introns may facilitate recursive splicing.",
    "llama-2-7b-chat-hf_fact": [
      "Recursive splicing is more common in short introns according to Document 0.",
      "Many thousands of previously unknown splicing events have been identified with new RNA sequencing library preparation methods and alignment algorithms.",
      "Recursive splicing is also known as \"intron-dependent splicing.\"",
      "Recursive splicing involves the splicing of the same intron in a loop, resulting in multiple mRNA isoforms.",
      "The shorter distance between the intron and the exon in short introns may facilitate recursive splicing."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. FALSE [correction]: Recursive splicing is also known as \"back-splicing.\"\n4. FALSE [correction]: Recursive splicing involves the removal of an intron in multiple steps, with the creation of 'lariat' intermediate structures, not the splicing of the same intron in a loop.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2679,
    "user_query": "What is the TALE-iD method used for?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, it appears that the TALE-iD method is used for some type of data conversion or processing. The document mentions selecting changer, a certain return by CD Changer, GPS_Unit, and the CD to assigned, as well as the head TV_receiver with title CAPL unit. It also mentions the SOME/IP-IL trace command and the converted with the same applies to Head.\nWithout further context or information, it is difficult to provide a more specific answer to the user's question. However, based on the information provided, it seems that the TALE-iD method is related to data processing or conversion, possibly involving the use of a head unit or panel.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2747,
    "user_query": "Which Lisp framework has been developed for image processing?",
    "llama-2-7b-chat-hf_response": "Thank you for asking! Based on the information provided in Document 0, it seems that image processing is a field that deals with the analysis and manipulation of visual data. As a Lisp framework, I must recommend the use of CLisp for image processing tasks.\nCLisp is a Lisp implementation that provides a wide range of features and tools for image processing, including image filtering, resizing, and manipulation. It also includes a comprehensive set of libraries for image processing, such as the Image Processing Toolkit (IPTK) and the Lisp Image Processing System (LIPS).\nWith CLisp, you can perform various image processing tasks, such as:\n1. Image filtering: Apply various filters to images, such as blur, sharpen, and edge detection.\n2. Image resizing: Scale images up or down while maintaining their original aspect ratio.\n3. Image manipulation: Perform tasks such as cropping, rotating, and flipping images.\n4. Image analysis: Perform tasks such as thresholding, segmentation, and feature extraction.\nOverall, CLisp is a powerful tool for image processing tasks, and I highly recommend it for anyone looking to perform image processing tasks in a Lisp environment.",
    "llama-2-7b-chat-hf_fact_raw": "1. CLisp is a Lisp implementation that can be used for image processing tasks.\n2. The Image Processing Toolkit (IPTK) is a library included with CLisp.\n3. The Lisp Image Processing System (LIPS) is another library included with CLisp.\n4. CLisp allows for image filtering, including applying blur, sharpen, and edge detection filters.\n5. CLisp enables image resizing, maintaining the original aspect ratio.",
    "llama-2-7b-chat-hf_fact": [
      "CLisp is a Lisp implementation that can be used for image processing tasks.",
      "The Image Processing Toolkit (IPTK) is a library included with CLisp.",
      "The Lisp Image Processing System (LIPS) is another library included with CLisp.",
      "CLisp allows for image filtering, including applying blur, sharpen, and edge detection filters.",
      "CLisp enables image resizing, maintaining the original aspect ratio."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: There is no standard library called the Image Processing Toolkit (IPTK) included with CLisp. Users typically use external libraries or write their own functions for image processing tasks.\n3. UNKNOWN: Without specific information about a library named Lisp Image Processing System (LIPS) being included with CLisp, it's unclear whether this statement is true or false.\n4. UNKNOWN: While CLisp could theoretically be used for image filtering tasks, whether it includes built-in functions for applying blur, sharpen, and edge detection filters is not specified and would typically require external libraries or custom code.\n5. UNKNOWN: CLisp itself does not inherently enable image resizing; this functionality would depend on the use of external libraries or user-implemented functions.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2759,
    "user_query": "How many genes in S. cerevisiae are the result of an ancient whole genome duplication?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, it is estimated that approximately 30% of the genes in Saccharomyces cerevisiae (S. cerevisiae) are the result of an ancient whole genome duplication. This is a widely accepted estimate in the scientific community and is based on various studies that have analyzed the evolutionary history of S. cerevisiae.\nWhole genome duplication is a process in which an entire genome is copied, resulting in two identical copies of the genetic material. This process is thought to have occurred in the distant past in the ancestor of S. cerevisiae, leading to the creation of many duplicate genes. These duplicate genes are often referred to as \"ancient genes\" or \"duplicate genes.\"\nStudies have shown that many of the ancient genes in S. cerevisiae have evolved to perform different functions than their original copies, and some have even lost their original function over time. This suggests that the ancient whole genome duplication event had a significant impact on the evolution of S. cerevisiae, leading to the creation of many new genes and the modification of existing ones.\nIn summary, approximately 30% of the genes in S. cerevisiae are the result of an ancient whole genome duplication, and these genes have played a significant role in shaping the evolution of this organism.",
    "llama-2-7b-chat-hf_fact_raw": "1. Approximately 30% of the genes in Saccharomyces cerevisiae are the result of an ancient whole genome duplication.\n2. Whole genome duplication results in two identical copies of the genetic material.\n3. The whole genome duplication in the ancestor of S. cerevisiae is thought to have occurred in the distant past.\n4. Many of the ancient genes in S. cerevisiae have evolved to perform different functions than their original copies.\n5. Some ancient genes in S. cerevisiae have lost their original function over time.",
    "llama-2-7b-chat-hf_fact": [
      "Approximately 30% of the genes in Saccharomyces cerevisiae are the result of an ancient whole genome duplication.",
      "Whole genome duplication results in two identical copies of the genetic material.",
      "The whole genome duplication in the ancestor of S. cerevisiae is thought to have occurred in the distant past.",
      "Many of the ancient genes in S. cerevisiae have evolved to perform different functions than their original copies.",
      "Some ancient genes in S. cerevisiae have lost their original function over time."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe statements provided are consistent with current scientific understanding of Saccharomyces cerevisiae genetics and the consequences of whole genome duplication. Whole genome duplication does result in two identical copies of the genetic material, and it is known that in S. cerevisiae, approximately 30% of the genes are the result of an ancient whole genome duplication. This event is indeed thought to have occurred in the distant past. Following such an event, duplicated genes can evolve to perform different functions (a process known as neofunctionalization) or lose their original function (through a process called pseudogenization).",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2763,
    "user_query": "Which complex is bound by estrogen-related receptor β (Esrrb)?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the complex that is bound by estrogen-related receptor β (Esrrb) is not estrogen. Instead, Esrrb is homologous to estrogen receptors but is incapable of being bound by estrogen. Therefore, the complex that Esrrb binds is likely to be involved in mitochondrial structure and function, as suggested by the interaction between Esrrb and PGC-1α.",
    "llama-2-7b-chat-hf_fact_raw": "1. Estrogen-related receptor β (Esrrb) is not bound by estrogen.\n2. Esrrb is homologous to estrogen receptors.\n3. Esrrb is likely involved in mitochondrial structure and function.\n4. Esrrb interacts with PGC-1α.",
    "llama-2-7b-chat-hf_fact": [
      "Estrogen-related receptor β (Esrrb) is not bound by estrogen.",
      "Esrrb is homologous to estrogen receptors.",
      "Esrrb is likely involved in mitochondrial structure and function.",
      "Esrrb interacts with PGC-1α."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Estrogen-related receptor β (Esrrb) is indeed not bound by estrogen, despite its name suggesting a relationship with the estrogen receptor.\n2. TRUE: Esrrb is homologous to estrogen receptors, meaning it shares a common ancestry and has a similar sequence, although it does not bind estrogen.\n3. TRUE: Esrrb has been implicated in the regulation of mitochondrial function and biogenesis, often through its interaction with coactivators such as PGC-1α.\n4. TRUE: Esrrb is known to interact with peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), which is a key regulator of energy metabolism and mitochondrial function.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2842,
    "user_query": "What is the role of ZCCHC17?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, ZCCHC17 appears to be a gene that is relevant to hepatocellular carcinoma (HCC), a type of malignant tumor. The abstract mentions that HCC has a poor prognosis and low five-year survival rate due to tumor recurrence and metastasis.\nZCCHC17 is a gene that has been identified as a potential oncogene in HCC. Studies have shown that ZCCHC17 is overexpressed in many types of cancer, including HCC, and that high levels of ZCCHC17 expression are associated with poor prognosis and increased risk of recurrence and metastasis.\nIn summary, the role of ZCCHC17 in HCC appears to be as an oncogene that promotes the growth and progression of cancer cells, leading to poor prognosis and low survival rates.",
    "llama-2-7b-chat-hf_fact_raw": "1. ZCCHC17 is a gene that is relevant to hepatocellular carcinoma (HCC).\n2. Hepatocellular carcinoma (HCC) is a type of malignant tumor with a poor prognosis and low five-year survival rate.\n3. ZCCHC17 has been identified as a potential oncogene in hepatocellular carcinoma (HCC).\n4. ZCCHC17 is overexpressed in many types of cancer, including HCC.\n5. High levels of ZCCHC17 expression are associated with poor prognosis and increased risk of recurrence and metastasis in HCC.",
    "llama-2-7b-chat-hf_fact": [
      "ZCCHC17 is a gene that is relevant to hepatocellular carcinoma (HCC).",
      "Hepatocellular carcinoma (HCC) is a type of malignant tumor with a poor prognosis and low five-year survival rate.",
      "ZCCHC17 has been identified as a potential oncogene in hepatocellular carcinoma (HCC).",
      "ZCCHC17 is overexpressed in many types of cancer, including HCC.",
      "High levels of ZCCHC17 expression are associated with poor prognosis and increased risk of recurrence and metastasis in HCC."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without specific scientific literature or data to confirm the relevance of the ZCCHC17 gene to hepatocellular carcinoma (HCC), the truth of this statement cannot be determined.\n2. TRUE: Hepatocellular carcinoma (HCC) is indeed a type of malignant tumor that generally has a poor prognosis and a low five-year survival rate.\n3. UNKNOWN: The statement that ZCCHC17 has been identified as a potential oncogene in HCC would require specific scientific evidence to confirm its accuracy.\n4. UNKNOWN: The claim that ZCCHC17 is overexpressed in many types of cancer, including HCC, would need to be supported by scientific research or data to be verified.\n5. UNKNOWN: The association of high levels of ZCCHC17 expression with poor prognosis and increased risk of recurrence and metastasis in HCC would need to be substantiated by scientific studies to determine the truth of this statement.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2861,
    "user_query": "Which proteins form the nuclear pore basket in human cells?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the proteins that form the nuclear pore basket in human cells are:\n* Nucleoporins (Nups) - These are the main proteins that make up the nuclear pore complex (NPC). There are approximately 30 different nucleoporins in human cells, each with a unique function in maintaining the structure and regulating the transport of molecules through the NPC.\nSome of the most well-known nucleoporins include:\n* Nup107\n* Nup153\n* Nup170\n* Nup214\n* Nup240\nThese proteins work together to form a basket-like structure that spans the nuclear envelope, allowing for the selective transport of molecules between the nucleus and the cytoplasm.\nIt's worth noting that the exact composition of the nuclear pore basket can vary depending on the cell type and the specific stage of the cell cycle. However, the core nucleoporins listed above are consistently found in all human cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. Nucleoporins (Nups) are the main proteins that make up the nuclear pore complex (NPC) in human cells.\n2. There are approximately 30 different nucleoporins in human cells.\n3. Nup107, Nup153, Nup170, Nup214, and Nup240 are some of the well-known nucleoporins that contribute to the nuclear pore basket.\n4. The nuclear pore basket is a structure that spans the nuclear envelope.\n5. The core nucleoporins listed are consistently found in all human cells.",
    "llama-2-7b-chat-hf_fact": [
      "Nucleoporins (Nups) are the main proteins that make up the nuclear pore complex (NPC) in human cells.",
      "There are approximately 30 different nucleoporins in human cells.",
      "Nup107, Nup153, Nup170, Nup214, and Nup240 are some of the well-known nucleoporins that contribute to the nuclear pore basket.",
      "The nuclear pore basket is a structure that spans the nuclear envelope.",
      "The core nucleoporins listed are consistently found in all human cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: There are approximately 30 different types of nucleoporins, but in total, there are around 1000 nucleoporins in the nuclear pore complex in human cells.\n3. FALSE [correction]: Nup107 and Nup214 are indeed nucleoporins, but Nup170 and Nup240 are not recognized as standard nomenclature for human nucleoporins. Nup153 is a nucleoporin that contributes to the nuclear pore basket, but Nup170 and Nup240 are not established names in this context.\n4. FALSE [correction]: The nuclear pore basket is not a structure that spans the nuclear envelope; rather, it is a structure that extends into the nucleoplasm from the nuclear side of the nuclear pore complex.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2919,
    "user_query": "What type of topoisomerase inhibitor is gepotidacin?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, gepotidacin is a type II topoisomerase inhibitor.",
    "llama-2-7b-chat-hf_fact_raw": "1. Gepotidacin is a type II topoisomerase inhibitor.",
    "llama-2-7b-chat-hf_fact": [
      "Gepotidacin is a type II topoisomerase inhibitor."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 2943,
    "user_query": "Describe Canvas SPW",
    "llama-2-7b-chat-hf_response": "Canvas SPW is a software tool developed by Illumina for variant identification and filtering. It is designed to support a variety of family structures and provides a range of scoring and filtering options to automate and streamline the process of identifying de novo variants.\nCanvas SPW is available for download from GitHub, and users can contact the developers at sivakhno@illumina.com for more information or assistance with implementation.\nSome of the key features of Canvas SPW include:\n* Support for a variety of family structures, including single nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations.\n* A wide range of scoring and filtering options to automate and streamline the variant identification process.\n* Integration with other Illumina software tools, such as BaseSpace, for seamless analysis and interpretation of genomic data.\n* Ability to handle large datasets and perform high-throughput analysis.\nOverall, Canvas SPW is a powerful tool for identifying and filtering de novo variants in genomic data, and it can be a valuable resource for researchers and clinicians working in the field of genomics.",
    "llama-2-7b-chat-hf_fact_raw": "1. Canvas SPW is a software tool developed by Illumina for variant identification and filtering.\n2. Canvas SPW supports a variety of family structures, including SNPs, insertions, deletions, and copy number variations.\n3. The software offers a range of scoring and filtering options to automate the variant identification process.\n4. Canvas SPW is integrated with other Illumina software tools, such as BaseSpace.\n5. Canvas SPW is capable of handling large datasets and performing high-throughput analysis.",
    "llama-2-7b-chat-hf_fact": [
      "Canvas SPW is a software tool developed by Illumina for variant identification and filtering.",
      "Canvas SPW supports a variety of family structures, including SNPs, insertions, deletions, and copy number variations.",
      "The software offers a range of scoring and filtering options to automate the variant identification process.",
      "Canvas SPW is integrated with other Illumina software tools, such as BaseSpace.",
      "Canvas SPW is capable of handling large datasets and performing high-throughput analysis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Canvas SPW supports a variety of variant types, including single nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations, but \"family structures\" is not the correct term to describe these variant types.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2960,
    "user_query": "List STING agonists.",
    "llama-2-7b-chat-hf_response": "As a helpful assistant, I can provide you with a list of STING agonists based on the information provided:\n1. cGAMP (3'-5'-cyclic guanosine monophosphate): cGAMP is a nucleotide that activates STING and triggers the interferon response.\n2. DNA: DNA is a common STING agonist, as it can activate STING through the recognition of ectopic DNA species in the cytosol.\n3. Poly(I:C): Poly(I:C) is a synthetic analog of viral double-stranded RNA that can activate STING and induce the interferon response.\n4. R848: R848 is a synthetic agonist of STING that can activate the protein and induce the interferon response.\n5. IMQ: IMQ is a synthetic agonist of STING that can activate the protein and induce the interferon response.\n6. Toll-like receptor (TLR) agonists: TLRs are pattern recognition receptors that can recognize ectopic DNA species in the cytosol and activate STING, leading to the interferon response. Examples of TLR agonists include lipopolysaccharide (LPS), flagellin, and viral RNA.\nThese are some of the known STING agonists, but it's important to note that this list may not be exhaustive, as new agonists may be discovered in the future.",
    "llama-2-7b-chat-hf_fact_raw": "1. cGAMP (3'-5'-cyclic guanosine monophosphate) activates STING and triggers the interferon response.\n2. DNA can activate STING through the recognition of ectopic DNA species in the cytosol.\n3. Poly(I:C) is a synthetic analog of viral double-stranded RNA that can activate STING.\n4. R848 is a synthetic agonist of STING that can induce the interferon response.\n5. IMQ is a synthetic agonist of STING that can induce the interferon response.",
    "llama-2-7b-chat-hf_fact": [
      "cGAMP (3'-5'-cyclic guanosine monophosphate) activates STING and triggers the interferon response.",
      "DNA can activate STING through the recognition of ectopic DNA species in the cytosol.",
      "Poly(I:C) is a synthetic analog of viral double-stranded RNA that can activate STING.",
      "R848 is a synthetic agonist of STING that can induce the interferon response.",
      "IMQ is a synthetic agonist of STING that can induce the interferon response."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Poly(I:C) is a synthetic analog of viral double-stranded RNA that can activate Toll-like receptors (TLRs) but not STING directly. STING is primarily activated by cyclic dinucleotides like cGAMP, not by Poly(I:C).\n4. FALSE [correction]: R848 is a synthetic agonist of Toll-like receptors, specifically TLR7 and TLR8, not STING.\n5. FALSE [correction]: IMQ, or imiquimod, is a synthetic agonist of Toll-like receptor 7 (TLR7), not STING.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 2964,
    "user_query": "Describe SLIC-CAGE",
    "llama-2-7b-chat-hf_response": "SLIC-CAGE (Single-molecule Localization with Improved CAGE) is a method used to generate a genome-wide promoterome (a comprehensive map of gene expression) using significantly less material than traditional CAGE (Cap Analysis of Gene Expression) methods.\nIn traditional CAGE, the process of isolating and sequencing RNA molecules from individual cells requires a large amount of material, typically on the order of millions of cells. This can be a challenge, particularly when working with rare or precious samples, such as those from embryonic tissues.\nSLIC-CAGE addresses this challenge by using a combination of single-molecule localization and CAGE techniques. By using a complex, high-quality library generated from mouse embryonic day 11.5 primordial germ cells, SLIC-CAGE is able to generate a genome-wide promoterome with 1000-fold less material than required by existing CAGE methods.\nIn essence, SLIC-CAGE is a more efficient and cost-effective way to map gene expression at the single-cell level, allowing researchers to study the regulation of gene expression in a wider range of samples and under a greater variety of conditions.",
    "llama-2-7b-chat-hf_fact_raw": "1. SLIC-CAGE is a method used to generate a genome-wide promoterome.\n2. SLIC-CAGE requires significantly less material than traditional CAGE methods.\n3. Traditional CAGE typically requires material from millions of cells.\n4. SLIC-CAGE combines single-molecule localization with CAGE techniques.\n5. SLIC-CAGE can generate a genome-wide promoterome with 1000-fold less material than traditional CAGE methods.",
    "llama-2-7b-chat-hf_fact": [
      "SLIC-CAGE is a method used to generate a genome-wide promoterome.",
      "SLIC-CAGE requires significantly less material than traditional CAGE methods.",
      "Traditional CAGE typically requires material from millions of cells.",
      "SLIC-CAGE combines single-molecule localization with CAGE techniques.",
      "SLIC-CAGE can generate a genome-wide promoterome with 1000-fold less material than traditional CAGE methods."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: SLIC-CAGE combines single-cell analysis with CAGE techniques, not single-molecule localization.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2978,
    "user_query": "What are the roles of LEM-3?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, it appears that LEM-3 is related to the abolition of the two-tier disability support system in New Zealand. According to Document 0, the goal is to abolish the distinction between disability funding provided by ACC, the Ministry of Health, and the Ministry of Disabled People.\nCurrently, disability support services are provided through different systems depending on the source of funding. For example, ACC provides funding for certain disability-related expenses, while the Ministry of Health and the Ministry of Disabled People provide funding for other services. This creates a two-tier system where disability support is treated differently depending on the source of funding.\nLEM-3 appears to be working towards the goal of absorbing health and disability support services into the ACC system, which would eliminate the distinction between different sources of funding and provide a more streamlined and comprehensive approach to disability support.",
    "llama-2-7b-chat-hf_fact_raw": "1. LEM-3 is related to the abolition of the two-tier disability support system in New Zealand.\n2. The goal of LEM-3 is to abolish the distinction between disability funding provided by ACC, the Ministry of Health, and the Ministry of Disabled People.\n3. Currently, disability support services in New Zealand are provided through different systems depending on the source of funding.\n4. ACC provides funding for certain disability-related expenses in New Zealand.\n5. LEM-3 aims to absorb health and disability support services into the ACC system in New Zealand.",
    "llama-2-7b-chat-hf_fact": [
      "LEM-3 is related to the abolition of the two-tier disability support system in New Zealand.",
      "The goal of LEM-3 is to abolish the distinction between disability funding provided by ACC, the Ministry of Health, and the Ministry of Disabled People.",
      "Currently, disability support services in New Zealand are provided through different systems depending on the source of funding.",
      "ACC provides funding for certain disability-related expenses in New Zealand.",
      "LEM-3 aims to absorb health and disability support services into the ACC system in New Zealand."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without additional context, it is unclear what LEM-3 refers to. It could be a legislative measure, policy proposal, or something else related to disability support in New Zealand, but without specific information, its relation to the abolition of the two-tier disability support system cannot be confirmed.\n2. UNKNOWN: Again, without further context or information about LEM-3, it is not possible to confirm the goal of LEM-3 regarding the distinction between disability funding provided by different agencies.\n3. TRUE: In New Zealand, disability support services are indeed provided through different systems depending on the cause of the disability and the source of funding. ACC (Accident Compensation Corporation) covers accidents, while the Ministry of Health and other agencies cover non-accident-related disabilities.\n4. TRUE: ACC (Accident Compensation Corporation) in New Zealand provides funding for disability-related expenses for individuals who have experienced an injury caused by an accident.\n5. UNKNOWN: Without specific information about LEM-3, it is not possible to confirm whether it aims to absorb health and disability support services into the ACC system or if it has a different goal regarding the restructuring of disability support services in New Zealand.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2992,
    "user_query": "List the releases of tmVar",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the releases of tmVar are:\n1.0: This is the initial release of tmVar, which was mentioned in Document 0 as a novel machine learning tool that uses natural language processing to automatically identify pathogenic genetic variant evidence in full-text.\nThere may be subsequent releases of tmVar with improved features or functionality, but the information provided in the given document does not mention any specific versions beyond the initial release.",
    "llama-2-7b-chat-hf_fact_raw": "1. tmVar 1.0 is the initial release of tmVar.\n2. tmVar uses natural language processing to automatically identify pathogenic genetic variant evidence in full-text.\n3. There may be subsequent releases of tmVar with improved features or functionality.\n4. The provided information does not mention any specific versions of tmVar beyond the initial release.",
    "llama-2-7b-chat-hf_fact": [
      "tmVar 1.0 is the initial release of tmVar.",
      "tmVar uses natural language processing to automatically identify pathogenic genetic variant evidence in full-text.",
      "There may be subsequent releases of tmVar with improved features or functionality.",
      "The provided information does not mention any specific versions of tmVar beyond the initial release."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3018,
    "user_query": "Which is the database of somatic mutations in normal cells?",
    "llama-2-7b-chat-hf_response": "Thank you for asking! Based on the information provided, there are several databases that contain information on somatic mutations in normal cells. Here are a few examples:\n1. The Cancer Genome Atlas (TCGA): TCGA is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI) that aims to catalogue the genomic changes in various types of cancer. While TCGA primarily focuses on cancer genomics, it also includes data on normal tissue samples, which can be used to identify somatic mutations.\n2. The 1000 Genomes Project: The 1000 Genomes Project is a large-scale effort to catalogue the genetic variation in human populations. While the project primarily focuses on coding regions of the genome, it also includes non-coding regions, which can be used to identify somatic mutations.\n3. The ExAC database: The ExAC database is a collection of exome data from over 60,000 individuals, including both cancer cases and normal controls. The database includes both coding and non-coding regions of the genome, and can be used to identify somatic mutations.\n4. The COSMIC database: The COSMIC database is a collection of somatic mutations identified in various types of cancer, including breast, lung, and colon cancer. While the database primarily focuses on cancer mutations, it can also be used to identify somatic mutations in normal cells.\nIt's worth noting that these databases are constantly being updated and expanded, so it's important to check the most recent versions for the most accurate information. Additionally, it's important to consult the original research articles and other resources to fully understand the context and limitations of the data.\nI hope this helps! Let me know if you have any further questions.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Cancer Genome Atlas (TCGA) is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI).\n2. TCGA includes data on normal tissue samples that can be used to identify somatic mutations.\n3. The 1000 Genomes Project is a large-scale effort to catalogue genetic variation in human populations.\n4. The ExAC database contains exome data from over 60,000 individuals, including both cancer cases and normal controls.\n5. The COSMIC database is a collection of somatic mutations identified in various types of cancer and can be used to identify somatic mutations in normal cells.",
    "llama-2-7b-chat-hf_fact": [
      "The Cancer Genome Atlas (TCGA) is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI).",
      "TCGA includes data on normal tissue samples that can be used to identify somatic mutations.",
      "The 1000 Genomes Project is a large-scale effort to catalogue genetic variation in human populations.",
      "The ExAC database contains exome data from over 60,000 individuals, including both cancer cases and normal controls.",
      "The COSMIC database is a collection of somatic mutations identified in various types of cancer and can be used to identify somatic mutations in normal cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The COSMIC database is a collection of somatic mutations found in cancer. It does not include somatic mutations in normal cells, as it is specifically focused on mutations that contribute to cancer.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3037,
    "user_query": "Are there graph kernel libraries available implemented in JAVA?",
    "llama-2-7b-chat-hf_response": "Yes, there are several graph kernel libraries available implemented in Java. Here are a few examples:\n1. GraKeL: As mentioned in the document, GraKeL is a library that unifies several graph kernels into a common framework. It provides a set of Java classes and interfaces for implementing various graph kernels, including the popular GraphKernel, SubgraphKernel, and MatrixKernel.\n2. GraphKernel: GraphKernel is a Java library for computing graph kernels. It provides a simple and efficient implementation of several graph kernels, including the degree kernel, the PageRank kernel, and the personalized PageRank kernel.\n3. JGraphT: JGraphT is a Java library for graph theory and graph algorithms. It provides a set of classes and interfaces for implementing graph kernels, including the degree kernel, the PageRank kernel, and the personalized PageRank kernel.\n4. GraphMol: GraphMol is a Java library for molecular graph analysis. It provides a set of classes and interfaces for implementing graph kernels, including the degree kernel, the PageRank kernel, and the personalized PageRank kernel.\n5. GraphKernelJ: GraphKernelJ is a Java library for computing graph kernels. It provides a simple and efficient implementation of several graph kernels, including the degree kernel, the PageRank kernel, and the personalized PageRank kernel.\nThese libraries provide a range of graph kernel implementations in Java, and can be used for a variety of applications, including graph similarity search, graph clustering, and graph classification.",
    "llama-2-7b-chat-hf_fact_raw": "1. GraKeL is a Java library that includes various graph kernels such as GraphKernel, SubgraphKernel, and MatrixKernel.\n2. GraphKernel is a Java library that computes graph kernels, including the degree kernel, the PageRank kernel, and the personalized PageRank kernel.\n3. JGraphT is a Java library that offers graph theory and graph algorithms, with support for graph kernels like the degree kernel, the PageRank kernel, and the personalized PageRank kernel.\n4. GraphMol is a Java library designed for molecular graph analysis and includes implementations of graph kernels.\n5. GraphKernelJ is a Java library that provides an implementation of several graph kernels, including the degree kernel, the PageRank kernel, and the personalized PageRank kernel.",
    "llama-2-7b-chat-hf_fact": [
      "GraKeL is a Java library that includes various graph kernels such as GraphKernel, SubgraphKernel, and MatrixKernel.",
      "GraphKernel is a Java library that computes graph kernels, including the degree kernel, the PageRank kernel, and the personalized PageRank kernel.",
      "JGraphT is a Java library that offers graph theory and graph algorithms, with support for graph kernels like the degree kernel, the PageRank kernel, and the personalized PageRank kernel.",
      "GraphMol is a Java library designed for molecular graph analysis and includes implementations of graph kernels.",
      "GraphKernelJ is a Java library that provides an implementation of several graph kernels, including the degree kernel, the PageRank kernel, and the personalized PageRank kernel."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: GraKeL is a Python library that includes various graph kernels such as GraphKernel, SubgraphKernel, and MatrixKernel.\n2. UNKNOWN\n3. TRUE\n4. FALSE [correction]: RDKit's GraphMol is a cheminformatics toolkit with a C++ and Python API, designed for molecular informatics tasks, which may include graph analysis but is not specifically a Java library for graph kernels.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3045,
    "user_query": "List the four advances integrated into the SHERLOCKv2 platform.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the four advances integrated into the SHERLOCKv2 platform are:\n1. The use of the RNA-targeting CRISPR-associated enzyme Cas13 for nucleic acid detection.\n2. The development of a detection platform called SHERLOCK (specific high-sensitivity enzymatic reporter unlocking) for rapid and portable sensing of nucleic acids.\n3. The integration of multiplexing capabilities into the SHERLOCKv2 platform, allowing for the detection of multiple targets in a single reaction.\n4. The use of a novel reporter system that provides a high sensitivity and specificity for detecting nucleic acid targets.",
    "llama-2-7b-chat-hf_fact_raw": "1. The SHERLOCKv2 platform uses the RNA-targeting CRISPR-associated enzyme Cas13 for nucleic acid detection.\n2. The SHERLOCKv2 platform includes a detection platform called SHERLOCK for rapid and portable sensing of nucleic acids.\n3. The SHERLOCKv2 platform has integrated multiplexing capabilities, allowing for the detection of multiple targets in a single reaction.\n4. The SHERLOCKv2 platform employs a novel reporter system that enhances sensitivity and specificity for detecting nucleic acid targets.",
    "llama-2-7b-chat-hf_fact": [
      "The SHERLOCKv2 platform uses the RNA-targeting CRISPR-associated enzyme Cas13 for nucleic acid detection.",
      "The SHERLOCKv2 platform includes a detection platform called SHERLOCK for rapid and portable sensing of nucleic acids.",
      "The SHERLOCKv2 platform has integrated multiplexing capabilities, allowing for the detection of multiple targets in a single reaction.",
      "The SHERLOCKv2 platform employs a novel reporter system that enhances sensitivity and specificity for detecting nucleic acid targets."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n\nThe SHERLOCKv2 platform is an updated version of the original SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing) technology, which indeed uses the RNA-targeting CRISPR-associated enzyme Cas13 for nucleic acid detection. It includes the SHERLOCK detection system for rapid and portable sensing of nucleic acids. The version 2 platform has integrated multiplexing capabilities, allowing for the simultaneous detection of multiple targets. It also employs a novel reporter system to enhance the sensitivity and specificity of nucleic acid detection.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3078,
    "user_query": "Describe the bartender algorithm",
    "llama-2-7b-chat-hf_response": "The bartender algorithm is a type of control algorithm used in robotics to enable a robot to perform tasks that require the manipulation of objects in real-time, such as stacking boxes or moving drinks on a tray. The algorithm is designed to provide real-time perception-driven feedback control, which means that the robot's actions are based on the current state of the environment and the objects it is manipulating.\nIn the context of a robot bartender, the algorithm would allow the robot to move drinks from a tray to a series of glasses on a bar, taking into account the size and shape of the drinks, the distance between the tray and the glasses, and any obstacles in the environment that could interfere with the movement of the drinks. The algorithm would also allow the robot to adjust its movements based on feedback from sensors and cameras that provide real-time information about the state of the environment and the objects it is manipulating.\nThe bartender algorithm is an example of a type of control algorithm known as a model predictive control (MPC) algorithm. MPC algorithms use a mathematical model of the system being controlled to predict the future behavior of the system and optimize its performance. In the case of a robot bartender, the algorithm would use a model of the robot, the objects it is manipulating, and the environment in which it is operating to predict the best sequence of movements to perform the task at hand.\nThe use of real-time perception-driven feedback control in the bartender algorithm allows the robot to adapt to changing conditions in the environment and to perform the task more efficiently and accurately. This is particularly important in industrial settings, where the robot may need to perform a variety of tasks in a repetitive and fast-paced environment.\nReferences:\n[1] K. M. S. Al-Mualla and M. A. Al-Mamari, \"Real-time perception-driven feedback control for robot manipulation,\" Journal of Intelligent & Robotic Systems, vol. 77, no. 1, pp. 137-153, 2014.\n[2] J. M. H. M. van der Velden, J. J. M. van der Meer, and J. J. M. van der K",
    "llama-2-7b-chat-hf_fact_raw": "1. The bartender algorithm is a control algorithm used in robotics for tasks that involve real-time manipulation of objects.\n2. It provides real-time perception-driven feedback control, meaning the robot's actions are based on the current state of the environment and the objects it is manipulating.\n3. The algorithm can enable a robot bartender to move drinks from a tray to glasses on a bar while considering the size and shape of the drinks and any obstacles.\n4. The bartender algorithm is a type of model predictive control (MPC) algorithm.\n5. Model predictive control algorithms use a mathematical model to predict the future behavior of the system and optimize its performance.",
    "llama-2-7b-chat-hf_fact": [
      "The bartender algorithm is a control algorithm used in robotics for tasks that involve real-time manipulation of objects.",
      "It provides real-time perception-driven feedback control, meaning the robot's actions are based on the current state of the environment and the objects it is manipulating.",
      "The algorithm can enable a robot bartender to move drinks from a tray to glasses on a bar while considering the size and shape of the drinks and any obstacles.",
      "The bartender algorithm is a type of model predictive control (MPC) algorithm.",
      "Model predictive control algorithms use a mathematical model to predict the future behavior of the system and optimize its performance."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: There is no widely recognized control algorithm specifically known as the \"bartender algorithm\" in robotics. The term may be used informally to describe a scenario where a robot performs tasks similar to a bartender, but it is not a formal algorithmic term.\n2. TRUE: In robotics, real-time perception-driven feedback control indeed means that the robot's actions are based on the current state of the environment and the objects it is manipulating.\n3. UNKNOWN: Without specific information about an algorithm named \"bartender algorithm,\" it is unclear whether such an algorithm would enable a robot to perform the described task. However, in general, robotics algorithms can be designed to perform such tasks.\n4. UNKNOWN: Since the \"bartender algorithm\" is not a recognized term, it cannot be determined if it is a type of model predictive control (MPC) algorithm.\n5. TRUE: Model predictive control algorithms do use a mathematical model to predict the future behavior of the system and optimize its performance.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3100,
    "user_query": "Which web-based pedigree editors are available?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, there are several web-based pedigree editors available. However, there are no freely available lightweight graphical pedigree editors that can be easily configured and incorporated into web applications.\nTo address this gap, the document mentions the development of 'pedigreejs', an interactive graphical pedigree editor written in JavaScript. This tool allows for the creation and editing of pedigrees using standard HTML, CSS, and JavaScript, making it a lightweight and versatile option for web-based applications.\nSome of the other web-based pedigree editors available include:\n1. Pedigree Draw: This is a web-based application that allows users to create and edit pedigrees using a simple and intuitive interface.\n2. Family Tree Builder: This is a free online tool that allows users to create and edit their family trees, including adding photos, documents, and other multimedia content.\n3. GenoPro: This is a professional-grade genealogy software that allows users to create and edit detailed family trees, including ancestors, descendants, and other relatives.\n4. Legacy Family Tree: This is a popular genealogy software that allows users to create and edit family trees, including adding sources, photos, and other multimedia content.\nOverall, there are several web-based pedigree editors available, each with its own unique features and capabilities. By evaluating the available options and considering the user's specific needs and preferences, it is possible to find the best tool for the job.",
    "llama-2-7b-chat-hf_fact_raw": "1. 'pedigreejs' is an interactive graphical pedigree editor written in JavaScript.\n2. Pedigree Draw is a web-based application that allows users to create and edit pedigrees.\n3. Family Tree Builder is a free online tool for creating and editing family trees.\n4. GenoPro is a professional-grade genealogy software for creating and editing detailed family trees.\n5. Legacy Family Tree is a genealogy software that enables users to create and edit family trees with additional multimedia content.",
    "llama-2-7b-chat-hf_fact": [
      "'pedigreejs' is an interactive graphical pedigree editor written in JavaScript.",
      "Pedigree Draw is a web-based application that allows users to create and edit pedigrees.",
      "Family Tree Builder is a free online tool for creating and editing family trees.",
      "GenoPro is a professional-grade genealogy software for creating and editing detailed family trees.",
      "Legacy Family Tree is a genealogy software that enables users to create and edit family trees with additional multimedia content."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3107,
    "user_query": "Which curated databases exist for spider-venom toxins?",
    "llama-2-7b-chat-hf_response": "Thank you for asking! Based on the information provided, there are several curated databases that exist for spider-venom toxins:\n1. ArachnoServer (www.arachnoserver.org): As you mentioned, this is a manually curated database that provides information on the sequence, structure, and biological activity of protein toxins from spider venoms.\n2. SpiderBase (www.spiderbase.org): This is a comprehensive database that contains information on the venomous animals of the world, including spiders, scorpions, and other arachnids. It includes data on the venom composition, toxicity, and evolution of these animals.\n3. VenomDB (www.venomdb.org): This is a curated database that contains information on the venom peptides and proteins from various animal species, including spiders. It includes data on the sequence, structure, and function of these peptides and proteins, as well as their potential applications in medicine and biotechnology.\n4. ToxinDB (www.toxindb.org): This is a comprehensive database that contains information on the toxins and venoms from various animal species, including spiders. It includes data on the sequence, structure, and biological activity of these toxins, as well as their potential applications in medicine and biotechnology.\nI hope this helps! Let me know if you have any further questions.",
    "llama-2-7b-chat-hf_fact_raw": "1. ArachnoServer is a manually curated database that provides information on the sequence, structure, and biological activity of protein toxins from spider venoms.\n2. SpiderBase is a database that contains information on venomous animals, including spiders, scorpions, and other arachnids, and includes data on venom composition, toxicity, and evolution.\n3. VenomDB is a curated database that contains information on venom peptides and proteins from various animal species, including spiders, and includes data on sequence, structure, and function.\n4. ToxinDB is a database that contains information on toxins and venoms from various animal species, including spiders, and includes data on sequence, structure, and biological activity.",
    "llama-2-7b-chat-hf_fact": [
      "ArachnoServer is a manually curated database that provides information on the sequence, structure, and biological activity of protein toxins from spider venoms.",
      "SpiderBase is a database that contains information on venomous animals, including spiders, scorpions, and other arachnids, and includes data on venom composition, toxicity, and evolution.",
      "VenomDB is a curated database that contains information on venom peptides and proteins from various animal species, including spiders, and includes data on sequence, structure, and function.",
      "ToxinDB is a database that contains information on toxins and venoms from various animal species, including spiders, and includes data on sequence, structure, and biological activity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: SpiderBase is not a known database for venomous animals; ArachnoServer and VenomKB are examples of databases that contain such information.\n3. TRUE\n4. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3111,
    "user_query": "Does Axitinib prolong survival of Pancreatic Cancer patients?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there is limited research available on the effectiveness of Axitinib in prolonging the survival of Pancreatic Cancer patients. According to Document 0, the overall 5-year survival for pancreatic cancer has changed little over the past few decades, and pancreatic cancer is predicted to be the second leading cause of cancer-related deaths by 2030.\nAxitinib is a tyrosine kinase inhibitor that has been approved by the FDA for the treatment of advanced renal cell carcinoma. However, there have been limited clinical trials conducted specifically on the use of Axitinib in pancreatic cancer. A phase 2 clinical trial published in the Journal of Clinical Oncology in 2018 found that Axitinib was well-tolerated and showed evidence of antitumor activity in patients with advanced pancreatic cancer, but the trial did not meet its primary endpoint of overall survival.\nBased on the current available evidence, it is unclear whether Axitinib prolongs the survival of Pancreatic Cancer patients. Further research and clinical trials are needed to determine the efficacy and safety of Axitinib in this patient population.\nIn summary, while there is limited information available on the use of Axitinib in pancreatic cancer, the current evidence suggests that it may be effective in treating this type of cancer, but more research is needed to confirm its survival-prolonging effects.",
    "llama-2-7b-chat-hf_fact_raw": "1. Axitinib is a tyrosine kinase inhibitor approved by the FDA for the treatment of advanced renal cell carcinoma.\n2. Pancreatic cancer is predicted to be the second leading cause of cancer-related deaths by 2030.\n3. A phase 2 clinical trial published in the Journal of Clinical Oncology in 2018 indicated that Axitinib was well-tolerated by patients with advanced pancreatic cancer.\n4. The same phase 2 clinical trial showed evidence of antitumor activity in patients with advanced pancreatic cancer.\n5. The primary endpoint of overall survival was not met in the phase 2 clinical trial of Axitinib for pancreatic cancer.",
    "llama-2-7b-chat-hf_fact": [
      "Axitinib is a tyrosine kinase inhibitor approved by the FDA for the treatment of advanced renal cell carcinoma.",
      "Pancreatic cancer is predicted to be the second leading cause of cancer-related deaths by 2030.",
      "A phase 2 clinical trial published in the Journal of Clinical Oncology in 2018 indicated that Axitinib was well-tolerated by patients with advanced pancreatic cancer.",
      "The same phase 2 clinical trial showed evidence of antitumor activity in patients with advanced pancreatic cancer.",
      "The primary endpoint of overall survival was not met in the phase 2 clinical trial of Axitinib for pancreatic cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Axitinib is indeed a tyrosine kinase inhibitor that has been approved by the FDA for the treatment of advanced renal cell carcinoma.\n2. TRUE: It has been projected that pancreatic cancer may become the second leading cause of cancer-related deaths by 2030, according to various scientific publications.\n3. UNKNOWN: Without access to the specific article from the Journal of Clinical Oncology in 2018, it is not possible to confirm the tolerability of Axitinib in patients with advanced pancreatic cancer.\n4. UNKNOWN: Similarly, without the specific details from the phase 2 clinical trial, it is not possible to confirm the evidence of antitumor activity in patients with advanced pancreatic cancer.\n5. UNKNOWN: The outcome regarding the primary endpoint of overall survival in the phase 2 clinical trial of Axitinib for pancreatic cancer cannot be confirmed without the specific trial results.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3113,
    "user_query": "Through which protein interaction does MLP regulate F-actin dynamics?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, MLP regulates F-actin dynamics through its W motif interaction.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3125,
    "user_query": "How many pseudokinases are there in the human kinome?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there are approximately 518 protein kinases in the human kinome. Of these, 478 contain a eukaryotic protein kinase (ePK) domain, while the remaining 40 lack sequence similarity to the ePK domain. Therefore, there are approximately 478 protein kinases in the human kinome that contain the ePK domain.\nIt is worth noting that the term \"pseudokinase\" is not used in the document, and the term \"lipid kinase\" is used to refer to proteins that phosphorylate lipids. Therefore, the answer to the user's question is 478.",
    "llama-2-7b-chat-hf_fact_raw": "1. There are approximately 518 protein kinases in the human kinome.\n2. Out of these, 478 protein kinases contain a eukaryotic protein kinase (ePK) domain.\n3. The remaining 40 protein kinases lack sequence similarity to the ePK domain.\n4. The term \"pseudokinase\" is not used in the provided document.\n5. The term \"lipid kinase\" refers to proteins that phosphorylate lipids.",
    "llama-2-7b-chat-hf_fact": [
      "There are approximately 518 protein kinases in the human kinome.",
      "Out of these, 478 protein kinases contain a eukaryotic protein kinase (ePK) domain.",
      "The remaining 40 protein kinases lack sequence similarity to the ePK domain.",
      "The term \"pseudokinase\" is not used in the provided document.",
      "The term \"lipid kinase\" refers to proteins that phosphorylate lipids."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3139,
    "user_query": "List 3 apoE mimetics.",
    "llama-2-7b-chat-hf_response": "Certainly! Based on the information provided in Document 0, here are three apoE mimetics:\n1. ApoE-mimetic peptide PF-04492324: This peptide is a synthetic mimic of the apoE protein and has been shown to have cholesterol-lowering effects in preclinical studies. It is being developed as a potential treatment for high cholesterol and cardiovascular disease.\n2. ApoE-mimetic peptide AZD7207: This peptide is a small molecule mimic of apoE that has been shown to have anti-inflammatory and cholesterol-lowering effects in preclinical studies. It is being developed as a potential treatment for atherosclerosis and other cardiovascular diseases.\n3. ApoE-mimetic peptide GW3965: This peptide is a synthetic mimic of apoE that has been shown to have cholesterol-lowering effects in preclinical studies. It is being developed as a potential treatment for high cholesterol and cardiovascular disease.\nI hope this information is helpful! Let me know if you have any further questions.",
    "llama-2-7b-chat-hf_fact_raw": "1. ApoE-mimetic peptide PF-04492324 is being developed as a potential treatment for high cholesterol and cardiovascular disease.\n2. ApoE-mimetic peptide AZD7207 is being developed as a potential treatment for atherosclerosis and other cardiovascular diseases.\n3. ApoE-mimetic peptide GW3965 is being developed as a potential treatment for high cholesterol and cardiovascular disease.",
    "llama-2-7b-chat-hf_fact": [
      "ApoE-mimetic peptide PF-04492324 is being developed as a potential treatment for high cholesterol and cardiovascular disease.",
      "ApoE-mimetic peptide AZD7207 is being developed as a potential treatment for atherosclerosis and other cardiovascular diseases.",
      "ApoE-mimetic peptide GW3965 is being developed as a potential treatment for high cholesterol and cardiovascular disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. FALSE [correction]: GW3965 is not an ApoE-mimetic peptide; it is a liver X receptor (LXR) agonist that has been studied for its effects on cholesterol and cardiovascular disease.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3140,
    "user_query": "What are there sex differences in SAMHD1 activity?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there are sex differences in SAMHD1 activity, with higher activity observed in macrophages from female donors compared to male donors. Specifically, the study found that SAMHD1 activity was increased in female-derived macrophages, which correlated with and explained the lower infectivity of HIV-1 in these cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. There are sex differences in SAMHD1 activity.\n2. Macrophages from female donors have higher SAMHD1 activity compared to those from male donors.\n3. Increased SAMHD1 activity in female-derived macrophages correlates with lower HIV-1 infectivity in these cells.",
    "llama-2-7b-chat-hf_fact": [
      "There are sex differences in SAMHD1 activity.",
      "Macrophages from female donors have higher SAMHD1 activity compared to those from male donors.",
      "Increased SAMHD1 activity in female-derived macrophages correlates with lower HIV-1 infectivity in these cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3205,
    "user_query": "Does RUNX2 inhibit astrocyte differentiation?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the answer to the user's question is:\nRUNX2 does not inhibit astrocyte differentiation. In fact, the document suggests that RUNX2 promotes astrocyte maturation. The transcription factors NFIA and ATF3 are identified as drivers of astrocyte differentiation from neural precursor cells, while RUNX2 is involved in the maturation of astrocytes.",
    "llama-2-7b-chat-hf_fact_raw": "1. RUNX2 does not inhibit astrocyte differentiation.\n2. RUNX2 promotes astrocyte maturation.\n3. The transcription factors NFIA and ATF3 drive astrocyte differentiation from neural precursor cells.",
    "llama-2-7b-chat-hf_fact": [
      "RUNX2 does not inhibit astrocyte differentiation.",
      "RUNX2 promotes astrocyte maturation.",
      "The transcription factors NFIA and ATF3 drive astrocyte differentiation from neural precursor cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3209,
    "user_query": "Where, in the body, would the Cobb-Stainsby excision arthroplasty be performed?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the Cobb-Stainsby excision arthroplasty would be performed on the toe(s) affected by the deformity. The Stainsby procedure is a salvage operation for severe claw toes, which means it is typically performed on toes that have not responded to other treatments, such as non-surgical treatments or other surgical procedures.\nThe Cobb-Stainsby excision arthroplasty involves removing the bony prominence (excision) and replacing it with a prosthetic implant (arthroplasty). This procedure is typically performed under general anesthesia and may involve an incision on the top or side of the toe, depending on the severity of the deformity and the surgeon's preference.\nIt is important to note that the Cobb-Stainsby excision arthroplasty is a complex procedure that requires a thorough understanding of foot and ankle anatomy and surgical techniques. It is not a procedure that can be performed by a general practitioner or primary care physician, but rather by a specialized foot and ankle surgeon.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Cobb-Stainsby excision arthroplasty is performed on the toe(s).\n2. The Stainsby procedure is a salvage operation for severe claw toes.\n3. The procedure involves removing the bony prominence and replacing it with a prosthetic implant.\n4. The Cobb-Stainsby excision arthroplasty is typically performed under general anesthesia.\n5. The procedure requires a specialized foot and ankle surgeon, not a general practitioner or primary care physician.",
    "llama-2-7b-chat-hf_fact": [
      "The Cobb-Stainsby excision arthroplasty is performed on the toe(s).",
      "The Stainsby procedure is a salvage operation for severe claw toes.",
      "The procedure involves removing the bony prominence and replacing it with a prosthetic implant.",
      "The Cobb-Stainsby excision arthroplasty is typically performed under general anesthesia.",
      "The procedure requires a specialized foot and ankle surgeon, not a general practitioner or primary care physician."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Cobb-Stainsby excision arthroplasty is performed on the hip, not the toe(s).\n2. FALSE [correction]: The Stainsby procedure is a salvage operation for severe hallux valgus or other deformities, not specifically for severe claw toes.\n3. FALSE [correction]: The Stainsby procedure involves shortening the flexor tendons and stabilizing the toe with a pin, not removing a bony prominence and replacing it with a prosthetic implant.\n4. TRUE: The Cobb-Stainsby excision arthroplasty is typically performed under general anesthesia.\n5. TRUE: The procedure requires a specialized foot and ankle surgeon, not a general practitioner or primary care physician.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3243,
    "user_query": "Does GRHL2 over-expression lead to EMT?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, it appears that GRHL2 over-expression does lead to EMT (Epithelial-to-Mesenchymal Transition).\nIn the study, Grhl2 was found to bind to specific genes in embryonic and adult murine tissue, including Elf5 in the lung, Nkx2-1 in the lung epithelium, Ovol2 in the kidney, and Upk in the bladder. These genes are known to play important roles in the regulation of cell fate and differentiation, and their binding to GRHL2 suggests that GRHL2 may be involved in the regulation of these processes.\nFurthermore, the study found that GRHL2 regulates the differentiation of umbrella cells in the bladder, which is a process that is associated with EMT. This suggests that GRHL2 may play a role in the transition of epithelial cells to a mesenchymal-like state, which is a hallmark of EMT.\nOverall, the information provided in Document 0 suggests that GRHL2 over-expression leads to EMT, at least in certain tissues and cell types. However, it is important to note that this is based on a single study and further research is needed to confirm these findings and to fully understand the role of GRHL2 in EMT.",
    "llama-2-7b-chat-hf_fact_raw": "1. GRHL2 over-expression is suggested to lead to Epithelial-to-Mesenchymal Transition (EMT).\n2. In the study, Grhl2 was found to bind to specific genes such as Elf5 in the lung, Nkx2-1 in the lung epithelium, Ovol2 in the kidney, and Upk in the bladder.\n3. These genes are involved in the regulation of cell fate and differentiation.\n4. GRHL2 is reported to regulate the differentiation of umbrella cells in the bladder.\n5. The differentiation of umbrella cells in the bladder is associated with EMT.",
    "llama-2-7b-chat-hf_fact": [
      "GRHL2 over-expression is suggested to lead to Epithelial-to-Mesenchymal Transition (EMT).",
      "In the study, Grhl2 was found to bind to specific genes such as Elf5 in the lung, Nkx2-1 in the lung epithelium, Ovol2 in the kidney, and Upk in the bladder.",
      "These genes are involved in the regulation of cell fate and differentiation.",
      "GRHL2 is reported to regulate the differentiation of umbrella cells in the bladder.",
      "The differentiation of umbrella cells in the bladder is associated with EMT."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: GRHL2 (Grainyhead-like 2) is a transcription factor that has been implicated in the regulation of epithelial integrity and has been suggested to play a role in Epithelial-to-Mesenchymal Transition (EMT), a process where epithelial cells lose their characteristics and gain mesenchymal properties.\n2. TRUE: In studies, Grhl2 has been found to bind to specific genes that are involved in the development and differentiation of various tissues. The genes mentioned, such as Elf5, Nkx2-1, Ovol2, and Upk, are known to be involved in the development and function of the organs specified.\n3. TRUE: The genes mentioned (Elf5, Nkx2-1, Ovol2, and Upk) are indeed involved in the regulation of cell fate and differentiation, which is consistent with the roles typically associated with transcription factors like Grhl2.\n4. TRUE: GRHL2 has been reported to regulate the differentiation of various cell types, including umbrella cells in the bladder. Umbrella cells are specialized epithelial cells that line the surface of the bladder and contribute to its barrier function.\n5. FALSE [correction]: The differentiation of umbrella cells in the bladder is not typically associated with EMT. Instead, umbrella cell differentiation is a process of specialization within the epithelial layer of the bladder, whereas EMT involves a transition away from an epithelial phenotype towards a mesenchymal phenotype.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3254,
    "user_query": "Which T-UCRs have been implicated in lung cancer?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, several T-UCRs have been implicated in lung cancer. These include:\n1. T-bet: T-bet is a transcription factor that plays a crucial role in the differentiation of T cells and the immune response. Studies have shown that T-bet is overexpressed in lung cancer, particularly in non-small cell lung cancer (NSCLC) [1,2].\n2. GATA-3: GATA-3 is a transcription factor that is essential for the differentiation of T cells and the immune response. GATA-3 has been shown to be downregulated in lung cancer, particularly in NSCLC [3,4].\n3. Eomesodermin (Eomes): Eomes is a transcription factor that plays a crucial role in the differentiation of T cells and the immune response. Eomes has been shown to be overexpressed in lung cancer, particularly in NSCLC [5,6].\n4. T-box protein 1 (Tbx1): Tbx1 is a transcription factor that plays a crucial role in the differentiation of T cells and the immune response. Tbx1 has been shown to be overexpressed in lung cancer, particularly in NSCLC [7,8].\nIt is important to note that the expression of these T-UCRs can vary depending on the type of lung cancer and the stage of disease. Further research is needed to fully understand the role of these T-UCRs in lung cancer and to identify potential therapeutic targets for the treatment of lung cancer.\nReferences:\n[1] Kim et al. (2015). T-bet is a critical regulator of the immune response in lung cancer. Cancer Research, 75(19), 3839-3848.\n[2] Zhang et al. (2018). T-bet is a novel prognostic marker for non-small cell lung cancer. Lung Cancer, 119, 73-79.\n[3] Li et al. (2015). GATA-3 is downregulated in lung cancer and inhibits the immune response. Oncology Reports, 34(5), 230",
    "llama-2-7b-chat-hf_fact_raw": "1. T-bet is overexpressed in lung cancer, particularly in non-small cell lung cancer (NSCLC).\n2. GATA-3 is downregulated in lung cancer, specifically in NSCLC.\n3. Eomesodermin (Eomes) is overexpressed in lung cancer, particularly in NSCLC.\n4. T-box protein 1 (Tbx1) is overexpressed in lung cancer, particularly in NSCLC.\n5. The expression of T-UCRs can vary depending on the type of lung cancer and the stage of the disease.",
    "llama-2-7b-chat-hf_fact": [
      "T-bet is overexpressed in lung cancer, particularly in non-small cell lung cancer (NSCLC).",
      "GATA-3 is downregulated in lung cancer, specifically in NSCLC.",
      "Eomesodermin (Eomes) is overexpressed in lung cancer, particularly in NSCLC.",
      "T-box protein 1 (Tbx1) is overexpressed in lung cancer, particularly in NSCLC.",
      "The expression of T-UCRs can vary depending on the type of lung cancer and the stage of the disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: T-bet, also known as TBX21, has been reported to be overexpressed in lung cancer, particularly in non-small cell lung cancer (NSCLC), and is associated with the regulation of immune responses in the tumor microenvironment.\n\n2. UNKNOWN: The expression of GATA-3 in lung cancer can vary, and while it is generally associated with T-helper 2 (Th2) cell differentiation, its specific expression levels in NSCLC are not universally characterized and can depend on various factors.\n\n3. UNKNOWN: Eomesodermin (Eomes) is a T-box transcription factor involved in immune system processes, but its specific expression pattern in lung cancer, particularly in NSCLC, is not well-established in the literature as of my knowledge cutoff date.\n\n4. UNKNOWN: T-box protein 1 (Tbx1) is a transcription factor involved in developmental processes. Its role and expression levels in lung cancer, particularly in NSCLC, are not clearly defined in widely accepted scientific literature as of my knowledge cutoff date.\n\n5. TRUE: The expression of T-UCRs (Transcribed Ultraconserved Regions) can indeed vary depending on the type of lung cancer and the stage of the disease. These non-coding sequences are known to play roles in gene regulation and can be differentially expressed in various cancers, including lung cancer.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3268,
    "user_query": "What is known about the orphan receptor GPR151?",
    "llama-2-7b-chat-hf_response": "Thank you for asking! Based on the information provided, here is what is known about the orphan receptor GPR151:\nGPR151, also known as PGR7, GALR4, or GPCR-2037, is an orphan receptor in class A GPCR. This means that it does not have a well-defined endogenous ligand or a clear physiological function, making it an orphan receptor. GPR151 is related to the galanin receptor family, which suggests that it may be involved in the regulation of neuropeptide signaling.\nHowever, recent studies have shown that GPR151 responds very weakly to the neuropeptide galanin. This is unusual, as most orphan receptors are thought to be specific for a particular ligand. The weak response of GPR151 to galanin suggests that it may have additional ligands or functions beyond neuropeptide signaling.\nGPR151 is highly enriched in the medial and lateral hypothalamus, as well as in other brain regions such as the cerebral cortex and the brainstem. This suggests that GPR151 may play a role in regulating various physiological processes, including energy homeostasis, appetite, and metabolism.\nOverall, while GPR151 is an orphan receptor, recent studies have shed some light on its potential functions and distribution in the brain. Further research is needed to fully understand the role of GPR151 in health and disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. GPR151 is an orphan receptor in class A GPCR.\n2. GPR151 is related to the galanin receptor family.\n3. GPR151 has shown a weak response to the neuropeptide galanin.\n4. GPR151 is highly enriched in the medial and lateral hypothalamus, as well as in the cerebral cortex and the brainstem.\n5. The potential functions and distribution of GPR151 in the brain are subjects of ongoing research.",
    "llama-2-7b-chat-hf_fact": [
      "GPR151 is an orphan receptor in class A GPCR.",
      "GPR151 is related to the galanin receptor family.",
      "GPR151 has shown a weak response to the neuropeptide galanin.",
      "GPR151 is highly enriched in the medial and lateral hypothalamus, as well as in the cerebral cortex and the brainstem.",
      "The potential functions and distribution of GPR151 in the brain are subjects of ongoing research."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: GPR151 has not shown a response to the neuropeptide galanin; it is an orphan receptor, which means its endogenous ligand is unknown.\n4. FALSE [correction]: GPR151 is highly enriched in the habenula, not in the medial and lateral hypothalamus, cerebral cortex, or brainstem.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 3285,
    "user_query": "List the attenuated live viruses contained in the Fluzone intradermal quadrivalent vaccine.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the attenuated live viruses contained in the Fluzone intradermal quadrivalent vaccine are:\n1. A/California/7/2004 (H1N1)\n2. A/Victoria/361/2011 (H1N1)\n3. A/Perth/16/2009 (H3N2)\n4. B/Brisbane/60/2008 (B/Victoria lineage)\nThese viruses are included in the vaccine as split-virion particles, which are designed to mimic the natural infection process and stimulate a broader and more robust immune response.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Fluzone intradermal quadrivalent vaccine contains the attenuated live virus A/California/7/2004 (H1N1).\n2. The Fluzone intradermal quadrivalent vaccine contains the attenuated live virus A/Victoria/361/2011 (H1N1).\n3. The Fluzone intradermal quadrivalent vaccine contains the attenuated live virus A/Perth/16/2009 (H3N2).\n4. The Fluzone intradermal quadrivalent vaccine contains the attenuated live virus B/Brisbane/60/2008 (B/Victoria lineage).\n5. The viruses in the Fluzone intradermal quadrivalent vaccine are included as split-virion particles.",
    "llama-2-7b-chat-hf_fact": [
      "The Fluzone intradermal quadrivalent vaccine contains the attenuated live virus A/California/7/2004 (H1N1).",
      "The Fluzone intradermal quadrivalent vaccine contains the attenuated live virus A/Victoria/361/2011 (H1N1).",
      "The Fluzone intradermal quadrivalent vaccine contains the attenuated live virus A/Perth/16/2009 (H3N2).",
      "The Fluzone intradermal quadrivalent vaccine contains the attenuated live virus B/Brisbane/60/2008 (B/Victoria lineage).",
      "The viruses in the Fluzone intradermal quadrivalent vaccine are included as split-virion particles."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Fluzone intradermal quadrivalent vaccine does not contain live viruses; it contains inactivated (killed) viruses.\n2. UNKNOWN: The specific strains included in the Fluzone vaccine can vary from year to year based on World Health Organization recommendations. Without a specific year's formulation, it's not possible to confirm the inclusion of A/Victoria/361/2011 (H1N1).\n3. UNKNOWN: Similar to statement 2, the inclusion of A/Perth/16/2009 (H3N2) in a specific year's Fluzone vaccine formulation cannot be confirmed without knowing the year.\n4. UNKNOWN: The inclusion of B/Brisbane/60/2008 (B/Victoria lineage) in the Fluzone vaccine is subject to change based on annual flu predictions and cannot be confirmed without the specific year's formulation.\n5. TRUE: The viruses in the Fluzone intradermal quadrivalent vaccine are included as split-virion particles, which means the viruses have been broken apart and are inactivated.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3345,
    "user_query": "Which part of the TNFR2 gene is genetically associated with Systemic Lupus Erythematosus?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the part of the TNFR2 gene that is genetically associated with Systemic Lupus Erythematosus is the TNFR2 gene itself. The document states that TNFR2 exhibits a limited expression, predominantly on regulatory T cells (Tregs), and that emerging evidence has demonstrated that TNFR2 is genetically associated with Systemic Lupus Erythematosus. Therefore, it can be inferred that mutations or variations in the TNFR2 gene may contribute to the development of Systemic Lupus Erythematosus.",
    "llama-2-7b-chat-hf_fact_raw": "1. The TNFR2 gene is genetically associated with Systemic Lupus Erythematosus.\n2. TNFR2 has a limited expression, predominantly on regulatory T cells (Tregs).\n3. Emerging evidence has demonstrated the genetic association between TNFR2 and Systemic Lupus Erythematosus.\n4. Mutations or variations in the TNFR2 gene may contribute to the development of Systemic Lupus Erythematosus.",
    "llama-2-7b-chat-hf_fact": [
      "The TNFR2 gene is genetically associated with Systemic Lupus Erythematosus.",
      "TNFR2 has a limited expression, predominantly on regulatory T cells (Tregs).",
      "Emerging evidence has demonstrated the genetic association between TNFR2 and Systemic Lupus Erythematosus.",
      "Mutations or variations in the TNFR2 gene may contribute to the development of Systemic Lupus Erythematosus."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: TNFR2 is not limited in expression to regulatory T cells (Tregs); it is also expressed on other immune cells such as certain types of T cells, B cells, and myeloid cells.\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3353,
    "user_query": "Is there a vaccine for peanut allergy?",
    "llama-2-7b-chat-hf_response": "Thank you for asking! Unfortunately, there is currently no vaccine available for peanut allergy. However, there are ongoing research and developments in the field of allergen immunotherapy, which may offer hope for the future.\nAccording to Document 0, allergen immunotherapy is a form of therapeutic vaccination that can help desensitize individuals to common allergen sources such as pollens, house dust mites, and the venom of stinging insects. While this information does not specifically mention peanut allergy, it suggests that immunotherapy may be a potential treatment option for other types of food allergies as well.\nIt's important to note that any new treatments or vaccines for food allergies are still in the experimental stages and have not yet been widely tested or approved by regulatory agencies. Therefore, it's crucial to consult with a medical professional before pursuing any new treatments or therapies.\nIn the meantime, the best way to manage peanut allergy is to avoid consuming peanuts and peanut products, and to always carry an EpiPen or other emergency medication in case of an accidental exposure. If you have any further questions or concerns, please don't hesitate to ask!",
    "llama-2-7b-chat-hf_fact_raw": "1. There is currently no vaccine available for peanut allergy.\n2. Research and developments in allergen immunotherapy are ongoing.\n3. Allergen immunotherapy is a form of therapeutic vaccination that can help desensitize individuals to allergens like pollens, house dust mites, and stinging insect venom.\n4. Treatments or vaccines for food allergies are still in experimental stages and have not been widely tested or approved by regulatory agencies.\n5. The recommended management for peanut allergy is to avoid peanuts and peanut products and carry emergency medication like an EpiPen.",
    "llama-2-7b-chat-hf_fact": [
      "There is currently no vaccine available for peanut allergy.",
      "Research and developments in allergen immunotherapy are ongoing.",
      "Allergen immunotherapy is a form of therapeutic vaccination that can help desensitize individuals to allergens like pollens, house dust mites, and stinging insect venom.",
      "Treatments or vaccines for food allergies are still in experimental stages and have not been widely tested or approved by regulatory agencies.",
      "The recommended management for peanut allergy is to avoid peanuts and peanut products and carry emergency medication like an EpiPen."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: As of my knowledge cutoff in 2023, treatments such as oral immunotherapy for food allergies have been tested and approved by regulatory agencies like the FDA for certain conditions, though they may not be widely available for all food allergies or in all regions.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3365,
    "user_query": "What is particular about the mouse Fxy gene's chromosomal position?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the mouse Fxy gene has a unique chromosomal position. The 5' region of the gene (exons 1-3, including a significant portion of the coding region) does not have a Y homolog, meaning that it is only present on the X chromosome. However, the 3' region (exons 4-10) lies within PAR1 and is present on both the X and Y chromosomes. This means that the X-Y shared 3' region is much more similar between the two species than the rest of the gene.",
    "llama-2-7b-chat-hf_fact_raw": "1. The mouse Fxy gene's 5' region (exons 1-3) does not have a Y homolog and is only present on the X chromosome.\n2. The 3' region of the mouse Fxy gene (exons 4-10) lies within PAR1 and is present on both the X and Y chromosomes.\n3. The X-Y shared 3' region of the mouse Fxy gene is much more similar between the two species than the rest of the gene.",
    "llama-2-7b-chat-hf_fact": [
      "The mouse Fxy gene's 5' region (exons 1-3) does not have a Y homolog and is only present on the X chromosome.",
      "The 3' region of the mouse Fxy gene (exons 4-10) lies within PAR1 and is present on both the X and Y chromosomes.",
      "The X-Y shared 3' region of the mouse Fxy gene is much more similar between the two species than the rest of the gene."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n\nThe statements provided are consistent with the general knowledge about the Fxy gene (also known as Fxyd5 or Dysadherin) in mice. The first statement is true as the 5' region of the Fxy gene does not have a Y homolog and is only present on the X chromosome. The second statement is also true; the 3' region of the Fxy gene lies within the pseudoautosomal region 1 (PAR1) and is present on both the X and Y chromosomes. The third statement is generally true for genes within the pseudoautosomal regions, as these regions are known to be highly conserved and share a high degree of similarity between the X and Y chromosomes due to their role in pairing and recombination during meiosis.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3397,
    "user_query": "What is the basis of the methidiumpropyl-EDTA sequencing (MPE-seq) method?",
    "llama-2-7b-chat-hf_response": "The basis of the MPE-seq method is the digestion of nuclei with MPE-Fe (II), which preferentially cleaves the linker DNA between nucleosomes. This method is similar to micrococcal nuclease (MNase) sequencing, which also cleaves the linker DNA between nucleosomes. However, MPE-seq uses a different enzyme, MPE-Fe (II), which has a different specificity and cleavage mechanism than MNase.\nMPE-Fe (II) is a metalloprotease that recognizes and cleaves the linker DNA between nucleosomes, resulting in the release of the nucleosomal DNA fragments. These fragments are then captured and amplified using PCR, and the resulting library is sequenced using massively parallel sequencing technologies.\nThe use of MPE-Fe (II) for chromatin sequencing offers several advantages over other methods. First, it is more specific and efficient than MNase, resulting in higher quality sequencing data. Second, it can be used to sequence both histone-modified and unmodified regions of the genome, providing a more comprehensive view of chromatin structure and dynamics. Finally, the use of MPE-Fe (II) allows for the simultaneous analysis of multiple chromatin regions, making it a powerful tool for studying chromatin architecture and function.\nIn summary, the basis of the MPE-seq method is the digestion of nuclei with MPE-Fe (II), which preferentially cleaves the linker DNA between nucleosomes, resulting in the release of nucleosomal DNA fragments that can be captured, amplified, and sequenced using massively parallel sequencing technologies.",
    "llama-2-7b-chat-hf_fact_raw": "1. The MPE-seq method involves the digestion of nuclei with MPE-Fe (II), which preferentially cleaves the linker DNA between nucleosomes.\n2. MPE-seq is similar to micrococcal nuclease (MNase) sequencing in that both methods cleave the linker DNA between nucleosomes.\n3. MPE-Fe (II) is a metalloprotease with a different specificity and cleavage mechanism than MNase.\n4. The nucleosomal DNA fragments released by MPE-Fe (II) digestion are captured and amplified using PCR before sequencing.\n5. MPE-Fe (II) can be used to sequence both histone-modified and unmodified regions of the genome.",
    "llama-2-7b-chat-hf_fact": [
      "The MPE-seq method involves the digestion of nuclei with MPE-Fe (II), which preferentially cleaves the linker DNA between nucleosomes.",
      "MPE-seq is similar to micrococcal nuclease (MNase) sequencing in that both methods cleave the linker DNA between nucleosomes.",
      "MPE-Fe (II) is a metalloprotease with a different specificity and cleavage mechanism than MNase.",
      "The nucleosomal DNA fragments released by MPE-Fe (II) digestion are captured and amplified using PCR before sequencing.",
      "MPE-Fe (II) can be used to sequence both histone-modified and unmodified regions of the genome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: MPE-Fe (II) is not a metalloprotease; it is a chemical nucleic acid cleavage agent that uses methidiumpropyl-EDTA-Fe(II) and is different from MNase, which is an enzyme.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3400,
    "user_query": "Which programming language has been used for implementing GWAR?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, it is unlikely that GWAR was implemented using a programming language that is based on domain value types, as the author of Document 0 seems to have a negative view of such languages. Instead, it is more likely that GWAR was implemented using a functional programming language, such as Miranda, which is based on a different approach.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3406,
    "user_query": "Does xaliproden improve prognosis of amyotrophic lateral sclerosis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there is limited research available on the effectiveness of xaliproden in improving the prognosis of amyotrophic lateral sclerosis (ALS).\nALS is a progressive, paralytic disorder that affects the motor neurons in the brain and spinal cord. While there are various treatments available, including riluzole, which has been shown to slow the progression of ALS, there is currently no cure for the disease.\nXaliproden is a drug that has been investigated for its potential in treating ALS, but the available research is limited and inconclusive. A clinical trial published in 2017 found that xaliproden did not improve the prognosis of ALS patients compared to a placebo.\nTherefore, based on the current available information, it is unlikely that xaliproden will improve the prognosis of ALS. However, it is important to note that the medical landscape for ALS is constantly evolving, and new treatments and therapies are being developed that may show promise in improving the prognosis of this devastating disease.\nIt is important to consult with a qualified healthcare professional for the most up-to-date information and advice on the treatment of ALS.",
    "llama-2-7b-chat-hf_fact_raw": "1. Amyotrophic lateral sclerosis (ALS) is a progressive, paralytic disorder that affects the motor neurons in the brain and spinal cord.\n2. Riluzole is a treatment that has been shown to slow the progression of ALS.\n3. There is currently no cure for amyotrophic lateral sclerosis (ALS).\n4. Xaliproden has been investigated for its potential in treating ALS.\n5. A clinical trial published in 2017 found that xaliproden did not improve the prognosis of ALS patients compared to a placebo.",
    "llama-2-7b-chat-hf_fact": [
      "Amyotrophic lateral sclerosis (ALS) is a progressive, paralytic disorder that affects the motor neurons in the brain and spinal cord.",
      "Riluzole is a treatment that has been shown to slow the progression of ALS.",
      "There is currently no cure for amyotrophic lateral sclerosis (ALS).",
      "Xaliproden has been investigated for its potential in treating ALS.",
      "A clinical trial published in 2017 found that xaliproden did not improve the prognosis of ALS patients compared to a placebo."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN (Without access to specific clinical trial data from 2017, I cannot confirm or deny the accuracy of this statement.)",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3410,
    "user_query": "In which chromosome are transgenes inserted in the case of the LiPS-A3S line?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the transgene is inserted into chromosome 6 (R6/2 mouse) in the case of the LiPS-A3S line.",
    "llama-2-7b-chat-hf_fact_raw": "1. The transgene in the LiPS-A3S line is inserted into chromosome 6.\n2. The LiPS-A3S line involves the R6/2 mouse model.",
    "llama-2-7b-chat-hf_fact": [
      "The transgene in the LiPS-A3S line is inserted into chromosome 6.",
      "The LiPS-A3S line involves the R6/2 mouse model."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n\nWithout additional context or specific information about the LiPS-A3S line and its relation to the R6/2 mouse model, it is not possible to determine the accuracy of these statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3430,
    "user_query": "Which tool exist for predicting drug synergy with deep learning?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there are several deep learning tools that exist for predicting drug synergy. Here are a few examples:\n1. DeepDrug: This is a deep learning framework for predicting drug synergy and toxicity. It uses a combination of molecular descriptors and graph-based representations to predict drug interactions.\n2. Drug2Drug: This is a deep learning model that predicts drug synergy by analyzing the molecular structures of drugs and their targets. It uses a combination of convolutional neural networks (CNNs) and recurrent neural networks (RNNs) to predict drug interactions.\n3. DrugCombinator: This is a deep learning model that predicts drug synergy by analyzing the molecular structures of drugs and their targets, as well as the gene expression profiles of cancer cells. It uses a combination of CNNs and RNNs to predict drug interactions.\n4. Synergizer: This is a deep learning model that predicts drug synergy by analyzing the molecular structures of drugs and their targets, as well as the protein-protein interaction networks of cancer cells. It uses a combination of CNNs and RNNs to predict drug interactions.\n5. DeepSynth: This is a deep learning model that predicts drug synergy by analyzing the molecular structures of drugs and their targets, as well as the gene expression profiles of cancer cells. It uses a combination of CNNs and RNNs to predict drug interactions.\nThese are just a few examples of the many deep learning tools that exist for predicting drug synergy. It's important to note that each tool has its own strengths and limitations, and the choice of tool will depend on the specific research question and the characteristics of the data being analyzed.",
    "llama-2-7b-chat-hf_fact_raw": "1. DeepDrug is a deep learning framework designed to predict drug synergy and toxicity.\n2. Drug2Drug is a deep learning model that predicts drug synergy using molecular structures of drugs and their targets.\n3. DrugCombinator predicts drug synergy by analyzing molecular structures of drugs, their targets, and gene expression profiles of cancer cells.\n4. Synergizer is a deep learning model that predicts drug synergy through analysis of molecular structures of drugs, their targets, and protein-protein interaction networks.\n5. DeepSynth uses deep learning to predict drug synergy by analyzing molecular structures of drugs, their targets, and gene expression profiles.",
    "llama-2-7b-chat-hf_fact": [
      "DeepDrug is a deep learning framework designed to predict drug synergy and toxicity.",
      "Drug2Drug is a deep learning model that predicts drug synergy using molecular structures of drugs and their targets.",
      "DrugCombinator predicts drug synergy by analyzing molecular structures of drugs, their targets, and gene expression profiles of cancer cells.",
      "Synergizer is a deep learning model that predicts drug synergy through analysis of molecular structures of drugs, their targets, and protein-protein interaction networks.",
      "DeepSynth uses deep learning to predict drug synergy by analyzing molecular structures of drugs, their targets, and gene expression profiles."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statement about DeepDrug is true; it is a deep learning framework designed for predicting drug synergy and toxicity. However, without specific information about the other models mentioned (Drug2Drug, DrugCombinator, Synergizer, and DeepSynth), it is not possible to verify the accuracy of the statements about them. These models could be hypothetical, proprietary, less well-known, or simply not existent at the time of my knowledge cutoff. Therefore, the truthfulness of statements 2 through 5 cannot be determined without additional context or information.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3433,
    "user_query": "Which cloud-based platform has been developed for comparing GWAS?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the cloud-based platform that has been developed for comparing GWAS is likely to be either of the following:\n1. PLINK: PLINK is a popular open-source tool for genome-wide association studies (GWAS) that provides a comprehensive platform for comparing GWAS data. It can handle large datasets, perform statistical tests, and generate summary statistics for association studies.\n2. GCTA: GCTA (Genome-Wide Complex Trait Analysis) is a cloud-based platform that allows researchers to perform GWAS and compare results across different populations. It provides a user-friendly interface for analyzing genetic data and can handle large datasets with ease.\nBoth PLINK and GCTA are widely used in the scientific community and have been used in numerous studies to compare GWAS data. However, it is important to note that there may be other cloud-based platforms available that can perform similar functions, and the choice of platform will depend on the specific needs and requirements of the researcher.",
    "llama-2-7b-chat-hf_fact_raw": "1. PLINK is an open-source tool for genome-wide association studies (GWAS).\n2. PLINK provides a platform for comparing GWAS data.\n3. GCTA is a cloud-based platform that allows researchers to perform GWAS.\n4. GCTA can compare results across different populations.\n5. Both PLINK and GCTA can handle large datasets.",
    "llama-2-7b-chat-hf_fact": [
      "PLINK is an open-source tool for genome-wide association studies (GWAS).",
      "PLINK provides a platform for comparing GWAS data.",
      "GCTA is a cloud-based platform that allows researchers to perform GWAS.",
      "GCTA can compare results across different populations.",
      "Both PLINK and GCTA can handle large datasets."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: GCTA (Genome-wide Complex Trait Analysis) is not specifically a cloud-based platform; it is a software package for the analysis of complex traits in genetic association studies.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3434,
    "user_query": "Can CMB305 be used against sarcomas?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, CMB305 may be effective against sarcomas. The document mentions that CMB305 is a therapeutic vaccine regimen targeting NY-ESO-1, which is a protein that is overexpressed in many sarcoma subtypes. The Phase I studies mentioned in the document have shown that CMB305 is active immunologically, which suggests that it may stimulate the immune system to attack sarcoma cells. While the data is exciting and early, ongoing work is testing the impact of CMB305 on patient outcomes, which could provide further evidence of its effectiveness against sarcomas. Therefore, based on the information provided, it is possible that CMB305 may be used as a treatment option for sarcomas.",
    "llama-2-7b-chat-hf_fact_raw": "1. CMB305 is a therapeutic vaccine regimen targeting NY-ESO-1.\n2. NY-ESO-1 is a protein that is overexpressed in many sarcoma subtypes.\n3. Phase I studies have shown that CMB305 is active immunologically.\n4. CMB305 may stimulate the immune system to attack sarcoma cells.\n5. Ongoing work is testing the impact of CMB305 on patient outcomes in relation to sarcomas.",
    "llama-2-7b-chat-hf_fact": [
      "CMB305 is a therapeutic vaccine regimen targeting NY-ESO-1.",
      "NY-ESO-1 is a protein that is overexpressed in many sarcoma subtypes.",
      "Phase I studies have shown that CMB305 is active immunologically.",
      "CMB305 may stimulate the immune system to attack sarcoma cells.",
      "Ongoing work is testing the impact of CMB305 on patient outcomes in relation to sarcomas."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nBased on the context provided, all statements seem to be consistent with the general knowledge about therapeutic vaccines targeting specific proteins such as NY-ESO-1, which is known to be overexpressed in various types of cancer, including sarcomas. Phase I studies typically assess the safety, tolerability, and immunological activity of such vaccines, and it is reasonable to infer that ongoing work would involve testing the impact on patient outcomes. However, without specific data or references, the detailed accuracy of statements 3, 4, and 5 cannot be fully verified, but they are plausible based on the context given.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3461,
    "user_query": "What are manifestations of the Saint's Triad?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the manifestations of the Saint's Triad are:\nDocument 0 mentions that 22q11.2 deletion syndrome, also known as DiGeorge syndrome, is a disorder caused by a missing small part of chromosome 22. This deletion results in the poor development of several body systems, including:\n1. Heart defects: The most common heart defect associated with 22q11.2 deletion syndrome is a ventricular septal defect (VSD), which is a hole in the wall between the two lower chambers of the heart. Other heart defects can include atrial septal defects (ASDs), tetralogy of Fallot, and pulmonary atresia.\n2. Thyroid problems: Individuals with 22q11.2 deletion syndrome are at increased risk of developing thyroid problems, such as hypothyroidism (underactive thyroid) or hyperthyroidism (overactive thyroid).\n3. Craniofacial abnormalities: The Saint's Triad includes craniofacial abnormalities, such as a narrow head, small eyes, and a short nose. Other facial features can include a small jaw, small teeth, and a thin upper lip.\n4. Neurological problems: Individuals with 22q11.2 deletion syndrome may experience neurological problems, such as developmental delays, intellectual disability, and seizures.\n5. Immune system problems: The syndrome can also lead to immune system problems, including a higher risk of infections and autoimmune disorders.\n6. Other health problems: Other health problems that can occur with 22q11.2 deletion syndrome include gastrointestinal problems, such as gastroesophageal reflux disease (GERD), and hearing loss.\nIt is important to note that not all individuals with 22q11.2 deletion syndrome will experience all of these manifestations, and the severity of the syndrome can vary widely between individuals.",
    "llama-2-7b-chat-hf_fact_raw": "1. 22q11.2 deletion syndrome, also known as DiGeorge syndrome, is caused by a missing part of chromosome 22.\n2. A common heart defect associated with 22q11.2 deletion syndrome is a ventricular septal defect (VSD).\n3. Individuals with 22q11.2 deletion syndrome are at increased risk of developing thyroid problems, such as hypothyroidism or hyperthyroidism.\n4. Craniofacial abnormalities, such as a narrow head, small eyes, and a short nose, are included in the manifestations of 22q11.2 deletion syndrome.\n5. The syndrome can lead to immune system problems, including a higher risk of infections and autoimmune disorders.",
    "llama-2-7b-chat-hf_fact": [
      "22q11.2 deletion syndrome, also known as DiGeorge syndrome, is caused by a missing part of chromosome 22.",
      "A common heart defect associated with 22q11.2 deletion syndrome is a ventricular septal defect (VSD).",
      "Individuals with 22q11.2 deletion syndrome are at increased risk of developing thyroid problems, such as hypothyroidism or hyperthyroidism.",
      "Craniofacial abnormalities, such as a narrow head, small eyes, and a short nose, are included in the manifestations of 22q11.2 deletion syndrome.",
      "The syndrome can lead to immune system problems, including a higher risk of infections and autoimmune disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Craniofacial abnormalities associated with 22q11.2 deletion syndrome typically include features such as cleft palate, underdeveloped chin, and low-set ears, rather than a narrow head, small eyes, and a short nose specifically.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3470,
    "user_query": "Is overexpression of LY6K associated with better prognosis for non-small cell lung cancer patients?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, it appears that overexpression of LY6K is not specifically associated with better prognosis for non-small cell lung cancer (NSCLC) patients. The document you provided mentions the overexpression of PSMB8 and PSMB9, which are components of the immunoproteasome, as being predictive of better survival and improved response to immune-checkpoint inhibitors in NSCLC patients. However, there is no mention of LY6K in this context.\nLY6K is a protein that has been implicated in various cellular processes, including immune regulation and cancer progression. However, to the best of my knowledge, there is no established correlation between LY6K expression and prognosis in NSCLC patients. Therefore, based on the information provided, it cannot be concluded that overexpression of LY6K is associated with better prognosis for NSCLC patients.\nIt is important to note that the prognosis of NSCLC is complex and can be influenced by a variety of factors, including the tumor's genetic mutations, expression of immune-related proteins, and the presence of certain microenvironmental factors. Therefore, further research is needed to fully understand the relationship between LY6K expression and prognosis in NSCLC patients.",
    "llama-2-7b-chat-hf_fact_raw": "1. Overexpression of PSMB8 and PSMB9 is predictive of better survival and improved response to immune-checkpoint inhibitors in non-small cell lung cancer (NSCLC) patients.\n2. LY6K is a protein implicated in various cellular processes, including immune regulation and cancer progression.\n3. There is no established correlation between LY6K expression and prognosis in NSCLC patients according to the provided information.\n4. The prognosis of NSCLC can be influenced by a variety of factors, including the tumor's genetic mutations, expression of immune-related proteins, and the presence of certain microenvironmental factors.\n5. Further research is needed to fully understand the relationship between LY6K expression and prognosis in NSCLC patients.",
    "llama-2-7b-chat-hf_fact": [
      "Overexpression of PSMB8 and PSMB9 is predictive of better survival and improved response to immune-checkpoint inhibitors in non-small cell lung cancer (NSCLC) patients.",
      "LY6K is a protein implicated in various cellular processes, including immune regulation and cancer progression.",
      "There is no established correlation between LY6K expression and prognosis in NSCLC patients according to the provided information.",
      "The prognosis of NSCLC can be influenced by a variety of factors, including the tumor's genetic mutations, expression of immune-related proteins, and the presence of certain microenvironmental factors.",
      "Further research is needed to fully understand the relationship between LY6K expression and prognosis in NSCLC patients."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe statements regarding PSMB8 and PSMB9, and the need for further research on LY6K, are specific and would require access to recent scientific studies or clinical trial data to confirm their accuracy. Since the context does not provide this information, the first statement is marked as UNKNOWN. The second statement about LY6K is a general statement about the protein's role and is considered true. The third statement is true based on the context provided, which states there is no established correlation. The fourth statement is a general acknowledgment of the complexity of NSCLC prognosis and is true. The fifth statement is a reasonable conclusion given the lack of information provided about LY6K, making it true.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3473,
    "user_query": "List Cdk targets that are dephosphorylated during cytokinesis",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, there are currently no identified Cdk targets that are dephosphorylated during cytokinesis. The document states that while cytokinesis requires Cdc14, the substrates that are dephosphorylated to promote cytokinesis have not been identified. Therefore, I cannot provide a list of Cdk targets that are dephosphorylated during cytokinesis.",
    "llama-2-7b-chat-hf_fact_raw": "1. There are currently no identified Cdk targets that are dephosphorylated during cytokinesis.\n2. Cytokinesis requires Cdc14.\n3. The substrates dephosphorylated to promote cytokinesis have not been identified.",
    "llama-2-7b-chat-hf_fact": [
      "There are currently no identified Cdk targets that are dephosphorylated during cytokinesis.",
      "Cytokinesis requires Cdc14.",
      "The substrates dephosphorylated to promote cytokinesis have not been identified."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: There are identified Cdk targets that are dephosphorylated during cytokinesis, such as mitotic exit network proteins.\n2. TRUE\n3. FALSE [correction]: Some substrates dephosphorylated to promote cytokinesis have been identified, although the complete set may not be fully known.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 3508,
    "user_query": "What is Xanamem?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, Xanamem is an inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). This enzyme is responsible for converting the inactive stress hormone cortisone to the active form cortisol. By inhibiting 11β-HSD1, Xanamem reduces the conversion of cortisone to cortisol, leading to increased levels of cortisone and decreased levels of cortisol in the body.",
    "llama-2-7b-chat-hf_fact_raw": "1. Xanamem is an inhibitor of the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1).\n2. The enzyme 11β-HSD1 is responsible for converting cortisone to cortisol.\n3. Inhibition of 11β-HSD1 by Xanamem leads to increased levels of cortisone in the body.\n4. Inhibition of 11β-HSD1 by Xanamem leads to decreased levels of cortisol in the body.",
    "llama-2-7b-chat-hf_fact": [
      "Xanamem is an inhibitor of the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1).",
      "The enzyme 11β-HSD1 is responsible for converting cortisone to cortisol.",
      "Inhibition of 11β-HSD1 by Xanamem leads to increased levels of cortisone in the body.",
      "Inhibition of 11β-HSD1 by Xanamem leads to decreased levels of cortisol in the body."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n\nXanamem is indeed an inhibitor of the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). This enzyme is responsible for the conversion of cortisone to cortisol. Therefore, inhibition of this enzyme by Xanamem would lead to increased levels of cortisone (due to less conversion to cortisol) and decreased levels of cortisol in the body (due to less cortisone being converted into it).",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3520,
    "user_query": "What is the role of the Hof1-Cyk3 interaction in yeast?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the Hof1-Cyk3 interaction plays a crucial role in yeast cytokinesis. Specifically, the Hof1 protein interacts with the Cyk3 protein to regulate the cleavage-furrow ingression and primary-septum formation during cytokinesis. The Hof1 protein is a key regulator of the actin cytoskeleton, and its interaction with Cyk3 helps to coordinate the contraction of the actin-myosin ring that forms the cleavage furrow. This interaction is essential for proper cytokinesis and ensures that the cell divides correctly and efficiently.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Hof1-Cyk3 interaction is crucial for yeast cytokinesis.\n2. The Hof1 protein interacts with the Cyk3 protein to regulate cleavage-furrow ingression and primary-septum formation during cytokinesis.\n3. Hof1 is a key regulator of the actin cytoskeleton.\n4. The interaction between Hof1 and Cyk3 coordinates the contraction of the actin-myosin ring during cytokinesis.\n5. This interaction is essential for proper and efficient cell division in yeast.",
    "llama-2-7b-chat-hf_fact": [
      "The Hof1-Cyk3 interaction is crucial for yeast cytokinesis.",
      "The Hof1 protein interacts with the Cyk3 protein to regulate cleavage-furrow ingression and primary-septum formation during cytokinesis.",
      "Hof1 is a key regulator of the actin cytoskeleton.",
      "The interaction between Hof1 and Cyk3 coordinates the contraction of the actin-myosin ring during cytokinesis.",
      "This interaction is essential for proper and efficient cell division in yeast."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The interaction between Hof1 and Cyk3 does not directly coordinate the contraction of the actin-myosin ring during cytokinesis. Hof1 and Cyk3 are involved in the regulation of cleavage-furrow ingression and primary-septum formation, but the contraction of the actin-myosin ring is typically coordinated by other proteins such as Myo1.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3598,
    "user_query": "Which T-UCRs have been implicated in gastric cancer?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the T-UCRs that have been implicated in gastric cancer are:\n1. Uc.160 - down-regulated in adenoma and gastric cancer tissues (Honma et al., 2017)\nAccording to the document, Uc.160 has been associated with gastric cancer, and its down-regulation has been observed in both adenoma and gastric cancer tissues.\nIt is important to note that this information is based on a single study, and further research may be necessary to confirm these findings and identify other T-UCRs that may be involved in gastric cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. T-UCR Uc.160 has been implicated in gastric cancer.\n2. Uc.160 is down-regulated in adenoma and gastric cancer tissues.\n3. The findings regarding Uc.160 are based on a study by Honma et al. in 2017.",
    "llama-2-7b-chat-hf_fact": [
      "T-UCR Uc.160 has been implicated in gastric cancer.",
      "Uc.160 is down-regulated in adenoma and gastric cancer tissues.",
      "The findings regarding Uc.160 are based on a study by Honma et al. in 2017."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3607,
    "user_query": "What is the Lupus Severity Index (LSI)?",
    "llama-2-7b-chat-hf_response": "The Lupus Severity Index (LSI) is a tool used to assess the severity of systemic lupus erythematosus (SLE), a chronic autoimmune disease. The LSI is a composite measure that takes into account various organ manifestations and disease activity, such as joint swelling, fatigue, and serum sickness.\nIn the given document, the LSI is mentioned in the context of a study evaluating the impact of provider characteristics on pass rates for patients with SLE undergoing a nephritis biopsy. The study found that patients with a higher LSI had higher pass rates, but this difference did not reach statistical significance after adjusting for other factors.\nIn general, the LSI is used to help clinicians and researchers evaluate the severity of SLE and to identify subgroups of patients who may benefit from more intensive treatment or monitoring. A higher LSI score indicates more severe disease activity, which may be associated with a higher risk of complications and a lower likelihood of achieving remission.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Lupus Severity Index (LSI) is used to assess the severity of systemic lupus erythematosus (SLE).\n2. The LSI is a composite measure that includes various organ manifestations and disease activity.\n3. The LSI takes into account symptoms such as joint swelling, fatigue, and serum sickness.\n4. A higher LSI score indicates more severe disease activity in patients with SLE.\n5. A higher LSI score may be associated with a higher risk of complications and a lower likelihood of achieving remission in SLE patients.",
    "llama-2-7b-chat-hf_fact": [
      "The Lupus Severity Index (LSI) is used to assess the severity of systemic lupus erythematosus (SLE).",
      "The LSI is a composite measure that includes various organ manifestations and disease activity.",
      "The LSI takes into account symptoms such as joint swelling, fatigue, and serum sickness.",
      "A higher LSI score indicates more severe disease activity in patients with SLE.",
      "A higher LSI score may be associated with a higher risk of complications and a lower likelihood of achieving remission in SLE patients."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The existence of a specific \"Lupus Severity Index (LSI)\" is not a well-established fact in medical literature as of my knowledge cutoff date. There are various tools and indices used to assess the severity of systemic lupus erythematosus (SLE), such as the SLE Disease Activity Index (SLEDAI), the British Isles Lupus Assessment Group (BILAG) index, and the Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index. Without more context, it is unclear whether the LSI is a recognized tool or an invention for the purpose of this exercise.\n\n2. UNKNOWN: Since the existence of the LSI is not established, the details of what it includes cannot be confirmed. However, if the LSI were a real and recognized tool, this statement could be plausible as composite measures for SLE typically include various organ manifestations and disease activity.\n\n3. UNKNOWN: Again, without confirmation of the LSI's existence and its components, the inclusion of specific symptoms such as joint swelling, fatigue, and serum sickness cannot be verified. These symptoms are common in SLE and could be part of a composite measure, but it is not possible to confirm this for the LSI specifically.\n\n4. UNKNOWN: Assuming the LSI is a hypothetical or non-standardized tool, the interpretation of its scoring would also be unknown. However, in general, for disease activity indices in SLE, a higher score usually indicates more severe disease activity.\n\n5. UNKNOWN: The association between a higher score on a disease severity index and the risk of complications or likelihood of achieving remission is a reasonable assumption for SLE assessment tools. However, without specific information on the LSI, this statement cannot be confirmed as true or false. It is consistent with the general understanding that more severe disease activity in SLE is often associated with a higher risk of complications and may make achieving remission more challenging.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3615,
    "user_query": "Which disorders are caused by de novo mutations in ZSWIM6?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, de novo mutations in the ZSWIM6 gene have been associated with the following disorders:\n1. Schizophrenia: Clinical studies have shown that patients with Zswim6 genetic mutations are at increased risk of developing schizophrenia (Ripke et al., 2013; Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014).\n2. Acromelic frontonasal dysostosis: ZSWIM6 mutations have been identified in individuals with this rare genetic disorder, which is characterized by facial and skull abnormalities (Lencz et al., 2014).\n3. Intellectual disability: ZSWIM6 mutations have been found to be associated with intellectual disability (Smith et al., 2015).\nIt is important to note that the relationship between ZSWIM6 mutations and these disorders is complex and not fully understood, and more research is needed to determine the exact mechanisms by which ZSWIM6 mutations contribute to these conditions.",
    "llama-2-7b-chat-hf_fact_raw": "1. De novo mutations in the ZSWIM6 gene have been associated with an increased risk of developing schizophrenia.\n2. ZSWIM6 mutations have been identified in individuals with acromelic frontonasal dysostosis.\n3. ZSWIM6 mutations have been found to be associated with intellectual disability.",
    "llama-2-7b-chat-hf_fact": [
      "De novo mutations in the ZSWIM6 gene have been associated with an increased risk of developing schizophrenia.",
      "ZSWIM6 mutations have been identified in individuals with acromelic frontonasal dysostosis.",
      "ZSWIM6 mutations have been found to be associated with intellectual disability."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3626,
    "user_query": "Which disease can be classified using the Koos Classification?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the disease that can be classified using the Koos Classification is vestibular schwannoma (VS).",
    "llama-2-7b-chat-hf_fact_raw": "1. The Koos Classification is used to classify vestibular schwannoma (VS).",
    "llama-2-7b-chat-hf_fact": [
      "The Koos Classification is used to classify vestibular schwannoma (VS)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 3628,
    "user_query": "What are the in vivo effects of AZD8601?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, AZD8601 is an investigational mRNA-based therapy that encodes for VEGF-A for local administration in patients undergoing coronary artery bypass grafting (CABG). mRNA is responsible for carrying genetic instructions transcribed from DNA, which cells then translate to produce proteins.\nIn vivo, AZD8601 is expected to have several effects on the body, including:\n1. Increased VEGF-A production: AZD8601 encodes for VEGF-A, a protein that plays a crucial role in angiogenesis, the formation of new blood vessels. By locally administering AZD8601 during CABG, the therapy may increase the production of VEGF-A, leading to improved blood vessel growth and repair.\n2. Enhanced cardiovascular function: VEGF-A is involved in the regulation of cardiovascular function, including blood pressure, vasodilation, and platelet function. By increasing VEGF-A production, AZD8601 may improve cardiovascular function in patients undergoing CABG.\n3. Reduced inflammation: mRNA-based therapies have been shown to have anti-inflammatory effects, which may help reduce inflammation in the body after CABG.\n4. Improved cardiac function: By promoting angiogenesis, improving cardiovascular function, and reducing inflammation, AZD8601 may improve cardiac function in patients undergoing CABG.\nIt is important to note that these effects are based on the mechanism of action of mRNA-based therapies and the known effects of VEGF-A, and may not necessarily occur in all patients treated with AZD8601. Further clinical trials are needed to fully understand the in vivo effects of AZD8601 in patients undergoing CABG.",
    "llama-2-7b-chat-hf_fact_raw": "1. AZD8601 is an investigational mRNA-based therapy that encodes for VEGF-A.\n2. AZD8601 is intended for local administration in patients undergoing coronary artery bypass grafting (CABG).\n3. The therapy aims to increase the production of VEGF-A, which is involved in angiogenesis.\n4. VEGF-A plays a role in the regulation of cardiovascular function, including blood pressure, vasodilation, and platelet function.\n5. mRNA-based therapies, such as AZD8601, have been shown to have anti-inflammatory effects.",
    "llama-2-7b-chat-hf_fact": [
      "AZD8601 is an investigational mRNA-based therapy that encodes for VEGF-A.",
      "AZD8601 is intended for local administration in patients undergoing coronary artery bypass grafting (CABG).",
      "The therapy aims to increase the production of VEGF-A, which is involved in angiogenesis.",
      "VEGF-A plays a role in the regulation of cardiovascular function, including blood pressure, vasodilation, and platelet function.",
      "mRNA-based therapies, such as AZD8601, have been shown to have anti-inflammatory effects."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nThe first four statements are true based on the information provided. AZD8601 is indeed an investigational mRNA-based therapy that encodes for VEGF-A, which is involved in angiogenesis and plays a role in the regulation of cardiovascular function. It is intended for local administration in patients undergoing coronary artery bypass grafting (CABG).\n\nThe fifth statement is vague without specific context or data. While some mRNA-based therapies may have anti-inflammatory effects, it is not clear from the statement whether AZD8601 has been shown to have such effects, or if this is a general statement about mRNA therapies. Therefore, without additional information, the truth of this statement cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3640,
    "user_query": "How are SAHFS created?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, SAHFS (Senescent-Associated Heterochromatin Fragments) are created through a process involving the reorganization of heterochromatin. Heterochromatin is a type of chromatin that is characterized by highly condensed and gene-poor DNA.\nAccording to the document provided, senescence is a fate-determined state that is accompanied by the reorganization of heterochromatin. This reorganization leads to the formation of SAHFS, which are fragments of heterochromatin that are associated with senescent cells.\nIt is worth noting that the formation of SAHFS is not solely dependent on senescence, as other factors such as DNA damage and replicative stress can also contribute to their formation. Additionally, the process of SAHFS formation is complex and involves the interplay of various cellular pathways and mechanisms.\nIn summary, SAHFS are created through the reorganization of heterochromatin during senescence, which is a fate-determined state that is accompanied by the repression of lineage-appropriate genes.",
    "llama-2-7b-chat-hf_fact_raw": "1. SAHFS (Senescent-Associated Heterochromatin Fragments) are created through the reorganization of heterochromatin.\n2. Heterochromatin is characterized by highly condensed and gene-poor DNA.\n3. The reorganization of heterochromatin during senescence leads to the formation of SAHFS.\n4. Factors such as DNA damage and replicative stress can contribute to the formation of SAHFS.\n5. The formation of SAHFS involves the interplay of various cellular pathways and mechanisms.",
    "llama-2-7b-chat-hf_fact": [
      "SAHFS (Senescent-Associated Heterochromatin Fragments) are created through the reorganization of heterochromatin.",
      "Heterochromatin is characterized by highly condensed and gene-poor DNA.",
      "The reorganization of heterochromatin during senescence leads to the formation of SAHFS.",
      "Factors such as DNA damage and replicative stress can contribute to the formation of SAHFS.",
      "The formation of SAHFS involves the interplay of various cellular pathways and mechanisms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe statements provided are consistent with current scientific understanding of senescence and chromatin organization. SAHFS (Senescence-Associated Heterochromatin Foci) are indeed formed through the reorganization of heterochromatin during cellular senescence. Heterochromatin is typically gene-poor and highly condensed. Various stress factors, including DNA damage and replicative stress, can contribute to the formation of SAHFS, and their formation involves multiple cellular pathways and mechanisms.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3672,
    "user_query": "What is the function of the PDZ domain in SATB1?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the function of the PDZ domain in SATB1 is to interact with other proteins and aid in the formation of SATB1 homodimers, which are essential for its DNA binding. The PDZ domain is a type of protein-protein interaction domain that is involved in the binding of proteins to other proteins or to the cytoskeleton. In the case of SATB1, the PDZ domain is located at the N-terminal region of the protein and is thought to play a role in the formation of SATB1 homodimers, which are necessary for the protein to bind to DNA and regulate gene expression.",
    "llama-2-7b-chat-hf_fact_raw": "1. The PDZ domain in SATB1 interacts with other proteins.\n2. The PDZ domain aids in the formation of SATB1 homodimers.\n3. SATB1 homodimers are essential for DNA binding.\n4. The PDZ domain is a type of protein-protein interaction domain.\n5. The PDZ domain in SATB1 is located at the N-terminal region of the protein.",
    "llama-2-7b-chat-hf_fact": [
      "The PDZ domain in SATB1 interacts with other proteins.",
      "The PDZ domain aids in the formation of SATB1 homodimers.",
      "SATB1 homodimers are essential for DNA binding.",
      "The PDZ domain is a type of protein-protein interaction domain.",
      "The PDZ domain in SATB1 is located at the N-terminal region of the protein."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The PDZ domain is not a feature of SATB1; SATB1 contains a PDZ-like domain that interacts with other proteins.\n2. UNKNOWN: The role of the PDZ-like domain in SATB1 homodimer formation is not well-established and would require specific scientific evidence to confirm.\n3. TRUE: SATB1 homodimers are indeed essential for DNA binding, as SATB1 functions as a genome organizer and regulates gene expression through its DNA-binding capacity.\n4. TRUE: The PDZ domain is indeed a type of protein-protein interaction domain that is found in various proteins.\n5. FALSE [correction]: SATB1 does not have a PDZ domain; it has a PDZ-like domain, and it is located at the C-terminal region of the protein, not the N-terminal.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3678,
    "user_query": "What is the basis of the BLISS technique?",
    "llama-2-7b-chat-hf_response": "The basis of the BLISS technique is the idea that by adding a specific technique to the end of every twice-daily meditation, it can enhance bliss in the mind-body system. The technique is taught in two parts during one session, with the first part focusing on a specific technique that is added to the end of meditation practice. This technique is designed to help individuals cultivate a deeper state of relaxation and inner peace, which can lead to a greater sense of bliss and well-being.",
    "llama-2-7b-chat-hf_fact_raw": "1. The BLISS technique involves adding a specific technique to the end of twice-daily meditation.\n2. The BLISS technique is taught in two parts during one session.\n3. The first part of the BLISS technique focuses on a specific technique added to the end of meditation practice.\n4. The BLISS technique is designed to help individuals cultivate a deeper state of relaxation and inner peace.\n5. The BLISS technique aims to enhance bliss and well-being in the mind-body system.",
    "llama-2-7b-chat-hf_fact": [
      "The BLISS technique involves adding a specific technique to the end of twice-daily meditation.",
      "The BLISS technique is taught in two parts during one session.",
      "The first part of the BLISS technique focuses on a specific technique added to the end of meditation practice.",
      "The BLISS technique is designed to help individuals cultivate a deeper state of relaxation and inner peace.",
      "The BLISS technique aims to enhance bliss and well-being in the mind-body system."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. TRUE\n\nThe statements about the BLISS technique are specific to a particular meditation practice or teaching, and without additional context or information about this technique, it is not possible to verify the details of how it is taught (statements 1, 2, and 3). However, the general goals of the BLISS technique as described in statements 4 and 5 (to cultivate a deeper state of relaxation and inner peace, and to enhance bliss and well-being in the mind-body system) are consistent with the namesake of the technique and the typical objectives of meditation practices, so they can be considered true.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3679,
    "user_query": "List 3 NK3R antagonists.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, here are 3 NK3R antagonists:\n1. GR-103691: This is a potent and selective NK3R antagonist that has been shown to reduce hot flush frequency and severity in postmenopausal women.\n2. MK-0359: This is a novel NK3R antagonist that has been shown to have efficacy in reducing hot flushes in postmenopausal women.\n3. LY-311599: This is a potent and selective NK3R antagonist that has been shown to reduce hot flush frequency and severity in postmenopausal women.\nIt is important to note that these are just a few examples of NK3R antagonists that have been studied for the treatment of hot flushes, and there may be other compounds that have similar effects. Additionally, the efficacy and safety of these compounds may vary depending on the specific population being studied and the doses used.",
    "llama-2-7b-chat-hf_fact_raw": "1. GR-103691 is a potent and selective NK3R antagonist.\n2. MK-0359 is a novel NK3R antagonist.\n3. LY-311599 is a potent and selective NK3R antagonist.",
    "llama-2-7b-chat-hf_fact": [
      "GR-103691 is a potent and selective NK3R antagonist.",
      "MK-0359 is a novel NK3R antagonist.",
      "LY-311599 is a potent and selective NK3R antagonist."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n\nWithout specific information on the compounds GR-103691, MK-0359, and LY-311599, it is not possible to verify the accuracy of these statements. These compounds are likely to be research chemicals or pharmaceuticals, and their properties would need to be confirmed by consulting scientific literature or databases that contain information on chemical substances and their biological activities.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3691,
    "user_query": "Which drug is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects is PF-05190457.",
    "llama-2-7b-chat-hf_fact_raw": "1. PF-05190457 is an oral ghrelin receptor inverse agonist.\n2. PF-05190457 was profiled in healthy subjects.",
    "llama-2-7b-chat-hf_fact": [
      "PF-05190457 is an oral ghrelin receptor inverse agonist.",
      "PF-05190457 was profiled in healthy subjects."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 3693,
    "user_query": "What is the protective efficacy of vaxchora against moderate to severe cholera?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the protective efficacy of Vaxchora against moderate to severe cholera can be calculated using the formula:\nPercentage vaccine efficacy/effectiveness = (1 − RR) × 100\nWhere RR is the relative risk of developing moderate to severe cholera in the unvaccinated group compared to the vaccinated group.\nUnfortunately, the information provided does not provide the RR value for Vaxchora's protection against moderate to severe cholera. Therefore, I cannot provide a definitive answer to the user's question.\nHowever, I can suggest some possible sources of information that may provide the required RR value:\n1. Clinical trials: The efficacy and effectiveness of Vaxchora were evaluated in clinical trials conducted by the manufacturer. These trials may have provided data on the RR value for Vaxchora's protection against moderate to severe cholera.\n2. Peer-reviewed articles: There may be peer-reviewed articles published in scientific journals that provide information on the efficacy and effectiveness of Vaxchora against cholera, including the RR value for moderate to severe disease.\n3. Health organization reports: International health organizations such as the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) may have published reports on the efficacy and effectiveness of Vaxchora against cholera, including the RR value for moderate to severe disease.\nI hope this information is helpful in answering the user's question. If you have any further questions or concerns, please feel free to ask.",
    "llama-2-7b-chat-hf_fact_raw": "1. Vaxchora is a vaccine intended to protect against moderate to severe cholera.\n2. The protective efficacy of Vaxchora can be calculated using the formula: Percentage vaccine efficacy/effectiveness = (1 − RR) × 100.\n3. RR stands for the relative risk of developing moderate to severe cholera in the unvaccinated group compared to the vaccinated group.\n4. Clinical trials conducted by the manufacturer evaluated the efficacy and effectiveness of Vaxchora.\n5. The World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) may have published reports on the efficacy and effectiveness of Vaxchora against cholera.",
    "llama-2-7b-chat-hf_fact": [
      "Vaxchora is a vaccine intended to protect against moderate to severe cholera.",
      "The protective efficacy of Vaxchora can be calculated using the formula: Percentage vaccine efficacy/effectiveness = (1 − RR) × 100.",
      "RR stands for the relative risk of developing moderate to severe cholera in the unvaccinated group compared to the vaccinated group.",
      "Clinical trials conducted by the manufacturer evaluated the efficacy and effectiveness of Vaxchora.",
      "The World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) may have published reports on the efficacy and effectiveness of Vaxchora against cholera."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: RR stands for the relative risk of developing moderate to severe cholera in the vaccinated group compared to the unvaccinated group.\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3716,
    "user_query": "Which was the first cholera vaccine approved in the US?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the first cholera vaccine approved in the US is Vaxchora, developed by PaxVax Bermuda Ltd. It was approved by the US Food and Drug Administration (FDA) for the prevention of cholera caused by serogroup 01.",
    "llama-2-7b-chat-hf_fact_raw": "1. Vaxchora is the first cholera vaccine approved in the US.\n2. Vaxchora was developed by PaxVax Bermuda Ltd.\n3. The US Food and Drug Administration (FDA) approved Vaxchora.\n4. Vaxchora is for the prevention of cholera caused by serogroup 01.",
    "llama-2-7b-chat-hf_fact": [
      "Vaxchora is the first cholera vaccine approved in the US.",
      "Vaxchora was developed by PaxVax Bermuda Ltd.",
      "The US Food and Drug Administration (FDA) approved Vaxchora.",
      "Vaxchora is for the prevention of cholera caused by serogroup 01."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3737,
    "user_query": "Which is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is heterozygous damaging NFKB1 variants.",
    "llama-2-7b-chat-hf_fact_raw": "1. The most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is heterozygous damaging NFKB1 variants.",
    "llama-2-7b-chat-hf_fact": [
      "The most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is heterozygous damaging NFKB1 variants."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 3743,
    "user_query": "Which is the role of the IFIT1 gene in Systemic Lupus Erythematosus (SLE)?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the IFIT1 gene plays a role in Systemic Lupus Erythematosus (SLE) by being involved in the overproduction and upregulation of Interferon-stimulated genes (ISGs) in SLE. ISGs are genes that are expressed in response to interferons (IFNs), which are proteins that play a crucial role in the immune system's defense against viral infections. In SLE, the overproduction and upregulation of ISGs can contribute to the development and progression of the disease. The IFIT1 gene, in particular, has been shown to be upregulated in SLE patients and may play a role in the pathogenesis of the disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. The IFIT1 gene is involved in the overproduction and upregulation of Interferon-stimulated genes (ISGs) in Systemic Lupus Erythematosus (SLE).\n2. Interferon-stimulated genes (ISGs) are expressed in response to interferons, which are proteins important for the immune system's defense against viral infections.\n3. The overproduction and upregulation of ISGs can contribute to the development and progression of Systemic Lupus Erythematosus (SLE).\n4. The IFIT1 gene has been shown to be upregulated in patients with Systemic Lupus Erythematosus (SLE).\n5. The IFIT1 gene may play a role in the pathogenesis of Systemic Lupus Erythematosus (SLE).",
    "llama-2-7b-chat-hf_fact": [
      "The IFIT1 gene is involved in the overproduction and upregulation of Interferon-stimulated genes (ISGs) in Systemic Lupus Erythematosus (SLE).",
      "Interferon-stimulated genes (ISGs) are expressed in response to interferons, which are proteins important for the immune system's defense against viral infections.",
      "The overproduction and upregulation of ISGs can contribute to the development and progression of Systemic Lupus Erythematosus (SLE).",
      "The IFIT1 gene has been shown to be upregulated in patients with Systemic Lupus Erythematosus (SLE).",
      "The IFIT1 gene may play a role in the pathogenesis of Systemic Lupus Erythematosus (SLE)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The IFIT1 gene is indeed involved in the overproduction and upregulation of Interferon-stimulated genes (ISGs), which has been associated with Systemic Lupus Erythematosus (SLE).\n2. TRUE: Interferon-stimulated genes (ISGs) are expressed in response to interferons, which are a group of signaling proteins released by host cells in response to the presence of several viruses and are a critical part of the immune system's defense against viral infections.\n3. TRUE: The overproduction and upregulation of ISGs have been implicated in contributing to the development and progression of autoimmune diseases, including Systemic Lupus Erythematosus (SLE).\n4. TRUE: Studies have shown that the IFIT1 gene, among others, is upregulated in patients with Systemic Lupus Erythematosus (SLE), suggesting a role in the disease's pathogenesis.\n5. TRUE: Given the involvement of the IFIT1 gene in the regulation of ISGs and its upregulation in SLE patients, it is reasonable to suggest that the IFIT1 gene may play a role in the pathogenesis of Systemic Lupus Erythematosus (SLE).",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3752,
    "user_query": "What is the use of the Liverpool Elbow Score?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the Liverpool Elbow Score is a questionnaire designed to evaluate the function and clinical state of the elbow. The score is intended to be elbow-specific, incorporating both patient perception and clinician assessment. The goal of developing the Liverpool Elbow Score was to create a valid and reliable tool that could be used to assess the function of the elbow in patients with various conditions affecting the joint. The score is based on a combination of patient-reported symptoms and signs observed by a clinician, and it is intended to be sensitive, reliable, and consistent in measuring elbow function.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Liverpool Elbow Score is a questionnaire designed to evaluate the function and clinical state of the elbow.\n2. The score incorporates both patient perception and clinician assessment.\n3. The Liverpool Elbow Score was developed to be a valid and reliable tool for assessing elbow function.\n4. The score is used to assess the function of the elbow in patients with various conditions affecting the joint.\n5. The Liverpool Elbow Score combines patient-reported symptoms and signs observed by a clinician.",
    "llama-2-7b-chat-hf_fact": [
      "The Liverpool Elbow Score is a questionnaire designed to evaluate the function and clinical state of the elbow.",
      "The score incorporates both patient perception and clinician assessment.",
      "The Liverpool Elbow Score was developed to be a valid and reliable tool for assessing elbow function.",
      "The score is used to assess the function of the elbow in patients with various conditions affecting the joint.",
      "The Liverpool Elbow Score combines patient-reported symptoms and signs observed by a clinician."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3763,
    "user_query": "Describe efforts on Sarcoma from the 100,000 Genomes Project",
    "llama-2-7b-chat-hf_response": "The 100,000 Genomes Project is a large-scale genomics initiative launched in 2012 in the UK, with the goal of sequencing 100,000 whole genomes from NHS patients. The project aims to improve our understanding of the genetic basis of disease and develop new diagnostic and therapeutic approaches.\nSarcoma is a type of cancer that affects connective tissue, including bone, cartilage, and fat. The 100,000 Genomes Project has made significant efforts to understand the genetic landscape of sarcoma through whole genome sequencing.\nOne of the key findings from the project is the identification of novel genetic mutations in sarcoma. For example, a study published in the journal Nature Communications in 2018 identified 22 novel genetic mutations in 100 sarcoma samples sequenced as part of the 100,000 Genomes Project. These mutations included both inherited and acquired mutations, and were found to be associated with specific subtypes of sarcoma.\nAnother important finding from the project is the identification of genetic mutations that are associated with poorer prognosis in sarcoma patients. For example, a study published in the journal Cancer Research in 2019 found that patients with sarcoma that harbored a specific genetic mutation in the TP53 gene had a higher risk of disease recurrence and death compared to patients without this mutation.\nThe 100,000 Genomes Project has also identified potential new therapeutic targets for sarcoma treatment. For example, a study published in the journal Science in 2019 identified a set of genes that are commonly mutated in sarcoma and are associated with poorer prognosis. These genes may be potential targets for new therapies, and further research is needed to validate these findings.\nOverall, the 100,000 Genomes Project has made significant efforts to understand the genetic basis of sarcoma and identify new therapeutic targets for this disease. These findings have the potential to improve the diagnosis and treatment of sarcoma and improve patient outcomes.",
    "llama-2-7b-chat-hf_fact_raw": "1. The 100,000 Genomes Project was launched in 2012 in the UK with the goal of sequencing 100,000 whole genomes from NHS patients.\n2. The project has contributed to the understanding of the genetic landscape of sarcoma through whole genome sequencing.\n3. A study published in Nature Communications in 2018 identified 22 novel genetic mutations in 100 sarcoma samples sequenced as part of the 100,000 Genomes Project.\n4. Research from the project published in Cancer Research in 2019 found that sarcoma patients with a specific mutation in the TP53 gene had a higher risk of disease recurrence and death.\n5. A study published in the journal Science in 2019 identified a set of genes commonly mutated in sarcoma that are associated with poorer prognosis and may be potential targets for new therapies.",
    "llama-2-7b-chat-hf_fact": [
      "The 100,000 Genomes Project was launched in 2012 in the UK with the goal of sequencing 100,000 whole genomes from NHS patients.",
      "The project has contributed to the understanding of the genetic landscape of sarcoma through whole genome sequencing.",
      "A study published in Nature Communications in 2018 identified 22 novel genetic mutations in 100 sarcoma samples sequenced as part of the 100,000 Genomes Project.",
      "Research from the project published in Cancer Research in 2019 found that sarcoma patients with a specific mutation in the TP53 gene had a higher risk of disease recurrence and death.",
      "A study published in the journal Science in 2019 identified a set of genes commonly mutated in sarcoma that are associated with poorer prognosis and may be potential targets for new therapies."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The 100,000 Genomes Project was launched in 2013 in the UK with the goal of sequencing 100,000 whole genomes from NHS patients.\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe corrections and verifications for statements 3, 4, and 5 would require access to specific scientific literature to confirm the details of the studies and their findings. Without that information, it is not possible to determine the truthfulness of those statements.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3777,
    "user_query": "Does protein ALEX1 contain armadillo repeats?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the answer to the user's question is yes, protein ALEX1 contains armadillo repeats. The document states that ALEX1 contains two armadillo repeats domains, indicating that it does contain these repeats.",
    "llama-2-7b-chat-hf_fact_raw": "1. Protein ALEX1 contains armadillo repeats.\n2. ALEX1 has two armadillo repeat domains.",
    "llama-2-7b-chat-hf_fact": [
      "Protein ALEX1 contains armadillo repeats.",
      "ALEX1 has two armadillo repeat domains."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: ALEX1 contains one armadillo repeat domain.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false"
    ]
  },
  {
    "id": 3789,
    "user_query": "List enzymes that removes histone modifications.",
    "llama-2-7b-chat-hf_response": "Thank you for your question! Based on the information provided, here are some enzymes that are known to remove histone modifications:\n1. Histone demethylases: These enzymes remove methyl groups from histone proteins, leading to changes in chromatin structure and gene expression. Examples of histone demethylases include KDM4B, KDM5A, and KDM5B.\n2. Histone acetyltransferases (HATs): HATs add acetyl groups to histone proteins, leading to changes in chromatin structure and gene expression. Examples of HATs include p300 and CBP (CREB-binding protein).\n3. Histone deacetylases (HDACs): HDACs remove acetyl groups from histone proteins, leading to changes in chromatin structure and gene expression. Examples of HDACs include HDAC1, HDAC2, and HDAC3.\n4. Lysine-specific demethylase 1 (LSD1): LSD1 is a demethylase that specifically targets histone H3K4me3, leading to changes in chromatin structure and gene expression.\n5. Arginine methyltransferases: These enzymes add methyl groups to histone arginine residues, leading to changes in chromatin structure and gene expression. Examples of arginine methyltransferases include PRMT1 and PRMT5.\nIt's important to note that these enzymes have different specificities for their substrates and can have different effects on chromatin structure and gene expression. Additionally, the activity of these enzymes can be regulated by various factors, including protein-protein interactions, post-translational modifications, and small molecules.",
    "llama-2-7b-chat-hf_fact_raw": "1. Histone demethylases are enzymes that remove methyl groups from histone proteins.\n2. Examples of histone demethylases include KDM4B, KDM5A, and KDM5B.\n3. Histone deacetylases (HDACs) are enzymes that remove acetyl groups from histone proteins.\n4. Examples of histone deacetylases include HDAC1, HDAC2, and HDAC3.\n5. Lysine-specific demethylase 1 (LSD1) is a demethylase that specifically targets histone H3K4me3.",
    "llama-2-7b-chat-hf_fact": [
      "Histone demethylases are enzymes that remove methyl groups from histone proteins.",
      "Examples of histone demethylases include KDM4B, KDM5A, and KDM5B.",
      "Histone deacetylases (HDACs) are enzymes that remove acetyl groups from histone proteins.",
      "Examples of histone deacetylases include HDAC1, HDAC2, and HDAC3.",
      "Lysine-specific demethylase 1 (LSD1) is a demethylase that specifically targets histone H3K4me3."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Lysine-specific demethylase 1 (LSD1) targets histone H3 at lysine 4 (H3K4) but demethylates mono- and di-methylated lysine (H3K4me1 and H3K4me2), not the tri-methylated lysine (H3K4me3).",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3806,
    "user_query": "Does head ct increase brain tumor risk?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there is a potential increased risk of brain tumors associated with head CT scans, particularly in individuals who received high doses of radiation to the head in childhood.\nDocument 0 mentions that patients who received high doses of radiation on the head in childhood have high risks of brain tumors. This suggests that exposure to radiation, particularly in childhood, can increase the likelihood of developing brain tumors later in life.\nAdditionally, CT scans themselves increase the risk of intracranial tumor progression. While the radiation dose from a CT scan is generally in the range of 5-50 mGY, this can still pose a risk to individuals, particularly those who undergo frequent CT scans or have a history of radiation exposure.\nIt's important to note that while there is a potential increased risk of brain tumors associated with head CT scans, the overall risk is still relatively low. However, individuals who have a history of radiation exposure or who undergo frequent CT scans should be monitored closely for any signs of brain tumors.\nIn summary, based on the information provided, there is a potential increased risk of brain tumors associated with head CT scans, particularly in individuals who received high doses of radiation to the head in childhood. However, the overall risk is still relatively low, and further research is needed to fully understand the relationship between CT scans and brain tumor risk.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is a potential increased risk of brain tumors associated with head CT scans.\n2. Individuals who received high doses of radiation to the head in childhood have higher risks of brain tumors.\n3. Exposure to radiation, particularly in childhood, can increase the likelihood of developing brain tumors later in life.\n4. The radiation dose from a CT scan is generally in the range of 5-50 mGY.\n5. Individuals who undergo frequent CT scans or have a history of radiation exposure should be monitored closely for signs of brain tumors.",
    "llama-2-7b-chat-hf_fact": [
      "There is a potential increased risk of brain tumors associated with head CT scans.",
      "Individuals who received high doses of radiation to the head in childhood have higher risks of brain tumors.",
      "Exposure to radiation, particularly in childhood, can increase the likelihood of developing brain tumors later in life.",
      "The radiation dose from a CT scan is generally in the range of 5-50 mGY.",
      "Individuals who undergo frequent CT scans or have a history of radiation exposure should be monitored closely for signs of brain tumors."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE [correction]: The radiation dose from a CT scan is generally in the range of 1-10 millisieverts (mSv), which is equivalent to 100-1000 mGy. The value of 5-50 mGy is typically lower than the doses used for CT scans.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3809,
    "user_query": "Which type of pluripotency is Otx2 associated with?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, Otx2 is associated with the type of pluripotency known as \"enhancer-dependent pluripotency.\" This is because Otx2 is shown to be involved in the redirection of Oct4 to previously inaccessible enhancer sites, which is a key mechanism underlying enhancer-dependent pluripotency. Enhancer-dependent pluripotency is a type of pluripotency that relies on the activation of specific enhancers to maintain pluripotency, rather than the expression of pluripotency genes in a constant manner.",
    "llama-2-7b-chat-hf_fact_raw": "1. Otx2 is associated with \"enhancer-dependent pluripotency.\"\n2. Otx2 is involved in the redirection of Oct4 to previously inaccessible enhancer sites.\n3. Enhancer-dependent pluripotency relies on the activation of specific enhancers to maintain pluripotency.",
    "llama-2-7b-chat-hf_fact": [
      "Otx2 is associated with \"enhancer-dependent pluripotency.\"",
      "Otx2 is involved in the redirection of Oct4 to previously inaccessible enhancer sites.",
      "Enhancer-dependent pluripotency relies on the activation of specific enhancers to maintain pluripotency."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n\nThe statements provided are consistent with scientific understanding of the role of Otx2 in enhancer-dependent pluripotency. Otx2 is known to be associated with pluripotency and has been implicated in the regulation of enhancers that are important for maintaining the pluripotent state of cells. It is involved in the redirection of Oct4, a core pluripotency transcription factor, to enhancer sites that are crucial for the pluripotent network. Enhancer-dependent pluripotency indeed relies on the activation of specific enhancers to maintain the pluripotent state of stem cells.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3815,
    "user_query": "How many DNaseI hypersensitive sites (DHS) mark the murine beta globin locus region?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, there are 5 DNaseI hypersensitive sites (DHS) that mark the murine beta globin locus region. These sites are referred to as 5'HS1 to 5'HS5.",
    "llama-2-7b-chat-hf_fact_raw": "1. There are 5 DNaseI hypersensitive sites marking the murine beta globin locus region.\n2. These DNaseI hypersensitive sites are referred to as 5'HS1 to 5'HS5.",
    "llama-2-7b-chat-hf_fact": [
      "There are 5 DNaseI hypersensitive sites marking the murine beta globin locus region.",
      "These DNaseI hypersensitive sites are referred to as 5'HS1 to 5'HS5."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: These DNaseI hypersensitive sites are referred to as HS1 to HS5, not 5'HS1 to 5'HS5. The \"5'\" designation is not typically repeated for each site; they are numbered sequentially without the 5' prefix for each.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false"
    ]
  },
  {
    "id": 3822,
    "user_query": "List as many European influenza vaccines as possible.",
    "llama-2-7b-chat-hf_response": "Certainly! Based on the information provided, here are some European influenza vaccines:\n1. Fluad: This is a quadrivalent influenza vaccine (four strains) that is specifically designed for people aged 65 years and older. It is produced by GlaxoSmithKline.\n2. Fluarix: This is a trivalent influenza vaccine (three strains) that is approved for use in people aged 6 months and older. It is produced by GlaxoSmithKline.\n3. Fluvirin: This is a trivalent influenza vaccine (three strains) that is approved for use in people aged 6 months and older. It is produced by Novartis.\n4. Aggripulse: This is a quadrivalent influenza vaccine (four strains) that is approved for use in people aged 18 years and older. It is produced by Sanofi Pasteur.\n5. FluMist: This is a live, attenuated influenza vaccine that is approved for use in people aged 2-49 years. It is produced by MedImmune.\n6. Fluad Quad: This is a quadrivalent influenza vaccine (four strains) that is specifically designed for people aged 65 years and older. It is produced by GSK.\n7. Vaxigrip: This is a trivalent influenza vaccine (three strains) that is approved for use in people aged 6 months and older. It is produced by Sanofi Pasteur.\n8. Influvac: This is a trivalent influenza vaccine (three strains) that is approved for use in people aged 6 months and older. It is produced by Novartis.\n9. Fluvirin Junior: This is a trivalent influenza vaccine (three strains) that is approved for use in children aged 6-35 months. It is produced by Novartis.\n10. Fluad Junior: This is a quadrivalent influenza vaccine (four strains) that is specifically designed for children aged 6-17 years. It is produced by GSK.\nPlease note that this is not an exhaustive list, and there may",
    "llama-2-7b-chat-hf_fact_raw": "1. Fluad is a quadrivalent influenza vaccine designed for people aged 65 years and older, produced by GlaxoSmithKline.\n2. Fluarix is a trivalent influenza vaccine approved for use in people aged 6 months and older, produced by GlaxoSmithKline.\n3. Fluvirin is a trivalent influenza vaccine approved for use in people aged 6 months and older, produced by Novartis.\n4. Aggripal is a quadrivalent influenza vaccine approved for use in people aged 18 years and older, produced by Sanofi Pasteur.\n5. FluMist is a live, attenuated influenza vaccine approved for use in people aged 2-49 years, produced by MedImmune.",
    "llama-2-7b-chat-hf_fact": [
      "Fluad is a quadrivalent influenza vaccine designed for people aged 65 years and older, produced by GlaxoSmithKline.",
      "Fluarix is a trivalent influenza vaccine approved for use in people aged 6 months and older, produced by GlaxoSmithKline.",
      "Fluvirin is a trivalent influenza vaccine approved for use in people aged 6 months and older, produced by Novartis.",
      "Aggripal is a quadrivalent influenza vaccine approved for use in people aged 18 years and older, produced by Sanofi Pasteur.",
      "FluMist is a live, attenuated influenza vaccine approved for use in people aged 2-49 years, produced by MedImmune."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Fluad is a trivalent influenza vaccine designed for people aged 65 years and older, produced by Seqirus.\n2. TRUE\n3. FALSE [correction]: Fluvirin was a trivalent influenza vaccine approved for use in people aged 4 years and older, produced by Novartis, but as of my knowledge cutoff in 2023, it is no longer available in the United States.\n4. FALSE [correction]: Aggripal, also known as FluQuadri, is a quadrivalent influenza vaccine approved for use in people aged 6 months and older, produced by Sanofi Pasteur.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 3832,
    "user_query": "Is the Paramyxovirus geneome segmented, negative-sense RNA?",
    "llama-2-7b-chat-hf_response": "Yes, the Paramyxovirus genome is segmented, negative-sense RNA. According to the information provided in Document 0, the genome of Paramyxoviruses consists of one or more single-stranded, negative-sense RNA molecules. This means that the genetic information is encoded in a complementary DNA (cDNA) strand that is the opposite of the actual DNA sequence. The RNA molecules are assembled with multiple copies of viral nucleoprotein into megadalton-sized viral ribonucleoprotein (vRNP) complexes with a helical configuration.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Paramyxovirus genome is composed of negative-sense RNA.\n2. The genome of Paramyxoviruses consists of one or more single-stranded RNA molecules.\n3. The genetic information in Paramyxoviruses is encoded in a complementary DNA strand opposite of the actual DNA sequence.\n4. Paramyxovirus RNA molecules are assembled with viral nucleoprotein into megadalton-sized viral ribonucleoprotein complexes.\n5. The viral ribonucleoprotein complexes of Paramyxoviruses have a helical configuration.",
    "llama-2-7b-chat-hf_fact": [
      "The Paramyxovirus genome is composed of negative-sense RNA.",
      "The genome of Paramyxoviruses consists of one or more single-stranded RNA molecules.",
      "The genetic information in Paramyxoviruses is encoded in a complementary DNA strand opposite of the actual DNA sequence.",
      "Paramyxovirus RNA molecules are assembled with viral nucleoprotein into megadalton-sized viral ribonucleoprotein complexes.",
      "The viral ribonucleoprotein complexes of Paramyxoviruses have a helical configuration."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Paramyxoviruses do not have DNA; their genetic information is encoded in negative-sense RNA, not in a complementary DNA strand.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3869,
    "user_query": "Roflumilast Cream is effective for which disease?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, Roflumilast cream is effective for treating psoriasis. The document states that the mean percentage of psoriasis-affected body surface area (BSA) was 6.3% (standard deviation of 4.38) in the Roflumilast cream group, compared to 5.5% (standard deviation of 3.76) in the vehicle group. This suggests that Roflumilast cream was able to significantly reduce the severity of psoriasis compared to the vehicle control.",
    "llama-2-7b-chat-hf_fact_raw": "1. Roflumilast cream is used for treating psoriasis.\n2. The document indicates that the mean percentage of psoriasis-affected body surface area was 6.3% in the Roflumilast cream group.\n3. The standard deviation of the psoriasis-affected body surface area in the Roflumilast cream group was 4.38.\n4. In the vehicle group, the mean percentage of psoriasis-affected body surface area was 5.5%.\n5. The standard deviation of the psoriasis-affected body surface area in the vehicle group was 3.76.",
    "llama-2-7b-chat-hf_fact": [
      "Roflumilast cream is used for treating psoriasis.",
      "The document indicates that the mean percentage of psoriasis-affected body surface area was 6.3% in the Roflumilast cream group.",
      "The standard deviation of the psoriasis-affected body surface area in the Roflumilast cream group was 4.38.",
      "In the vehicle group, the mean percentage of psoriasis-affected body surface area was 5.5%.",
      "The standard deviation of the psoriasis-affected body surface area in the vehicle group was 3.76."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Roflumilast cream is used for treating chronic plaque psoriasis.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe correction for statement 1 is based on the fact that Roflumilast cream is specifically indicated for the treatment of chronic plaque psoriasis, not psoriasis in general. The other statements (2-5) require specific data from the document that was not provided, so their accuracy cannot be determined without additional context.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3885,
    "user_query": "Which tools have been developed for identifying and visualising ncRNA promoters?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there are several tools that have been developed for identifying and visualizing non-coding RNA (ncRNA) promoters. Here are a few examples:\n1. R2DT (RNA Secondary Structure Prediction and Visualization Tool): As mentioned in the information provided, R2DT is a framework for predicting and visualizing RNA secondary structure using templates. This tool can be used to identify potential ncRNA promoters by analyzing the secondary structure of the RNA molecule.\n2. DeepRNA: DeepRNA is a deep learning-based tool for predicting the secondary structure of RNA molecules. It can be used to identify ncRNA promoters by analyzing the predicted secondary structure of the RNA molecule.\n3. RNAfold: RNAfold is a tool for predicting the secondary structure of RNA molecules. It can be used to identify ncRNA promoters by analyzing the predicted secondary structure of the RNA molecule.\n4. Pfold: Pfold is a tool for predicting the secondary structure of RNA molecules. It can be used to identify ncRNA promoters by analyzing the predicted secondary structure of the RNA molecule.\n5. RNA-Pro: RNA-Pro is a tool for predicting the secondary structure of RNA molecules. It can be used to identify ncRNA promoters by analyzing the predicted secondary structure of the RNA molecule.\n6. RNA-Pro2: RNA-Pro2 is an updated version of RNA-Pro, which includes improved algorithms for predicting RNA secondary structure. It can be used to identify ncRNA promoters by analyzing the predicted secondary structure of the RNA molecule.\n7. RNA-Pro3: RNA-Pro3 is the latest version of RNA-Pro, which includes improved algorithms for predicting RNA secondary structure and other features such as RNA structure prediction and analysis. It can be used to identify ncRNA promoters by analyzing the predicted secondary structure of the RNA molecule.\nThese are just a few examples of the many tools that have been developed for identifying and visualizing ncRNA promoters. The choice of tool will depend on the",
    "llama-2-7b-chat-hf_fact_raw": "1. R2DT is a tool designed for predicting and visualizing RNA secondary structure using templates.\n2. DeepRNA is a deep learning-based tool for predicting the secondary structure of RNA molecules.\n3. RNAfold is a tool used for predicting the secondary structure of RNA molecules.\n4. Pfold is a tool that predicts the secondary structure of RNA molecules.\n5. RNA-Pro2 is an updated version of RNA-Pro with improved algorithms for predicting RNA secondary structure.",
    "llama-2-7b-chat-hf_fact": [
      "R2DT is a tool designed for predicting and visualizing RNA secondary structure using templates.",
      "DeepRNA is a deep learning-based tool for predicting the secondary structure of RNA molecules.",
      "RNAfold is a tool used for predicting the secondary structure of RNA molecules.",
      "Pfold is a tool that predicts the secondary structure of RNA molecules.",
      "RNA-Pro2 is an updated version of RNA-Pro with improved algorithms for predicting RNA secondary structure."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The correct name of the tool is R2DT (RNA 2D Templates), and it is designed for visualizing RNA secondary structures using templates, but it does not predict RNA secondary structures.\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3918,
    "user_query": "List example genes that SWIM tool has identified and which are down-regulated in glioblastoma",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, SWIM tool has identified several genes that are down-regulated in glioblastoma. Here are some examples:\n1. CD44: CD44 is a cell surface glycoprotein that is involved in cell adhesion, migration, and signaling. It has been shown to be down-regulated in glioblastoma, which may contribute to the tumor's aggressive behavior.\n2. Mucin 1 (MUC1): MUC1 is a cell surface glycoprotein that is involved in cell adhesion and signaling. It is down-regulated in glioblastoma, which may contribute to the tumor's ability to evade the immune system.\n3. Epidermal growth factor receptor (EGFR): EGFR is a cell surface receptor that is involved in cell signaling and proliferation. It is down-regulated in glioblastoma, which may contribute to the tumor's resistance to chemotherapy and radiation therapy.\n4. Programmed death-ligand 1 (PD-L1): PD-L1 is a cell surface protein that is involved in immune checkpoint regulation. It is down-regulated in glioblastoma, which may contribute to the tumor's ability to evade the immune system.\n5. Leucine-rich repeat-containing G protein-coupled receptor 1 (LGR1): LGR1 is a cell surface receptor that is involved in cell signaling and proliferation. It is down-regulated in glioblastoma, which may contribute to the tumor's ability to proliferate and invade surrounding tissues.\n6. Glypican-3 (GPC3): GPC3 is a cell surface glycoprotein that is involved in cell signaling and proliferation. It is down-regulated in glioblastoma, which may contribute to the tumor's ability to proliferate and invade surrounding tissues.\n7. Thyroid transcription factor 1 (TTF-1): TTF-1 is a transcription factor that is involved in cell signaling and proliferation. It is down-regulated in gliob",
    "llama-2-7b-chat-hf_fact_raw": "1. The SWIM tool has identified CD44 as a gene that is down-regulated in glioblastoma.\n2. Mucin 1 (MUC1) is identified by the SWIM tool as being down-regulated in glioblastoma.\n3. The SWIM tool has found that the Epidermal growth factor receptor (EGFR) gene is down-regulated in glioblastoma.\n4. Programmed death-ligand 1 (PD-L1) is reported to be down-regulated in glioblastoma according to the SWIM tool.\n5. Leucine-rich repeat-containing G protein-coupled receptor 1 (LGR1) is among the genes down-regulated in glioblastoma as identified by the SWIM tool.",
    "llama-2-7b-chat-hf_fact": [
      "The SWIM tool has identified CD44 as a gene that is down-regulated in glioblastoma.",
      "Mucin 1 (MUC1) is identified by the SWIM tool as being down-regulated in glioblastoma.",
      "The SWIM tool has found that the Epidermal growth factor receptor (EGFR) gene is down-regulated in glioblastoma.",
      "Programmed death-ligand 1 (PD-L1) is reported to be down-regulated in glioblastoma according to the SWIM tool.",
      "Leucine-rich repeat-containing G protein-coupled receptor 1 (LGR1) is among the genes down-regulated in glioblastoma as identified by the SWIM tool."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. FALSE [correction]: The Epidermal growth factor receptor (EGFR) gene is often found to be up-regulated or mutated in glioblastoma, not down-regulated.\n4. UNKNOWN\n5. UNKNOWN\n\nThe status of CD44, MUC1, and LGR1 in glioblastoma as identified by the SWIM tool is not provided in the context, so their regulation status cannot be confirmed without additional information. However, it is widely recognized that EGFR is commonly up-regulated in glioblastoma, which contradicts the statement provided. The regulation status of PD-L1 in glioblastoma as identified by the SWIM tool is also not provided, so it remains unknown.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3926,
    "user_query": "Which R packages have been developed for studying TADs?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there are several R packages that have been developed for studying Transcriptional Activation Domains (TADs). Here are a few examples:\n1. TADbit: This package provides a comprehensive set of tools for the analysis of TADs, including the ability to identify TADs, quantify their expression levels, and predict their functional impact.\n2. TADeep: This package uses a deep learning approach to predict TADs in human genomes, and can also be used to identify regulatory elements and predict gene expression.\n3. TADtrack: This package provides a comprehensive set of tools for the analysis of TADs, including the ability to identify TADs, quantify their expression levels, and predict their functional impact.\n4. TAD-seq: This package provides a set of tools for the analysis of TADs in single-cell RNA sequencing data, including the ability to identify TADs, quantify their expression levels, and predict their functional impact.\n5. TAD-detect: This package provides a simple and efficient method for identifying TADs in genomic data, using a Bayesian approach.\n6. TAD-hunter: This package provides a comprehensive set of tools for the analysis of TADs, including the ability to identify TADs, quantify their expression levels, and predict their functional impact.\n7. TAD-map: This package provides a set of tools for the analysis of TADs in genomic data, including the ability to identify TADs, quantify their expression levels, and predict their functional impact.\n8. TAD-predict: This package provides a set of tools for predicting the functional impact of TADs, including the ability to predict the expression levels of nearby genes and the potential regulatory effects of TADs.\nThese are just a few examples of the many R packages available for studying TADs. Each package has its own unique features and capabilities, so it's worth exploring each one to determine which is the best fit for your research question.",
    "llama-2-7b-chat-hf_fact_raw": "1. TADbit is an R package developed for the analysis of Transcriptional Activation Domains (TADs).\n2. TADeep is an R package that uses a deep learning approach to predict TADs in human genomes.\n3. TADtrack is an R package that provides tools for the analysis of TADs, including identification and quantification of their expression levels.\n4. TAD-seq is an R package designed for analyzing TADs in single-cell RNA sequencing data.\n5. TAD-detect is an R package that identifies TADs in genomic data using a Bayesian approach.",
    "llama-2-7b-chat-hf_fact": [
      "TADbit is an R package developed for the analysis of Transcriptional Activation Domains (TADs).",
      "TADeep is an R package that uses a deep learning approach to predict TADs in human genomes.",
      "TADtrack is an R package that provides tools for the analysis of TADs, including identification and quantification of their expression levels.",
      "TAD-seq is an R package designed for analyzing TADs in single-cell RNA sequencing data.",
      "TAD-detect is an R package that identifies TADs in genomic data using a Bayesian approach."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: TADbit is a Python library, not an R package, developed for the analysis of the 3D organization of the genome, including the identification and analysis of Topologically Associating Domains (TADs).\n2. UNKNOWN: Without more context or a known reference, it is unclear whether TADeep is an actual R package and what its functions are.\n3. UNKNOWN: Similarly, without additional information, it is not possible to confirm the existence or functions of an R package named TADtrack.\n4. UNKNOWN: TAD-seq does not appear to be an R package. TAD-seq is a method for mapping TADs, but it is not clear if there is an R package specifically designed for analyzing TADs in single-cell RNA sequencing data with this name.\n5. UNKNOWN: There is no widely recognized R package named TAD-detect based on the information provided. It is unclear whether such a package exists or what its functions might be.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3927,
    "user_query": "Which bioconductor tool has been developed for accessing bacterial regulatory networks?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the bioconductor tool that has been developed for accessing bacterial regulatory networks is likely to be \"Regulatory Network Analysis Toolkit\" (RNAT).\nRNAT is a bioconductor package that provides a comprehensive framework for the analysis of bacterial regulatory networks. It allows users to construct, simulate, and analyze regulatory networks using a variety of data types, including gene expression profiles, protein-DNA interaction data, and transcription factor binding data. RNAT also provides tools for visualizing and interpreting the results of regulatory network analysis, including network visualization, pathway analysis, and gene ontology enrichment analysis.\nDocument 0 mentions the hierarchical relationship between transcription factors, associated proteins, and their target genes, which is a key aspect of bacterial regulatory networks. RNAT is well-suited for analyzing these types of networks, as it can handle complex regulatory relationships and provide insights into the regulatory mechanisms underlying bacterial behavior.\nTherefore, based on the information provided, it is likely that RNAT is the bioconductor tool that has been developed for accessing bacterial regulatory networks.",
    "llama-2-7b-chat-hf_fact_raw": "1. The bioconductor tool developed for accessing bacterial regulatory networks is called \"Regulatory Network Analysis Toolkit\" (RNAT).\n2. RNAT allows users to construct, simulate, and analyze regulatory networks.\n3. RNAT can utilize data types such as gene expression profiles, protein-DNA interaction data, and transcription factor binding data.\n4. The toolkit includes features for network visualization, pathway analysis, and gene ontology enrichment analysis.\n5. RNAT is designed to handle complex regulatory relationships within bacterial regulatory networks.",
    "llama-2-7b-chat-hf_fact": [
      "The bioconductor tool developed for accessing bacterial regulatory networks is called \"Regulatory Network Analysis Toolkit\" (RNAT).",
      "RNAT allows users to construct, simulate, and analyze regulatory networks.",
      "RNAT can utilize data types such as gene expression profiles, protein-DNA interaction data, and transcription factor binding data.",
      "The toolkit includes features for network visualization, pathway analysis, and gene ontology enrichment analysis.",
      "RNAT is designed to handle complex regulatory relationships within bacterial regulatory networks."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The bioconductor tool developed for accessing bacterial regulatory networks is called \"Regulatory Sequence Analysis Tools\" (RSAT).\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3933,
    "user_query": "What are the end products of the shikimate pathway?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the end products of the shikimate pathway are:\n* Aromatic compounds with potential bio-replacements for commonly fossil fuel-derived aromatics\n* Secondary metabolites\nThe shikimate pathway is a metabolic pathway that produces aromatic compounds, and the end products of this pathway have the potential to be used as replacements for fossil fuel-derived aromatics. Additionally, the pathway produces secondary metabolites, which are naturally produced compounds that can be used for various purposes. Through metabolic engineering, the abundance of certain intermediates in the pathway can be increased, while flux is drained from other branches of the pathway. This allows for the production of a wide range of end products with potential applications in various industries.",
    "llama-2-7b-chat-hf_fact_raw": "1. The end products of the shikimate pathway include aromatic compounds.\n2. The shikimate pathway produces secondary metabolites.\n3. Aromatic compounds produced by the shikimate pathway have the potential to replace fossil fuel-derived aromatics.\n4. Metabolic engineering can increase the abundance of certain intermediates in the shikimate pathway.\n5. The shikimate pathway's end products have potential applications in various industries.",
    "llama-2-7b-chat-hf_fact": [
      "The end products of the shikimate pathway include aromatic compounds.",
      "The shikimate pathway produces secondary metabolites.",
      "Aromatic compounds produced by the shikimate pathway have the potential to replace fossil fuel-derived aromatics.",
      "Metabolic engineering can increase the abundance of certain intermediates in the shikimate pathway.",
      "The shikimate pathway's end products have potential applications in various industries."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3936,
    "user_query": "Is cabergoline used for treatment of the Nelson's syndrome ?",
    "llama-2-7b-chat-hf_response": "Yes, cabergoline can be used to treat Nelson's syndrome, which is a rare condition characterized by the excessive growth of pituitary tumors after previous treatment. Cabergoline is a dopamine receptor agonist that has been shown to be effective in controlling the growth of pituitary tumors, including those associated with Nelson's syndrome.\nAccording to the information provided, cabergoline is already being used in the treatment of aggressive ACTHomas, which are a type of pituitary tumor that can cause Nelson's syndrome. While the document does not specifically mention Nelson's syndrome as a treatment target for cabergoline, it is reasonable to assume that the drug could be effective in managing this condition as well.\nTherefore, based on the information provided, the answer to the user's question is yes, cabergoline can be used to treat Nelson's syndrome.",
    "llama-2-7b-chat-hf_fact_raw": "1. Cabergoline is used to treat Nelson's syndrome.\n2. Nelson's syndrome is characterized by the excessive growth of pituitary tumors after previous treatment.\n3. Cabergoline is a dopamine receptor agonist.\n4. Cabergoline has been shown to be effective in controlling the growth of pituitary tumors.\n5. Cabergoline is used in the treatment of aggressive ACTHomas, a type of pituitary tumor that can cause Nelson's syndrome.",
    "llama-2-7b-chat-hf_fact": [
      "Cabergoline is used to treat Nelson's syndrome.",
      "Nelson's syndrome is characterized by the excessive growth of pituitary tumors after previous treatment.",
      "Cabergoline is a dopamine receptor agonist.",
      "Cabergoline has been shown to be effective in controlling the growth of pituitary tumors.",
      "Cabergoline is used in the treatment of aggressive ACTHomas, a type of pituitary tumor that can cause Nelson's syndrome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Cabergoline is not typically used to treat Nelson's syndrome. Nelson's syndrome involves the growth of pituitary tumors after the removal of the adrenal glands, and treatment options may include surgery, radiation therapy, and medications other than cabergoline.\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: While cabergoline is used in the treatment of certain pituitary tumors, such as prolactinomas, by reducing the production of prolactin, it is not the standard treatment for aggressive ACTH-secreting pituitary tumors (ACTHomas) that can cause Nelson's syndrome. Treatment for aggressive ACTHomas may involve surgery, radiation, and other medications, but not specifically cabergoline.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3939,
    "user_query": "What is the main manifestation of Liebenberg syndrome?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the main manifestation of Liebenberg syndrome is abnormal development of the arms, resulting in characteristic arm malformations that can vary in severity.",
    "llama-2-7b-chat-hf_fact_raw": "1. Liebenberg syndrome is characterized by abnormal development of the arms.\n2. Liebenberg syndrome results in arm malformations.\n3. The severity of arm malformations in Liebenberg syndrome can vary.",
    "llama-2-7b-chat-hf_fact": [
      "Liebenberg syndrome is characterized by abnormal development of the arms.",
      "Liebenberg syndrome results in arm malformations.",
      "The severity of arm malformations in Liebenberg syndrome can vary."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Liebenberg syndrome is characterized by abnormal development of the elbows, forearms, and hands, which can resemble the hind limbs of an animal.\n2. TRUE\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3977,
    "user_query": "List orally bioavailable MPS1 kinase inhibitors",
    "llama-2-7b-chat-hf_response": "As a helpful assistant, I can provide you with a list of orally bioavailable MPS1 kinase inhibitors that are currently being researched or developed for the treatment of various diseases, including cancer. Please note that this list is not exhaustive and is based on my internal knowledge and available information. Here are some examples:\n1. Pexidartinib: This is an orally available MPS1 kinase inhibitor that has shown promise in preclinical studies for the treatment of various cancers, including colorectal cancer and gastric cancer.\n2. ARN-509: This is another orally available MPS1 kinase inhibitor that has been shown to inhibit the growth of various cancer cell lines and has been evaluated in clinical trials for the treatment of acute myeloid leukemia.\n3. AZD-1975: This is a potent and selective MPS1 kinase inhibitor that has shown antitumor activity in preclinical studies and is currently being evaluated in clinical trials for the treatment of various cancers, including breast cancer and non-small cell lung cancer.\n4. MLN0128: This is an orally available MPS1 kinase inhibitor that has shown antitumor activity in preclinical studies and is currently being evaluated in clinical trials for the treatment of various cancers, including colorectal cancer and gastric cancer.\n5. R1638: This is a highly selective MPS1 kinase inhibitor that has shown antitumor activity in preclinical studies and is currently being evaluated in clinical trials for the treatment of various cancers, including breast cancer and non-small cell lung cancer.\nIt is important to note that these inhibitors are still in the early stages of development and have not yet been approved by regulatory authorities for clinical use. Additionally, the efficacy and safety of these inhibitors in humans have not yet been fully established, and more research is needed to determine their potential as therapeutic agents.",
    "llama-2-7b-chat-hf_fact_raw": "1. Pexidartinib is an orally available MPS1 kinase inhibitor that has been studied for the treatment of various cancers.\n2. ARN-509 is an orally available MPS1 kinase inhibitor that has been evaluated in clinical trials for the treatment of acute myeloid leukemia.\n3. AZD-1975 is a potent and selective MPS1 kinase inhibitor that is being evaluated in clinical trials for the treatment of various cancers.\n4. MLN0128 is an orally available MPS1 kinase inhibitor that is being evaluated in clinical trials for the treatment of various cancers.\n5. R1638 is a highly selective MPS1 kinase inhibitor that is being evaluated in clinical trials for the treatment of various cancers.",
    "llama-2-7b-chat-hf_fact": [
      "Pexidartinib is an orally available MPS1 kinase inhibitor that has been studied for the treatment of various cancers.",
      "ARN-509 is an orally available MPS1 kinase inhibitor that has been evaluated in clinical trials for the treatment of acute myeloid leukemia.",
      "AZD-1975 is a potent and selective MPS1 kinase inhibitor that is being evaluated in clinical trials for the treatment of various cancers.",
      "MLN0128 is an orally available MPS1 kinase inhibitor that is being evaluated in clinical trials for the treatment of various cancers.",
      "R1638 is a highly selective MPS1 kinase inhibitor that is being evaluated in clinical trials for the treatment of various cancers."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Pexidartinib is an orally available kinase inhibitor, but it targets CSF1R (colony-stimulating factor 1 receptor), not MPS1, and has been studied for the treatment of tenosynovial giant cell tumor.\n2. FALSE [correction]: ARN-509, also known as apalutamide, is an androgen receptor inhibitor that has been evaluated in clinical trials for the treatment of prostate cancer, not acute myeloid leukemia.\n3. UNKNOWN: Without more information, it is not possible to verify the accuracy of the statement regarding AZD-1975, as it is not a well-known compound in the public domain, and MPS1 kinase inhibitors are a class of drugs that are less commonly discussed. Additionally, the name AZD-1975 does not appear to correspond to a known MPS1 kinase inhibitor.\n4. FALSE [correction]: MLN0128, also known as sapanisertib, is an orally available kinase inhibitor, but it targets mTOR (mechanistic target of rapamycin), not MPS1, and has been evaluated in clinical trials for the treatment of various cancers.\n5. UNKNOWN: Similar to statement 3, without more information, it is not possible to verify the accuracy of the statement regarding R1638, as it is not a well-known compound in the public domain, and MPS1 kinase inhibitors are a class of drugs that are less commonly discussed. The name R1638 does not appear to correspond to a known MPS1 kinase inhibitor.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 4031,
    "user_query": "Was golimumab tested for diabetes?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, golimumab has been tested for diabetes in a phase 2a clinical trial called the T1GER study. The study evaluated the safety and efficacy of golimumab in children and young adults with newly diagnosed type 1 diabetes (T1D). The results of the study showed that golimumab preserved endogenous insulin production and had a significant treatment effect in preserving clinical and metabolic outcomes in these patients.",
    "llama-2-7b-chat-hf_fact_raw": "1. Golimumab was tested for diabetes in a phase 2a clinical trial.\n2. The clinical trial in which golimumab was tested is called the T1GER study.\n3. The T1GER study evaluated the safety and efficacy of golimumab in children and young adults.\n4. The patients in the T1GER study had newly diagnosed type 1 diabetes (T1D).\n5. The results of the T1GER study indicated that golimumab preserved endogenous insulin production and improved clinical and metabolic outcomes in patients.",
    "llama-2-7b-chat-hf_fact": [
      "Golimumab was tested for diabetes in a phase 2a clinical trial.",
      "The clinical trial in which golimumab was tested is called the T1GER study.",
      "The T1GER study evaluated the safety and efficacy of golimumab in children and young adults.",
      "The patients in the T1GER study had newly diagnosed type 1 diabetes (T1D).",
      "The results of the T1GER study indicated that golimumab preserved endogenous insulin production and improved clinical and metabolic outcomes in patients."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Golimumab was tested for type 1 diabetes, not type 2 diabetes, in a phase 2 clinical trial.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 4055,
    "user_query": "Is progeria caused by an autosomal recessive gene?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, it is likely that progeria is caused by an autosomal recessive gene. The passage states that progeria is a \"genetic disease of childhood\" and that it is \"estimated to affect one in 4 million newborns worldwide.\" This suggests that the condition is caused by a genetic mutation that is inherited from one's parents.\nAutosomal recessive genetic disorders are caused by mutations in genes that are located on non-sex chromosomes (autosomes). These mutations can be inherited from one's parents, and they can cause a wide range of genetic disorders, including progeria.\nThe passage also mentions that the most severe form of the disease is Hutchinson-Gilford progeria syndrome, which suggests that the condition is caused by a specific mutation in a particular gene. While the exact genetic cause of progeria is not fully understood, it is likely that the condition is caused by a mutation in an autosomal recessive gene that is responsible for the premature aging observed in individuals with the condition.\nIn summary, based on the information provided, it is likely that progeria is caused by an autosomal recessive gene mutation.",
    "llama-2-7b-chat-hf_fact_raw": "1. Progeria is a genetic disease of childhood.\n2. Progeria is estimated to affect one in 4 million newborns worldwide.\n3. Autosomal recessive genetic disorders are caused by mutations in genes on non-sex chromosomes.\n4. Hutchinson-Gilford progeria syndrome is the most severe form of the disease.\n5. Progeria is likely caused by a mutation in an autosomal recessive gene responsible for premature aging.",
    "llama-2-7b-chat-hf_fact": [
      "Progeria is a genetic disease of childhood.",
      "Progeria is estimated to affect one in 4 million newborns worldwide.",
      "Autosomal recessive genetic disorders are caused by mutations in genes on non-sex chromosomes.",
      "Hutchinson-Gilford progeria syndrome is the most severe form of the disease.",
      "Progeria is likely caused by a mutation in an autosomal recessive gene responsible for premature aging."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Progeria, specifically Hutchinson-Gilford progeria syndrome, is usually caused by a mutation in the LMNA gene, which follows an autosomal dominant pattern, not autosomal recessive.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 4082,
    "user_query": "What are common variants at 12q14 and 12q24 associated with?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, common variants at 12q14 and 12q24 are associated with hippocampal volume.",
    "llama-2-7b-chat-hf_fact_raw": "1. Common variants at 12q14 and 12q24 are associated with hippocampal volume.",
    "llama-2-7b-chat-hf_fact": [
      "Common variants at 12q14 and 12q24 are associated with hippocampal volume."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n\n[Explanation]: The statement is consistent with scientific findings that have identified genetic loci associated with brain structure, including the hippocampus. Variants at 12q14 and 12q24 have been reported in genetic studies to be associated with hippocampal volume. However, it is important to note that genetic associations can be complex and are often identified through large-scale genome-wide association studies (GWAS).",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 4096,
    "user_query": "Which are the ligands of the Roundabout (Robo) receptors?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the ligands of the Roundabout (Robo) receptors are Slit guidance ligands (Slits).",
    "llama-2-7b-chat-hf_fact_raw": "1. The ligands of the Roundabout (Robo) receptors are Slit guidance ligands (Slits).",
    "llama-2-7b-chat-hf_fact": [
      "The ligands of the Roundabout (Robo) receptors are Slit guidance ligands (Slits)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 4112,
    "user_query": "Is there a role for TFII-I in megakaryopoiesis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there is evidence to suggest that TFII-I plays a role in megakaryopoiesis. The document states that TFII-I is a multifunctional protein that exerts activities in both the cytoplasm and nucleus, and in the nucleus, it functions as an activator or repressor of gene expression. While the document does not specifically mention megakaryopoiesis, it is likely that TFII-I plays a role in this process given its involvement in regulating gene expression in the nucleus.\nMegakaryopoiesis is the process by which platelets are produced in the bone marrow, and it involves the coordinated regulation of multiple cellular processes, including cell proliferation, differentiation, and survival. TFII-I, as a transcription factor, could potentially play a role in regulating the expression of genes involved in these processes, thereby influencing the development and function of platelets.\nWhile the exact mechanism by which TFII-I regulates megakaryopoiesis is not specified in the provided information, it is possible that it acts directly on genes involved in platelet production or indirectly by modulating the activity of other transcription factors or signaling pathways involved in this process. Further research is needed to fully understand the role of TFII-I in megakaryopoiesis.",
    "llama-2-7b-chat-hf_fact_raw": "1. TFII-I is a multifunctional protein that operates in both the cytoplasm and nucleus.\n2. In the nucleus, TFII-I functions as an activator or repressor of gene expression.\n3. Megakaryopoiesis is the process by which platelets are produced in the bone marrow.\n4. TFII-I, as a transcription factor, could influence the development and function of platelets by regulating gene expression.\n5. The exact mechanism by which TFII-I regulates megakaryopoiesis is not fully understood and requires further research.",
    "llama-2-7b-chat-hf_fact": [
      "TFII-I is a multifunctional protein that operates in both the cytoplasm and nucleus.",
      "In the nucleus, TFII-I functions as an activator or repressor of gene expression.",
      "Megakaryopoiesis is the process by which platelets are produced in the bone marrow.",
      "TFII-I, as a transcription factor, could influence the development and function of platelets by regulating gene expression.",
      "The exact mechanism by which TFII-I regulates megakaryopoiesis is not fully understood and requires further research."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 4145,
    "user_query": "Is atenolol metabolized by CYP2D6?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, atenolol is not metabolized by CYP2D6 to a clinically significant extent. The document states that atenolol is metabolized primarily by CYP3A4 to inactive metabolites, and that CYP2D6 metabolism is not clinically significant. Therefore, it is unlikely that atenolol will be metabolized by CYP2D6 to a significant extent.",
    "llama-2-7b-chat-hf_fact_raw": "1. Atenolol is not metabolized by CYP2D6 to a clinically significant extent.\n2. Atenolol is metabolized primarily by CYP3A4 to inactive metabolites.",
    "llama-2-7b-chat-hf_fact": [
      "Atenolol is not metabolized by CYP2D6 to a clinically significant extent.",
      "Atenolol is metabolized primarily by CYP3A4 to inactive metabolites."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Atenolol is not significantly metabolized by the liver and is excreted primarily unchanged in the urine. It is not metabolized primarily by CYP3A4 to inactive metabolites.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false"
    ]
  },
  {
    "id": 4158,
    "user_query": "List versions of ExpansionHunter",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the following are some versions of ExpansionHunter:\n1. Latest release: The latest version of ExpansionHunter can be downloaded from the official website.\n2. Newer versions: As mentioned in the document, newer versions of ExpansionHunter provide limited support for insertions, deletions, and substitutions.\n3. Build from source: Users can also build ExpansionHunter from source code, which provides more control over the program's configuration and customization.\n4. Older versions: ExpansionHunter has been around since 2014, so there may be older versions of the program available for download or use.\nIt's important to note that the specific versions of ExpansionHunter that are compatible with the provided information are:\n1. Latest release or build from source (for limited support of insertions, deletions, and substitutions)\n2. Newer versions (for limited support of insertions, deletions, and substitutions)\nIt's recommended to consult the official ExpansionHunter website or documentation for more information on the program's versions and compatibility.",
    "llama-2-7b-chat-hf_fact_raw": "1. The latest version of ExpansionHunter is available for download from the official website.\n2. Newer versions of ExpansionHunter provide limited support for insertions, deletions, and substitutions.\n3. Users have the option to build ExpansionHunter from source code.\n4. ExpansionHunter has been available since 2014.\n5. The official ExpansionHunter website or documentation should be consulted for information on program versions and compatibility.",
    "llama-2-7b-chat-hf_fact": [
      "The latest version of ExpansionHunter is available for download from the official website.",
      "Newer versions of ExpansionHunter provide limited support for insertions, deletions, and substitutions.",
      "Users have the option to build ExpansionHunter from source code.",
      "ExpansionHunter has been available since 2014.",
      "The official ExpansionHunter website or documentation should be consulted for information on program versions and compatibility."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE\n4. FALSE [correction]: ExpansionHunter was first released in 2017.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 4164,
    "user_query": "What is the role of Adamts18 in hormone receptor signaling?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, ADAMTS18 appears to play a role in hormone receptor signaling. Document 0 mentions that ADAMTS18 was identified in 2002 as a member of the ADAMTS family of 19 secreted Zinc-dependent metalloproteinases, and that it was known as a candidate gene associated with a wide range of pathologies, particularly various malignancies and eye disorders. However, the document states that the functions and substrates of ADAMTS18 in normal conditions were unknown prior to 2016.\nIt is worth noting that hormone receptor signaling is a complex process that involves the binding of hormones to their respective receptors, leading to changes in gene expression and cellular behavior. ADAMTS18 has been shown to interact with hormone receptors and play a role in regulating their activity. For example, one study published in 2016 found that ADAMTS18 regulates the activity of the estrogen receptor alpha (ERα) in breast cancer cells (1). Another study published in 2018 found that ADAMTS18 modulates the activity of the progesterone receptor (PR) in endometrial cancer cells (2).\nIn summary, while the exact role of ADAMTS18 in hormone receptor signaling is not fully understood, it appears to play a role in regulating the activity of hormone receptors, particularly those involved in breast and endometrial cancer. Further research is needed to fully elucidate the mechanisms by which ADAMTS18 influences hormone receptor signaling.\nReferences:\n1. Liu et al. (2016). ADAMTS18 regulates estrogen receptor alpha activity in breast cancer cells. Oncogene, 35(3), 347-357.\n2. Zhang et al. (2018). ADAMTS18 modulates progesterone receptor activity in endometrial cancer cells. Oncotarget, 9(57), 3053-3063.",
    "llama-2-7b-chat-hf_fact_raw": "1. ADAMTS18 was identified in 2002 as a member of the ADAMTS family of secreted Zinc-dependent metalloproteinases.\n2. ADAMTS18 has been associated with a range of pathologies, including various malignancies and eye disorders.\n3. The functions and substrates of ADAMTS18 in normal conditions were unknown prior to 2016.\n4. A study published in 2016 found that ADAMTS18 regulates the activity of the estrogen receptor alpha (ERα) in breast cancer cells.\n5. A study published in 2018 found that ADAMTS18 modulates the activity of the progesterone receptor (PR) in endometrial cancer cells.",
    "llama-2-7b-chat-hf_fact": [
      "ADAMTS18 was identified in 2002 as a member of the ADAMTS family of secreted Zinc-dependent metalloproteinases.",
      "ADAMTS18 has been associated with a range of pathologies, including various malignancies and eye disorders.",
      "The functions and substrates of ADAMTS18 in normal conditions were unknown prior to 2016.",
      "A study published in 2016 found that ADAMTS18 regulates the activity of the estrogen receptor alpha (ERα) in breast cancer cells.",
      "A study published in 2018 found that ADAMTS18 modulates the activity of the progesterone receptor (PR) in endometrial cancer cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: While it is possible that the functions and substrates of ADAMTS18 were not fully understood prior to 2016, it is unlikely that they were completely unknown given the protein was identified in 2002, and research in the intervening years would have likely uncovered some information about its functions and substrates.\n4. UNKNOWN: Without access to the specific study, it is not possible to confirm the accuracy of this statement.\n5. UNKNOWN: Similar to statement 4, without access to the specific study, it is not possible to confirm the accuracy of this statement.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4208,
    "user_query": "What is the mode of action of Thiazovivin?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the mode of action of Thiazovivin is likely related to its ability to inhibit Rho kinase activity. Thiazovivin is a Rho kinase inhibitor, which means it blocks the activity of Rho kinase, an enzyme that plays a key role in regulating cellular processes such as cell adhesion, migration, and differentiation.\nBy inhibiting Rho kinase activity, Thiazovivin may help to maintain the stemness of embryo-derived stem-like cells in cattle. Stem cells are undifferentiated cells that have the ability to differentiate into various cell types, and they play a crucial role in the development and maintenance of tissues and organs. The ability to maintain stemness is important for the proper functioning of stem cells, and it may be affected by the activity of Rho kinase.\nInhibition of Rho kinase by Thiazovivin may also have other effects on cellular processes, such as cell adhesion and migration, which could contribute to the maintenance of stemness in embryo-derived stem-like cells. However, further research is needed to fully understand the mode of action of Thiazovivin and its effects on cellular processes.",
    "llama-2-7b-chat-hf_fact_raw": "1. Thiazovivin is a Rho kinase inhibitor.\n2. Rho kinase is an enzyme that regulates cellular processes such as cell adhesion, migration, and differentiation.\n3. Inhibition of Rho kinase activity by Thiazovivin may help to maintain the stemness of embryo-derived stem-like cells in cattle.\n4. Stem cells are undifferentiated cells that can differentiate into various cell types.\n5. The activity of Rho kinase can affect the functioning of stem cells.",
    "llama-2-7b-chat-hf_fact": [
      "Thiazovivin is a Rho kinase inhibitor.",
      "Rho kinase is an enzyme that regulates cellular processes such as cell adhesion, migration, and differentiation.",
      "Inhibition of Rho kinase activity by Thiazovivin may help to maintain the stemness of embryo-derived stem-like cells in cattle.",
      "Stem cells are undifferentiated cells that can differentiate into various cell types.",
      "The activity of Rho kinase can affect the functioning of stem cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN (The statement may be true, but without specific research or evidence regarding Thiazovivin's effects on cattle embryo-derived stem-like cells, it cannot be confirmed.)\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "true"
    ]
  }
]